Associations of environmental and lifestyle factors with lung function in youth and adulthood by Luzak, Agnes
 From 
Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine  
University Hospital of Munich, Ludwig-Maximilians-University 
Director: Prof. Dr. med Dennis Nowak 
and 
Institute of Epidemiology 
Helmholtz Zentrum München 
- German Research Center for Environmental Health (GmbH) 
Head of the research group Lung Epidemiology: Prof. Dr. med. Holger Schulz 
 
Associations of environmental and 
lifestyle factors with lung function  
in youth and adulthood 
 
Thesis 
Submitted for a Doctoral degree in Human Biology at the Faculty of Medicine, 
Ludwig-Maximilians-University of Munich 
 
By 
Agnes Luzak 
From 
Elbing 
 
2018 
  
 
 
 
 
 
 
With approval of the Medical Faculty of the 
Ludwig-Maximilians-University of Munich 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supervisor / Examiner:   Prof. Dr. med. Dennis Nowak 
Co-Examiners:      Prof. Dr. med. Jürgen Behr 
         Prof. Dr. med. Markus Ege 
         Prof. Dr. med. Jörg Schelling 
Co-Supervisor:      Prof. Dr. med. Holger Schulz 
Dean:        Prof. Dr. med. dent. Reinhard Hickel 
Date of oral examination:   09.07.2018 
  
 Contents 
Summary ................................................................................................................................. 4 
Zusammenfassung ................................................................................................................ 6 
Abbreviations ......................................................................................................................... 8 
1  Background ................................................................................................................. 9 
2  Rationale and Methods............................................................................................. 11 
2.1  Specific Aims ................................................................................................... 12 
2.1.1  Adolescents ................................................................................................ 12 
2.1.2  Adults ......................................................................................................... 12 
2.2  Methods ........................................................................................................... 13 
2.2.1  Study population ........................................................................................ 13 
2.2.2  Lung function measurements ..................................................................... 14 
2.3  Adolescents – Exposures and statistical analyses .......................................... 15 
2.4  Adults – Exposures and statistical analyses .................................................... 15 
3  Results and Discussion ........................................................................................... 17 
3.1  Adolescents ..................................................................................................... 17 
3.2  Adults ............................................................................................................... 17 
3.3  Strengths and Limitations ................................................................................ 19 
4  Conclusion ................................................................................................................ 20 
5  References ................................................................................................................ 21 
6  Publications comprised within this thesis ............................................................. 24 
6.1  Publication I ..................................................................................................... 24 
6.2  Publication II .................................................................................................... 33 
6.3  Publication III ................................................................................................... 56 
6.4  Publication IV ................................................................................................... 87 
6.5  Publication V .................................................................................................. 105 
7  Acknowledgements ................................................................................................ 134 
8  Publications ............................................................................................................ 135 
9  Affidavit ................................................................................................................... 137 
4 Summary  
Summary 
Numerous factors influence lung function throughout the life course. Exposure to risk factors 
such as passive smoke or respiratory infections early in life have the potential to affect lung 
function already during lung development and growth. Such insults may result in respiratory 
impairment, a higher susceptibility to chronic lung diseases, and abnormal lung function 
decline in adulthood. Although the main determinants of lung function variability are sex, age, 
height, and ethnicity, the inter-subject variability increases in older age, indicating a complex 
interplay of early life, environmental, and lifestyle factors throughout life. 
While many studies have identified factors that are associated with lung function, most 
examined only one or a few factors at specific periods of life or focused on specific lung 
diseases as outcomes. Research on the effects of diverse early and current factors at a certain 
stage or among lung-healthy populations is rare. Therefore, the purpose of this thesis was to 
investigate on a population-based level which factors are associated with lung function at two 
periods in life, in adolescence at the stage of almost finalized lung growth and adulthood during 
age-related lung function decline, respectively. A further aim was to determine which domains 
of respiratory function obtainable by spirometry, i.e. lung volume or airway function, are 
involved in the associations found. 
Cross-sectional analyses were carried out in adolescents using data from the two German 
birth cohorts GINIplus and LISAplus at the 15-year follow-up and further in adults aged 45-89 
years using population-based data of the KORA cohort studies. Early life events as well as 
current environmental and lifestyle factors were investigated in adolescents representing the 
stage of lung growth, while analyses at the stage of age-related lung function decline focused 
on environmental and lifestyle factors in adulthood.  
In adolescents, emphasis was put on the analysis of aeroallergen sensitization as it is 
associated with a higher risk of developing allergic respiratory diseases. Although the 
prevalence of sensitization to aeroallergens at age 15 years was high among adolescents with 
asthma or allergic rhinitis, the grade of sensitization to aeroallergens i.e. no sensitization up 
to polysensitization was not associated with lung volume or airway function in lung-healthy 
adolescents or those with asthma or rhinitis. 
Moreover, the associations of early life (e.g. parental atopy and education, birth weight, 
breastfeeding, peak weight velocity, and lower respiratory tract infections), current lifestyle 
and environmental factors (e.g. active smoking, serum vitamin D concentration, body mass 
index (BMI), and exposure to air pollution or second-hand smoke), and allergic diseases (e.g. 
asthma, rhinitis, and allergen sensitization) with spirometric lung function were analyzed. 
Besides the well-known determinants sex, height, and asthma, weight gain and pulmonary 
infections during infancy, as well as current BMI, indoor second-hand smoke exposure and 
serum vitamin D concentration were identified as prevalent factors associated with lung 
function in 15-year-olds. Overall, the results found for current environmental and lifestyle 
factors indicated associations with both lung volume and airway function, whereas weight gain 
and pulmonary infections in early life were consistently associated with lower airway function. 
However, early life events explained in median less than 5% of the variance, whereas at least 
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75% was captured by sex and height. Nevertheless, small effects already present during the 
stage of lung growth might have the potential to modify lung function in adolescence.   
In adults, environmental and lifestyle factors were analyzed using questionnaire-based 
information on five quality of life health domains (mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression). Because self-reported physical functioning was 
found to be associated with lung function, information on health domains was complemented 
by the investigation of self-reported physical activity levels. Moreover, the association between 
physical activity and lung function was more deeply analyzed using rarely investigated 
German population-based data on physical activity, obtained by accelerometers. Physical 
activity levels, duration pattern and associations with common chronic diseases including 
asthma and chronic obstructive pulmonary disease were analyzed. Furthermore, the 
association of time spent in moderate to vigorous physical activity (MVPA) with spirometric 
lung function, and additionally with measures of pulmonary gas exchange and respiratory 
muscle strength was examined in lung-healthy participants. 
Overall, adults spent about two thirds of the day in sedentary activity, whereas the median 
time spent in MVPA was only 3%. About 87% of MVPA was accumulated in MVPA bouts of 
less than 10 minutes, indicating sporadic activity instead of exercise. MVPA was lower among 
older and obese subjects, while common chronic diseases were not associated with time spent 
in MVPA. In lung-healthy adults, the most active participants had slightly higher volumetric 
indices, i.e. about 150 ml higher forced vital capacity and forced expiratory volume in 1 second 
compared to the least active participants which would correspond to a normal age-related 
decline of about 6 years. In line with this finding, self-reported inactivity, i.e. no or sporadic 
exercise, was negatively associated with spirometric volumes. This tendency was further 
supported by the associations found between slightly lower spirometric volumes and reporting 
problems with mobility and usual activities, respectively, whereas no associations were found 
for the other health domains. 
In summary, the results presented suggest that at the stage of lung growth in adolescence, 
specific early life events such as weight gain or pulmonary infections should be considered 
particularly in studies of airway function and, furthermore, that physical activity might be 
associated with lung volumes in lung-healthy adults representing the period of age-related 
lung function decline. Although these findings are not generalizable to other populations and 
the effect sizes found were small, the results nevertheless highlight the need to consider 
specific factors for the investigation of lung volumes and airway function at different age 
periods in life. Moreover, studies determining factors associated with lung function already in 
lung-healthy populations might help define starting points for early health interventions. 
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Zusammenfassung 
Das ganze Leben hindurch beeinflussen zahlreiche Faktoren die Lungenfunktion. Bereits in 
der frühen Entwicklungs- und Wachstumsphase der Lunge können Risikofaktoren, wie 
Passivrauchexposition oder respiratorische Erkrankungen, Beeinträchtigungen der 
Lungenfunktion verursachen, welche das Risiko für chronische Lungenerkrankungen im 
Erwachsenenalter erhöhen und eine schnellere altersabhängige Lungenfunktionsabnahme 
bedingen können. Obwohl Geschlecht, Alter, Größe und Herkunft, die interindividuelle 
Variabilität der Lungenfunktion maßgeblich bestimmen, steigt in höherem Alter die Variabilität 
der Lungenfunktion an, was auf eine komplexe, lebenslange Wechselwirkung von 
frühkindlichen Ereignissen sowie Umwelt- und Lebensstilfaktoren schließen lässt.  
Zahlreiche Studien haben Faktoren identifiziert, die mit der Lungenfunktion assoziiert sind, 
wobei die meisten davon lediglich einen oder nur einige Faktoren während spezifischer 
Lebensphasen untersucht haben oder den Fokus auf den Zusammenhang mit 
Lungenerkrankungen legten. Viel seltener sind hingegen Studien, die verschiedene frühe und 
gegenwärtige Faktoren während spezifischer Lebensphasen oder lungengesunde 
Populationen untersuchen. Ziel dieser Arbeit war es, auf Populationsebene zu untersuchen, 
welche Faktoren eine Assoziation mit spirometrischen Lungenfunktionsparametern während 
zweier spezifischer Lebensphasen zeigen: bei Jugendlichen in der finalen Phase des 
Lungenwachstums und bei Erwachsenen während der normalen altersbedingten 
Lungenfunktionsabnahme. Zudem wurde betrachtet welcher Bereich der Lungenfunktion, d.h. 
Lungenvolumen oder Atemwegsfunktion, potenzielle Zusammenhänge zeigt. 
In Querschnittsanalysen wurden Daten von 15-jährigen Jugendlichen aus zwei deutschen 
Geburtskohorten GINIplus und LISAplus sowie von Erwachsen im Alter von 45-89 Jahren aus 
den deutschen Kohortenstudien KORA ausgewertet. Frühkindliche Ereignisse und 
gegenwärtige Umwelt- und Lebensstilfaktoren wurden bei Jugendlichen untersucht, die die 
Lungenwachstumsphase repräsentieren. Bei Erwachsenen, in der Phase der 
Lungenfunktionsabnahme, lag der Fokus auf aktuellen Umwelt- und Lebensstilfaktoren. 
Bei Jugendlichen wurde zunächst spezifisch untersucht, ob die Sensibilisierung gegen 
Inhalationsallergene, die ein höheres Risiko für allergische respiratorische Erkrankungen 
birgt, bereits negativ mit Lungenfunktion assoziiert ist. Obwohl die Prävalenz von Asthma und 
allergischer Rhinitis bei sensibilisierten 15-Jährigen hoch war, wurde weder bei 
Lungengesunden, Asthmatikern, noch bei denen mit Rhinitis ein Zusammenhang zwischen 
dem Sensibilisierungsgrad, d.h. keine Sensibilisierung bis hin zur Polysensibilisierung, und 
Lungenvolumen oder Atemwegsfunktion beobachtet.  
Des Weiteren wurden Assoziationen zwischen Lungenfunktion und frühen Ereignissen (z.B. 
Atopie und Bildung der Eltern, Geburtsgewicht, Stillen, Gewichtszunahme, und untere 
Atemwegsinfekte), gegenwärtigen Umwelt- und Lebensstilfaktoren (z.B. Rauchen, Serum 
Vitamin D Konzentration, Body-Mass-Index (BMI), Belastung durch Luftverschmutzung, und 
Passivrauchexposition) und allergischen Erkrankungen (z.B. Asthma, Rhinitis, und Allergen-
sensibilisierung) bei 15-Jährigen untersucht. Neben den bekannten Determinanten, 
Geschlecht, Größe und Asthma, überwogen unter allen Faktoren die Assoziationen zwischen 
Lungenfunktion und folgenden Faktoren: frühe Gewichtszunahme und Lungeninfekte als 
frühkindliche Ereignisse sowie BMI, häusliche Passivrauchbelastung und Serum Vitamin D 
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Konzentration als gegenwärtige Faktoren bei 15-Jährigen. Während die gegenwärtigen 
Umwelt- und Lebensstilfaktoren Zusammenhänge sowohl mit Lungenvolumen als auch 
Atemwegsfunktion zeigten, waren die frühkindlichen Ereignisse, Gewichtszunahme und 
Lungeninfekte, vorwiegend mit geringerer Atemwegsfunktion assoziiert. Im Gegensatz zu 
Geschlecht und Größe, die rund 75% der Varianz erklärt haben, lag für frühe Ereignisse der 
Median bei unter 5% erklärter Varianz, wobei selbst kleine Effekte, die sich bereits während 
der Lungenwachstumsphase manifestieren, modulierend auf die Lungenfunktion im 
Jugendalter wirken können. 
Bei Erwachsenen wurden Umwelt- und Lebensstilfaktoren mithilfe von Fragen zu fünf 
gesundheitsbezogenen Domänen der Lebensqualität (Mobilität, Für sich selbst sorgen, 
Allgemeine Tätigkeiten, Schmerzen/körperliche Beschwerden und Angst/Depression) 
analysiert. Da Assoziationen zwischen körperlichem Gesundheitszustand und Lungenfunktion 
berichtet wurden, wurden auch fragebogenbasierte Daten zur körperlichen Aktivität in die 
Analysen einbezogen. Darüber hinaus wurden bisher selten auf deutscher Populationsebene 
untersuchte Akzelerometerdaten zur körperlichen Aktivität ausgewertet. Betrachtet wurden 
die verschiedenen Aktivitätslevel und ihre Dauer sowie ihr Zusammenhang mit häufigen 
chronischen Erkrankungen, wie Asthma oder chronisch obstruktiver Lungenerkrankung. Bei 
lungengesunden Teilnehmern wurde zudem der Zusammenhang zwischen moderater bis 
anstrengender körperlicher Aktivität (MVPA) und spirometrisch erfasster Lungenfunktion, 
sowie mit der pulmonalen Gasaustauschkapazität und Atemmuskelkraft analysiert. 
Rund zwei Drittel des Tages waren die Teilnehmer körperlich inaktiv, während im Schnitt nur 
rund 3% der Zeit in MVPA verbracht wurde. Insgesamt waren rund 87% der MVPA kürzer als 
10 Minuten in Folge, was mehr auf sporadische, statt sportliche Aktivität hindeutete. Ältere 
und adipöse Teilnehmer verzeichneten weniger MVPA, während keine Zusammenhänge mit 
den untersuchten chronischen Erkrankungen beobachtet wurden. Unter den Lungen-
gesunden hatten die aktivsten Teilnehmer im Vergleich zu den inaktivsten etwas höhere 
Lungenvolumina, d.h. eine um rund 150 ml höhere forcierte Vital- und Einsekundenkapazität, 
was einem normalen altersabhängigen Lungenfunktionsabfall von circa 6 Jahren entsprechen 
würde. Ergebnisse zur Aktivität basierend auf Fragebogendaten stützten dieses Ergebnis 
durch einen Zusammenhang zwischen Inaktivität, d.h. kein oder nur sporadischer Sport, und 
niedrigeren spirometrischen Volumina. Teilnehmer mit Problemen in den aktivitätsrelevanten 
Gesundheitsdomänen Mobilität und allgemeine Tätigkeiten zeigten die gleiche Tendenz, 
während für die anderen Gesundheitsdomänen keine Assoziationen beobachten wurden. 
Zusammenfassend deuten diese Ergebnisse darauf hin, dass bei Jugendlichen, in der finalen 
Phase des Lungenwachstums, spezifische frühkindliche Ereignisse wie Gewichtszunahme 
und Lungeninfekte besonders in Studien zur Atemwegsfunktion berücksichtigt werden sollten. 
Darüber hinaus wurde gezeigt, dass bereits bei lungengesunden Erwachsenen, in der Phase 
der Lungenfunktionsabnahme, körperliche Aktivität mit höheren Lungenvolumina assoziiert 
sein kann. Obwohl diese Ergebnisse nur eingeschränkt auf andere Populationen übertragbar 
sind und kleine Effekte beobachtet wurden, zeigen sie dennoch auf, dass spezifische Faktoren 
für verschiedene Lebensphasen zur Analyse von Lungenvolumen und Atemwegsfunktion 
berücksichtigt werden sollten. Zudem könnten Studien bei lungengesunden Personen dazu 
beitragen Ansätze für frühe Interventionen zu definieren. 
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Abbreviations 
BMI Body mass index 
COPD Chronic obstructive pulmonary disease  
CI Confidence interval 
EQ-5D EuroQol five dimensions questionnaire 
FEF25,50,75  Forced expiratory flows at 25%, 50% and 75% of exhaled FVC 
FEF25–75  Forced expiratory flow between 25% and 75% of FVC 
FEV1  Forced expiratory volume in 1 second 
FVC Forced vital capacity 
GINIplus German Infant study on the influence of Nutrition Intervention plus air pollution 
and genetics on allergy development  
KORA  Cooperative Health Research in the Region of Augsburg 
LISAplus  Life-style related factors on the development of the Immune System and 
Allergies in East and West Germany plus the influence of traffic emissions and 
genetics 
MVPA Moderate to vigorous physical activity 
PEF  Peak expiratory flow 
PImax  Maximal inspiratory mouth pressure 
TLCO  Transfer factor of the lung for carbon monoxide 
VA  Alveolar volume 
WHO World Health Organization 
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1 Background 
Structural lung development begins in utero and continues for the first few years of life until a 
plateau in lung growth is reached at the age of 20-25 years and subsequently followed by a 
slow age-related lung function decline [1, 2]. Heritability contributes highly to the inter-
individual variability of pulmonary function [3, 4]. Related to genetic variability, sex, age, height, 
and ethnicity were all shown to be key determinants of lung function [5-7]. However, various 
other factors were also found to be associated with lung function or chronic respiratory 
diseases and may therefore act as modifiers of lung function throughout the life course [1, 8-
12]. Thus, a continuous interplay between genetic predisposition, early life events, 
environmental and lifestyle factors, and disease is suggested to influence the variability of lung 
function during lung growth and age-related decline [11-14]. This is indicated by an increasing 
coefficient of variation for lung function parameters with age, beginning in adolescence, e.g. 
from near 10% at 15 years of age to about 18% at age 80 years for the forced vital capacity 
(FVC) [7]. An overview of factors that were investigated in this thesis are displayed in  
Figure 1. 
 
Figure 1 Overview of investigated factors that might be associated with lung function during the life 
course. Available data was used from the GINIplus, LISAplus, and KORA studies. 
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Most previous studies examined only one or a few factors at specific periods of life [8, 10, 15-
25]. For example, a study among youth showed a statistically significant association between 
birth weight and lung function at age 8-9 years, but not at age 14-17 years [16]. Moreover, low 
birth weight was shown to be associated with lower lung function in adults [17, 18]. In one 
epidemiological study in Tunisian children aged 6-16 years the interplay of socioeconomic 
status and several early life and environmental factors was addressed [26]. The type of 
heating, e.g. electric versus gas, was shown to have the strongest relation with lung function 
of healthy Tunisian children along with the well-established factors – sex, age, height and 
weight. 
Adverse influences occurring early in life may result in reduced lung growth and lung function 
impairment followed by a higher susceptibility to both chronic lung diseases and abnormal 
lung function decline in older age [1, 8, 12, 14]. Early life factors such as passive smoke 
exposure and respiratory infections during early childhood were found to be associated with 
decreased lung function in both child- and adulthood along with a higher risk of respiratory 
diseases such as asthma or chronic obstructive pulmonary disease (COPD) [8, 22-24]. 
Furthermore, air pollution showed negative effects on lung function in youth and adults, but as 
no clear most vulnerable time point could be determined this is suggestive of an interchanging 
effect based on exposure and accumulation over the life course [25, 27]. 
These studies suggest that the relative importance of factors might differ in certain stages of 
life and investigations at different age periods could add essential information on their impacts 
on lung health and respiratory function. Moreover, approaches that investigate the effects of 
diverse early and current factors at one age period are rare, but might contribute to the 
identification of major factors influential at specific stages of life.  
With respect to the phase of age-related lung function decline in adulthood, comprehensive 
research into the determinants of chronic lung disease is a major research focus due to both 
the considerable importance for clinical practice and the increasing burden of asthma and 
COPD worldwide [14, 28]. Thus, the associations between lung function and environmental 
and lifestyle factors such as physical activity or self-rated quality of life are often investigated 
through comparisons of participants with chronic lung diseases and controls or, as well in 
clinical populations and show negative effects with less activity and disease severity [15, 29-
35]. Whether these associations found in patients with respiratory diseases also apply to lung-
healthy populations is less well studied. Two population-based investigations found positive 
associations of physical functioning with lung function, whereas the association with mental 
functioning remained inconclusive [36, 37]. Likewise, questionnaire-based physical activity 
was shown to be associated with slower lung function decline [38-41]. More evidence is 
needed to determine whether even those with healthy lung function at the stage of age-related 
lung function decline might benefit from more physical activity and whether lung-healthy 
participants with favorable lung function show fewer health problems. 
Rationale and Methods 11 
2 Rationale and Methods 
The aim of this thesis was to investigate which factors are associated with lung function, 
analyzing cross-sectional data at specific age stages in life and differentiating between 
spirometric indices for lung volume and airway function (Figure 2). The stage of lung growth 
was addressed using data from two German birth cohorts at the 15-year follow-up and the 
stage of age-related decline was investigated using population-based data of adults aged 45-
89 years. This thesis is based on five publications. An overview of analyzed factors assigned 
to the corresponding publication is displayed in Figure 2. 
Figure 2 Overview and assignment to publications of investigated factors at the stage of lung growth in 
adolescents [I and II] and age-related decline in adulthood [III-V]. Available data was used from the 
GINIplus, LISAplus, and KORA studies. Shading and frame of the boxes indicate the publications [I-V] 
in which this factor was investigated as main focus.  
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The five publications have been published by Annals of Allergy, Asthma & Immunology [I], 
Respiratory Research [II], PLoS ONE [III], BMC Pulmonary Medicine [IV] and Quality of Life 
Research [V]. As first author of all five manuscripts, I was significantly involved in the definition 
of the research questions and study designs. Further, I was responsible for the statistical 
analyses, interpretation of results and manuscript preparation considering suggestions from 
my supervisors, co-authors and reviewers. 
2.1 Specific Aims 
2.1.1 Adolescents 
At the stage of lung growth in adolescents, available data comprised early life (e.g. parental 
atopy and education, birth weight, breastfeeding, peak weight velocity, lower respiratory tract 
infections), current lifestyle and environmental factors (e.g. active smoking, serum vitamin D 
concentration, body mass index (BMI), exposure to air pollution or second-hand smoke), and 
allergic diseases (e.g. asthma, rhinitis, aeroallergen sensitization). Overall, 21 early life events 
and current factors were available to be analyzed in a comprehensive approach. Furthermore, 
aeroallergen sensitization was more deeply analyzed as it is associated with a higher risk of 
developing allergic respiratory diseases and wheezing, but whether there is a direct 
association between higher grade of sensitization and lower lung function remained 
inconclusive [42-45]. 
According to the research aim two main objectives were defined as follows:  
 To investigate whether sensitization to common aeroallergens is associated with 
spirometric lung function parameters in 15-year-olds after stratification by allergic 
respiratory disease [Publication I].  
 To analyze associations of diverse early life events and current environmental and 
lifestyle factors with spirometric measures of central and peripheral airway function 
and, furthermore, to investigate the relative importance of early life events compared 
to current factors [Publication II]. 
2.1.2 Adults 
At the stage of age-related lung function decline in adults, information on five health 
dimensions - mobility, self-care, usual activities, pain/discomfort, and anxiety/depression 
assessed via the EuroQol 5 dimensions (EQ-5D) questionnaire were used [46]. These 
domains were considered as surrogate for environmental and lifestyle factors potentially 
reflecting positive and negative influences on lung function. Further, reported problems for the 
health domains mobility and usual activities i.e. domains related to physical functioning, were 
complemented by the investigation of self-reported physical activity levels. Moreover, physical 
activity was more deeply investigated because of its known association with lung function in 
clinical cohorts [31], while there is little existing evidence on this association regarding healthy 
lung function variability on a population-based level. Therefore, rarely investigated German 
population-based data on physical activity obtained by accelerometers over a one-week 
period were used to determine activity levels and its associations with different lung function 
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domains covering lung volume and airway function, as well as pulmonary gas exchange and 
respiratory muscle strength. 
According to the research aim three main objectives were defined as follows:  
 To characterize accelerometer-based overall physical activity, activity levels and 
duration pattern in German adults and to investigate the associations with common 
chronic diseases [Publication III]. 
 To investigate the association of accelerometer-based physical activity with respiratory 
function measured by spirometry and, moreover, with measures of pulmonary gas 
exchange (TLCO/VA) and inspiratory muscle strength (PImax) in lung-healthy German 
adults [Publication IV]. 
 To examine the associations of the health domains - mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression and self-reported physical inactivity with 
spirometric indices within the physiological variability of respiratory function of lung-
healthy German adults [Publication V]. 
2.2 Methods 
2.2.1 Study population 
In adolescents, data from the German Infant study on the influence of Nutrition Intervention 
plus air pollution and genetics on allergy development (GINIplus) [47] and the study on Life-
style related factors on the development of the Immune System and Allergies in East and West 
Germany plus the influence of traffic emissions and genetics (LISAplus) [48] were used (Figure 
3). Both are prospective German birth cohorts [49] with up to now each 15 years of follow-up.  
In GINIplus, 5991 full-term newborns were recruited between September 1995 and July 1998 
in the cities of Munich and Wesel. Newborns with a family history of allergic diseases were 
asked to participate in the intervention group to investigate the effect of three different types 
of hydrolyzed formula on allergy development (N=2252). All others participated in the 
observational group (N=3739). In LISAplus, 3094 full-term newborns were recruited between 
December 1997 and January 1999 in the area of Munich, Wesel, Leipzig and Bad Honnef. As 
the data of GINIplus and LISAplus were pooled for the analyses, only participants from Munich 
and Wesel were considered. For all analyses, lung function data of adolescents with mean 
age 15 years and a prevalence of females ranging from 49-51% was used.  
In adults, data from the KORA (Cooperative Health Research in the Region of Augsburg) 
research platform that comprises several population-based cohort studies was analyzed [50] 
(Figure 3). Investigations on accelerometer-based physical activity were performed in middle-
aged adults (48-68 years) of KORA FF4 considering common chronic diseases. For the 
analyses of health dimensions focusing on lung-healthy participants, data from KORA F4L 
and KORA Age was pooled to cover a broader age range (45-89 years). In all analyses, the 
prevalence of females was slightly higher (52-55%) than those for males.   
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Figure 3 Analyzed study populations in publications I to V. 
2.2.2 Lung function measurements 
Spirometry was performed in line with the American Thoracic Society and European 
Respiratory Society statements [51] and similarly in all studies. During 3 to 8 spirometric 
maneuvers both flow-volume and volume-time curves were monitored by trained examiners 
and visually inspected for validity of the result afterwards. Details have been published 
previously [52, 53]. Spirometric parameters included the FVC, forced expiratory volume in 1 
second (FEV1), Tiffeneau-Index (FEV1/FVC), peak expiratory flow (PEF), forced expiratory 
flows at 25% (FEF25), 50% (FEF50) and 75% (FEF75) of exhaled FVC and the mid-expiratory 
flow between 25% and 75% of FVC (FEF25–75). These spirometric parameters could be 
regarded as indicative of different domains of respiratory function [54, 55]: lung volume (FVC), 
airway function and lung volume (FEV1), airflow limitation (FEV1/FVC), flow rates for the larger 
conducting (PEF, FEF25) and peripheral airways (FEF50, FEF75 and FEF25–75). Standardized z-
scores for these parameters were calculated using reference equations for spirometry from 
the Global Lung Function Initiative [6] in order to provide comparable estimates to other 
studies and as well to support the findings when using absolute values.  
In addition to spirometry, the transfer factor of the lung for carbon monoxide divided by alveolar 
volume (TLCO/VA) as an index for pulmonary gas exchange and the maximal inspiratory 
mouth pressure (PImax) as a measure of respiratory muscle strength were investigated to gain 
more comprehensive information on potential associations between physical activity and lung 
function [Publication IV]. In line with international recommendations, both measures were 
obtained under guidance of trained examiners with the performance of up to 5 maneuvers for 
TLCO/VA and 3 to 15 maneuvers for PImax in order to obtain maximal acceptable measures 
[56, 57]. 
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2.3 Adolescents – Exposures and statistical analyses 
Serum Immunoglobulin E concentration was used to determine aeroallergen sensitization at 
age 15 years [Publication I]. An allergen mixture of cat, dog, mugwort, birch, timothy, rye, 
Dermatophagoides pteronyssinus, and Cladosporium herbarum was applied to screen for 
overall sensitization to aeroallergens followed by single assessment of each allergen if the 
screening showed a positive test result. According to the test results, participants were divided 
into four groups: (a) not sensitized, (b) a positive screening test, but low sensitization to the 
single allergens, (c) being sensitized to 1-2 single allergens, or (d) sensitization to >2 single 
allergens. 
Multiple linear regression models considering possible confounding covariates were 
performed stratifying the study population into lung-healthy participants, those with rhinitis and 
those with asthma, respectively. Lung function parameters were applied as dependent 
variables investigating sensitization as the main exposure variable in the models.  
Considering the sample sizes with available information in the GINIplus and LISAplus studies, 
factors that were shown to be associated with lung function in other studies were selected for 
investigation [Publication II]. The investigated covariates comprised early life events (e.g. 
maternal smoking during pregnancy, parental atopy, birth weight, breastfeeding), current 
environmental and lifestyle factors at age 15 years (e.g. air pollution, BMI, serum vitamin D 
concentration, active smoking), and allergic diseases (e.g. asthma, rhinitis, sensitization to 
aero- or food allergens). These data were obtained from parent-completed questionnaires at 
birth, yearly from 1 to 4, and at 6, 10 and 15 years of age in GINIplus. In LISAplus, data was 
collected at birth, 0.5, 1, 1.5, 2, 4, 6, 10 and 15 years of age. At the 15-year follow-up, a self-
report questionnaire for the adolescents and blood sample collection were included in both 
studies. 
In order to avoid overadjustment in the cross-sectional analyses at age 15 years, a best subset 
selection was performed for linear regression models adjusted for all covariates to determine 
relevant factors to be included in final models. This selection method compares a full-model 
to all possible subsets of variables in this model to determine a final model with preferably 
high precision and low bias [58]. The selection process was performed 1000 times, with two 
thirds of the population randomly selected to be included in the model each time. Covariates 
that remained in >70% of the replication models were considered for the final models and 
rerun in the total population. Associations found for each spirometric parameter were reported 
along with the sequential R2 contribution to the explained variance for each factor [59].   
2.4 Adults – Exposures and statistical analyses 
Physical activity was assessed with triaxial accelerometers worn at the hip [Publication III]. 
Measured accelerations per minute were recorded over a one week period along with a wear-
time diary completed by the participants. Each minute was classified into one of three activity 
levels (sedentary, light, or moderate to vigorous physical activity (MVPA)) [60]. Further, the 
duration of bouts spent in MVPA and the compliance to World Health Organization (WHO) 
recommendations of 150 minutes of MVPA per week spent in at least 10-minute bouts were 
assessed [61].  
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The average minutes per day per subject spent in each activity level were applied as 
dependent variables in separate negative binomial regression models. Stepwise (forward and 
backward) selection models were applied to define which covariates e.g. age, BMI, or common 
chronic diseases such as hypertension, diabetes or asthma were associated with any of the 
activity levels.  
Moreover, the association of MVPA quartiles (most active to least active according to sex-
specific MVPA distribution in the population), bout length and the achievement of the WHO 
recommendations with lung function of lung-healthy participants was analyzed by multiple 
linear regression models adjusted for possible confounders applying physical activity as the 
independent variable [Publication IV]. 
The EQ-5D-3L, representing a generic, preference-based health related quality of life 
instrument, was used to obtain information on the state of the five health dimensions: mobility, 
self-care, usual activities, pain/discomfort, and anxiety/depression [46]. For each of the five 
dimensions, the participants were asked to choose one of three levels of problem severity (no 
problems, some problems, and extreme problems). Furthermore, the association of self-
reported levels of activity (inactive, slightly active, moderately active and active) was defined 
based on the reported time spent exercising during summer and winter. Subjects were 
categorized as inactive if they reported irregular exercise (<1 hour/week) or no exercise at all 
whereas subjects reporting regularly >2 hours/week of exercise were categorized as active.  
Multiple linear regression models adjusted for possible confounders were calculated in lung-
healthy participants to investigate the relationships between each EQ-5D health dimension  
or physical activity level with spirometric parameters applied as dependent variables 
[Publication V]. 
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3 Results and Discussion 
3.1 Adolescents  
Being in the stage of almost finalized lung growth, 46% of 1719 adolescents were sensitized 
to aeroallergens. Lung function of adolescents with asthma was lower compared to lung-
healthy participants and to those with rhinitis, while spirometric parameters for lung volumes 
and airway function between lung-healthy participants and those with rhinitis did not differ. No 
associations were found between spirometric lung function and increasing sensitization grade 
in lung-healthy participants or those with rhinitis or asthma [Publication I]. Considering these 
results, sensitization was included only as a dichotomous variable (yes/no), without further 
stratification into sensitization grades in the best-subset selection analyses of publication II. 
Among the 21 diverse early life events or current environmental and lifestyle factors (Figure 
2), a higher peak weight velocity and early lung infections, as early life events, were associated 
with lower lung function parameters indicative of airway function [Publication II]. Of the 
considered current environmental and lifestyle factors at age 15 years, indoor second-hand 
smoke exposure, serum vitamin D concentration, and BMI were associated with both lung 
volume and airway function. 
Sex and height, well-known lung function determinants, captured most of the explained 
variance in the regression models (>75%), followed by BMI (≤23.7%). Other environmental 
and lifestyle factors such as serum vitamin D concentration contributed little in comparison to 
sex and height (≤2.1%). Early life events also explained just as little variance with a median of 
4.8% (range: 0.2–22.4%), but nevertheless showed consistent associations with airway 
function. All factors that were identified as relevant in the present study were supported by 
results found in other studies, most of which considered only one or a few factors at a time 
without reporting the relative importance of each factor [19-23]. For example, serum vitamin 
D concentration was positively associated with lung volume, which was also found in a study 
analyzing both adolescents and adults [21]. There were also factors that were not associated 
with lung function in the present analysis but have been shown to be associated with lung 
function in other studies, suggesting that the importance might vary between populations, 
assessment methods and certain stages in life. For example, maternal smoking during 
pregnancy or low socioeconomic status were shown to be associated with poor lung function 
in children and adolescents [23, 62], but for both factors no associations were found in the 
present study population. The fact that the prevalence of highly educated families was 68% in 
the analyzed population might have contributed to the lack of associations with factors that 
were found to be associated with low socioeconomic status, pointing out the need for 
differentiated analyses to define vulnerable subgroups. 
3.2 Adults  
Of 475 participants aged 48-68 years, only 14% met the WHO physical activity 
recommendation of at least 150 minutes of MVPA/week in bouts of at least 10 minutes. 
Overall, males engaged more in MVPA than females (median 35 vs. 28 minutes/day, 
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respectively). About 87% of MVPA was accumulated in bouts less than 10 minutes, indicating 
sporadic activity instead of exercise. In line with other studies, MVPA was lower among obese 
and older subjects [63, 64], but considered chronic diseases such as COPD, which is mainly 
pronounced in early disease stages in the KORA FF4 population, were not associated with 
time spent in MVPA [Publication III]. While studies in clinical cohorts have found that patients 
with COPD performed less physical activity compared to healthy controls [30, 31], the 
association of accelerometer-based physical activity with lung function in lung-healthy 
populations is unclear. In the present analysis of 341 lung-healthy participants representing 
the stage of age-related decline, positive associations of sex-specific MVPA-quartiles with 
FVC and FEV1 were found in regression models adjusted for possible confounders 
[Publication IV]. Participants in the most active quartile (i.e. >47 or >50 minutes/day spent in 
MVPA for females and males, respectively) had an estimated 155 ml [95% confidence interval 
(CI): 10, 301] higher FVC and 142 ml [95% CI: 23, 260] higher FEV1 than those in the least 
active quartile (i.e. <17 or <21 minutes of MVPA/day for females and males, respectively). 
These effect sizes would correspond to an age-related decline of about 6 years [65]. MVPA-
quartiles were not associated with pulmonary gas exchange (TLCO/VA) or maximal inspiratory 
muscle strength, i.e. PImax. Associations found with spirometric indices primarily indicative of 
lung volume were more pronounced among smokers, suggesting a higher benefit of being 
physically active for participants at a greater risk of chronic respiratory diseases. No study was 
found that used a directly comparable approach, but in line with the present result, a 
longitudinal study using questionnaire-based physical activity showed that current smokers 
with moderate and high activity had a decreased decline in FVC and FEV1 compared to 
smokers with low activity [41]. 
Considering the association found between MVPA and volumetric lung function indices, five 
health domains, including the domains mobility and usual activities as indicators for physical 
functioning, and also self-reported time spent in exercise were analyzed as surrogate for 
environmental and lifestyle factors in lung-healthy adults [Publication V]. Self-reported time 
spent in exercise was used to increase the sample size to 1132 participants. Amongst all 
participants, 24% were inactive and 32% reported to exercise more than 2 hours/week. While 
42% reported no problems in any EQ-5D health dimension, about half of the population 
reported pain/discomfort. Although the prevalence for mobility problems and problems with 
usual activities was much lower (17% and 13%, respectively), participants reporting problems 
in those domains had lower volumetric indices compared to those without problems for these 
domains. FEV1 was -99 ml (95% CI: -166; -32) and FVC was -109 ml (95% CI: -195; -24) lower 
among subjects with mobility problems controlling for sex, age, height and weight. Similar 
estimates were present for usual activities. Moreover, being inactive was negatively 
associated with FVC (-coefficient: -83 ml, 95% CI: -166; 0). These results are in line with two 
investigations from the United Kingdom showing positive associations between FEV1 and self-
reported physical functioning [36, 37], suggesting positive correlations between activity and 
volumetric lung function. Overall, the presented results obtained in a lung-healthy study 
population showed slightly lower lung function among less active participants and those with 
limited physical functioning, and hence add to the findings observed in previous studies in 
patients with lung disease [30-34]. 
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3.3 Strengths and Limitations 
A major strength of all included studies is the investigation of a broad range of standardized 
lung function parameters, obtained by spirometry, indicative of lung volume and airway 
function. Additionally, parameters for the less often investigated measures of gas exchange 
and respiratory muscle strength were analyzed in one study. The studies covered a wide age 
range, with focus on two periods in life. The period of lung growth was represented by 
adolescents at age 15 years, and the period of age-related lung function decline by adults 
from 45-89 years of age.  
In adolescents, data on a broad range of early life events, environmental and lifestyle factors, 
and allergic diseases at age 15 years were available to be analyzed. The results showed the 
relative contribution of factors to the explained variance of the models differentiating into 
volume, airways and airflow limitation.  
In adults, an approach covering environmental and lifestyle factors was performed using 
different health domains as well as questionnaire- and accelerometer-based information on 
physical activity. Evidence regarding the association between health domains or 
(accelerometer-based) physical activity and lung function in the general population without 
chronic lung diseases is rare. Therefore, the present studies meaningfully complement the 
evidence base for the assessed factors in lung-healthy populations at the population-level.  
All included studies are cross-sectional and do not allow for drawing conclusions about causal 
relations or long-term effects. Furthermore, loss to follow-up in the cohorts as well as selection 
bias are present. Early life factors were only available for analyses of adolescents. Moreover, 
missing information within the study population and preselection for lung-healthy participants 
limited the sample size and the generalizability of the results to other populations. Effect 
estimates were small, partly borderline significant and with broad confidence intervals, 
suggesting for example for physical activity that not all, but rather only certain individuals may 
benefit from physical activity with respect to their lung function indices. Therefore, bearing in 
mind these addressed limitations, the results should be interpreted with caution. 
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4 Conclusion 
The present cross-sectional investigations addressed the association of various factors on 
lung function at two periods in life; adolescence at age 15 years, in the period of lung growth, 
and adulthood from 45 to 89 years of age, representing the stage of age-related lung function 
decline. Data for adults focused on current environmental and lifestyle factors, while data on 
early life events as well as current environmental and lifestyle factors were available for 
adolescents.  
In adolescents, the results identified weight gain and pulmonary infections during infancy, as 
well as current BMI, indoor second-hand smoke exposure and serum vitamin D concentration, 
asthma, sex and height as prevalent factors associated with lung function. Associations with 
current factors were present for both lung volume and airway function, whereas weight gain 
and pulmonary infections in early life were consistently associated with lower airway function 
only. However, early life events explained in median less than 5% of the variance, whereas at 
least 75% were captured by sex and height.  
In lung-healthy adults, physical activity was found to be primarily associated with slightly higher 
volumetric indices. Both, self-reported inactivity as well as little measured time spent in MVPA, 
assessed by accelerometers, showed associations with lower volumetric lung function indices. 
The effect estimates showed a small difference between the least active and the most active 
group of participants of about 50 to 150 ml which would correspond to a normal age-related 
decline of about 2 to 6 years. This tendency was further supported by the associations found 
between slightly lower spirometric lung volume and reporting problems with either mobility or 
usual activities. The presented results suggest that being able to and indeed choosing to 
perform exercise may be associated with beneficial volumetric lung function even in lung-
healthy adults. 
Although these findings are not generalizable to other populations, they nevertheless support 
the inclusion of specific early life events in studies on airway function in adolescents and the 
consideration of physical activity, particularly for investigations on lung volumes in adults. 
Further, the results highlight the need for more studies considering both early and current 
factors at different stages in life in order to define specific associations relevant for the phases 
of lung growth and age-related decline, as well as to provide evidence for potential early 
interventions to foster lung health. 
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A B S T R A C T
Background: The prevalence of allergen sensitization reaches up to 46.6% in 14- to 17-year-old German
adolescents. Polysensitization is strongly associated with a higher risk of allergic rhinitis or asthma. Whether
or how sensitization also is related to lung function remains uncertain.
Objective: To assess whether sensitization to common inhalant allergens is associated with lung function in
adolescents after stratiﬁcation by allergic respiratory disease.
Methods: In total, 1,719 15-year-old participants of the German Infant Study on the Inﬂuence of Nutrition
Intervention plus Air Pollution and Genetics on Allergy Development (GINIplus) birth cohort provided
valid spirometric indices, including forced expiratory volume in 1 second, forced vital capacity (FVC),
forced expiratory ﬂow rate at 25% to 75% of the FVC, and speciﬁc immunoglobulin E (IgE) screening test to
8 inhalant allergens (ImmunoCAP). Complete information on allergic rhinitis and asthma status was
available for 1,128 subjects. Associations between lung function parameters and sensitization, classiﬁed
into 4 groups (no sensitization to polysensitization) were analyzed using adjusted linear regression
models.
Results: Among participants, 21.1% (n ¼ 347) had allergic rhinitis, 10.1% (n ¼ 119) had asthma, and
46.4% (n ¼ 798) had a positive screening test to inhalant allergens. Prevalences were consistently
higher in boys. The percentage of subjects with rhinitis or asthma increased from 5.8% in non-
sensitized subjects (n ¼ 620) to 69.4% in polysensitized subjects (n ¼ 144). Sensitization was not
associated with any spirometric parameter considered in subjects with allergic rhinitis, asthma, or
neither disease.
Conclusion: Although allergen-speciﬁc IgE concentrations can contribute to the identiﬁcation of subjects at
higher risk for allergic rhinitis and asthma, sensitization to inhalant allergens is not related to impaired
spirometric lung parameters within the different allergic respiratory disease subgroups.
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Introduction
Allergic sensitization is a highly prevalent condition; 55.5% of
10- to 19-year-olds who participated in the Third National Health
and Nutrition Examination Survey in the United States were found
to be sensitized to at least 1 allergen.1 This prevalence is similar to
that reported for 14- to 17-year-old German adolescents who
participated in the German Health Interview and Examination
Survey for Children and Adolescents (KiGGS; 46.6%).2 It is well
known that sensitization to inhalant or food allergens is associated
with allergic respiratory diseases, such as asthma and rhinitis, in
adults3e6 and children.1,2,7e9
However, sensitization status alone does not independently
predict the presence or absence of allergic diseases or symp-
toms.10 Of children no older than 17 years included in the KiGGS
study, 47.6% did not report an atopic disease, although they were
found to be sensitized to at least 1 inhalant allergen. The KiGGS
study also showed that allergic rhinitis was signiﬁcantly more
prevalent in polysensitized children compared with those sensi-
tized to 1 or 2 allergens.2 Asthma in children is associated with a
decrease in lung function, but to what extent allergen-speciﬁc
sensitization might contribute to this decrease is less appa-
rent.11e13 The relation of current sensitization to lung function is
even less analyzed.
Previous studies that have analyzed associations between lung
function and allergen-speciﬁc sensitization in children or adoles-
cents have focused mainly on asthma characteristics and have
yielded controversial results.14e17 Choi et al14 observed a signiﬁ-
cant negative association between forced expiratory volume in 1
second (FEV1) and allergen-speciﬁc immunoglobulin E (IgE) con-
centrations against house dust mites in subjects with asthma.
Although this result was not observed in the analysis of Matsui
et al,16 this latter study did ﬁnd associations between the sum of
allergen-speciﬁc IgE concentrations to cockroach, cat, house dust
mite, and mouse and decreases in FEV1 percent predicted and the
ratio of FEV1 to forced vital capacity (FVC). In another study, the
FEV1/FVC ratio also was associated with the sum of 6 allergen-
speciﬁc IgE values, but only in girls.15 It is difﬁcult to fully
compare these studies because of the use of different statistical
methods, selection of allergens, and spirometric indices consid-
ered.14e17 Further, these previous studies have used quantitative
speciﬁc IgE concentrations to a variety of allergens or the sum of
the speciﬁc IgE values. The use of a quantitative approach suggests
that the allergen-speciﬁc IgE concentrations are normally
distributed and that a linear inverse association exists between
these concentrations and lung function parameters. However,
extremely high IgE concentrations have the potential to be highly
inﬂuential in the results of such an analysis, a problem that can
be circumvented by analyzing associations with mono- or poly-
sensitization status instead.
Nonetheless, these previous studies appear to generally suggest
a tendency toward an inverse association between allergen-speciﬁc
IgE concentrations and spirometric parameters, although associa-
tions did not reach statistical signiﬁcance in many cases and
differed across studies.14e17
The aim of the present study was to assess whether an
elevated allergen-speciﬁc IgE concentration to 1 or 2 inhalant
allergens is associated with a decrease in lung function assessed
by spirometry in 15-year-olds, and whether this possible asso-
ciation is stronger in polysensitized adolescents. The impact of
disease manifestation on a possible association between
allergen-speciﬁc sensitization and spirometric lung function
was considered for 3 groups of subjects: (1) those without
allergic respiratory disease, (2) those with rhinitis but without
asthma, and (3) those with asthma only or with concomitant
rhinitis.
Methods
Study Population
This analysis is based on data derived from the 15-year follow-
up of the German Infant Study on the Inﬂuence of Nutrition
Intervention plus Air Pollution and Genetics on Allergy Develop-
ment (GINIplus). A total of 5,991 healthy full-term white neonates
born from September 1995 through July 1998 inWesel andMunich
were initially included in this German population-based prospec-
tive birth cohort. The intervention group was comprised of
children with a familial predisposition toward allergy who were
randomized at birth to 1 of 3 hydrolyzed formulas. Participating
newborns with or without familial predisposition who did not
receive any intervention served as the control group. Detailed in-
clusion criteria and the primary study design have been described
previously.18,19
Follow-up studies with assessment of blood parameters were
conducted at 6, 10, and 15 years of age. The inclusion criteria for
the present analysis were a valid lung function test result and
available data on allergen-speciﬁc IgE serum concentrations. Of
the 3,198 subjects who participated in the 15-year follow-up,
1,719 subjects met the criteria and are included in this analysis.
The GINIplus study was approved by 2 local ethics committees:
the Medical Council of North-Rhine-Westphalia (Ärztekammer
Nordrhein, Düsseldorf) for the study center in Wesel and the
Bavarian General Medical Council (Bayerische Landes-
ärztekammer, München) for the study center in Munich. Written
informed consent was obtained from all participating families.
Lung Function Measurements
Spirometry was performed before and after bronchodilation
with salbutamol in a sitting position while subjects were wearing
nose clips. Flow-volume curves were obtained using a
pneumotachograph-type spirometer (EasyOne Worldspirometer,
ndd, Zurich, Switzerland), which was calibrated daily using a 3-L
calibration pump supplied by the manufacturer. All measure-
ments were in line with American Thoracic Society (ATS) and
European Respiratory Society (ERS) recommendations.20 To
obtain optimal ﬂow-volume curves, the subjects performed at
least 3 and up to 8 trials per test under the guidance of specif-
ically trained examiners who concurrently monitored the ﬂow-
volume and volume-time curves. Trial results were checked
according to the acceptability criteria of the ATS and ERS.20 In
subjects without contraindications, a bronchodilator response
with a b-agonist was performed, in line with ATS and ERS rec-
ommendations.20 A 200-mg (2  1 puff of 100 mg) salbutamol
dose was delivered into a spacer (Volumatic; GlaxoSmithKline,
London, United Kingdom) by a metered-dose inhaler. The subject
was subsequently asked to take 5 slow and deep breaths from the
spacer with a breath-hold time of 5 to 10 seconds to allow
optimal particle deposition. Fifteen minutes later, the second
spirometry test was performed. According to ATS and ERS stan-
dards, a positive bronchodilation response was deﬁned as an
increase of more than 200 mL and 12% in FEV1 or FVC after
bronchodilation.21
Indices of the best maneuver for FEV1, FVC, FEV1/FVC ratio, and
forced expiratory ﬂow at 25% to 75% of the FVC (FEF25%e75%)
were analyzed. In addition, standardized z-scores of FEV1, FVC,
FEV1/FVC, and FEF25%e75%were calculated using reference equations
for spirometry from the Global Lung Function Initiative (GLI).22 Of
the 1,887 subjects (Munich, n ¼ 951; Wesel, n ¼ 936) who partici-
pated in spirometry, 65 subjects (3.4%) did not meet the accept-
ability criteria before bronchodilation, resulting in 1,822 valid test
results.
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IgE Measurements and Assessment of Sensitization Pattern
The serum level of speciﬁc IgE was determined by the Immu-
noCAP Speciﬁc IgE system (Phadia GmbH, Freiburg, Germany)
according to the manufacturer’s instructions. Two screening tests
were performed. The ﬁrst covered an inhalant allergen mixture
(sx1), which included cat, dog, mugwort, birch, timothy, rye,
Dermatophagoides pteronyssinus, and Cladosporium herbarum. The
second covered food allergens (fx5; egg white, codﬁsh, cow milk,
wheat, peanut, and soybean). For the 2 screening tests, a value
higher than 0.35 kU/L was considered positive. Subjects with a
positive test result for at least 1 of the screening tests underwent
allergen-speciﬁc testing for all allergens contained in the respective
mixture. The allergen-speciﬁc IgE concentrations were grouped on
a scale from 0 to 6, with cutoff values at 0, 0.35, 0.70, 3.50, 17.50, 50,
and 100 kU/L. The IgE concentration and cutoff values for having a
positive test result inﬂuences the probability of having clinical
symptoms that increase with increasing values.23e25 In this study,
the 3.50-kU/L (ImmunoCAP class 3) cutoff value for allergen-
speciﬁc IgE concentrations was chosen to ensure a high probabil-
ity of capturing clinically relevant sensitized cases.
Of the 3,198 subjects who participated in the 15-year follow-up,
1,912 provided blood samples for IgE analysis, only 1 of which was
excluded owing to a failed test.
The allergen-speciﬁc IgE concentrations in the present cohort
were not normally distributed; data accumulated near 0 and the
ImmunoCAP test range limit of 100 kU/L (Fig 1). A normal distri-
bution could not be achieved after logarithmic transformation. As
such, the application of a quantitative approach (linear regression)
would have been inappropriate. Thus, a qualitative approach was
applied in which the allergen-speciﬁc IgE concentrations were
categorized into grades of sensitization. Figure 2 shows the
stratiﬁcation of subjects into 4 groups according to the measured
allergen-speciﬁc IgE serum concentrations. IgE group 1 was
comprised of subjects with negative screening tests (0.35 kU/L)
for inhalant allergens. Subjects with a positive screening test
(>0.35 kU/L) but no positive allergen-speciﬁc sensitization test
(>3.5 kU/L) to 1 of the inhalant allergens were included in IgE
group 2. Higher grades of sensitization were included in IgE groups
3 and 4: subjects with allergen-speciﬁc sensitization to 1 or 2
inhalant allergens (IgE group 3) and subjects with allergen-speciﬁc
sensitization to more than 2 inhalant allergens (IgE group 4). To
assess the potential relevance of additional sensitization to food
allergens, another 3-level stratiﬁcation was considered: non-
sensitized subjects (IgE group 1), highly sensitized subjects to
inhalant allergens (IgE groups 3 and 4) but without food sensiti-
zation, and those in IgE groups 3 and 4with additional sensitization
to food allergens (ie, IgE concentration >0.35 kU/L in screening test
for food allergens).
Deﬁnition of Phenotypes
The presence of allergic diseases throughout childhood was
assessed using parent-completed written questionnaires during
the follow-ups of the study. Ultimately, yearly parental reports of
Figure 1. Z-scores of forced expiration volume in 1 second (FEV1) and allergen-speciﬁc IgE concentrations of subjects allergic to Dermatophagoides pteronyssinus (n¼ 306) and
timothy grass (n ¼ 360) stratiﬁed by allergic respiratory lung disease. Z-score FEV122 was adjusted for sex, ethnicity, age, and height.
Figure 2. Group stratiﬁcation according to speciﬁc IgE sensitization to inhalant
allergens.
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physician diagnoses of allergic diseases were available. Information
on current allergic symptoms was derived from the questionnaire
from the last follow-up (at 15 years of age), which asked for allergic
symptoms in the past 12 months.
Asthma was deﬁned based on the deﬁnition of the Global
Allergy and Asthma European Network (GA2LEN).26 Subjects were
considered as currently having asthma if they responded positively
to at least 2 of the 3 following questions: (1) Has a physician
diagnosed asthma in your child? This question was asked sepa-
rately for each year at 1, 2, 3, 4, 6, 10, and 15 years of age and
combined into an “asthma ever” variable. (2) Has your child taken
asthma medication during the past 12 months? (3) Has your child
had wheezing or whistling in the chest in the past 12 months?
The International Study of Asthma and Allergies in Childhood
(ISAAC) core questions served as the basis for the deﬁnition of
rhinitis.27 A child was considered as having current allergic rhinitis
if a positive answer to 1 of the following questions was provided:
(1) Has a physician diagnosed hay fever in your child at 11 to 15
years of age? (2) Has a physician diagnosed whole-year allergic
rhinitis in your child at 11 to 15 years of age? In a sensitivity
analysis, the ISAAC deﬁnition for current allergic rhinoconjuncti-
vitis symptoms was applied, which requires 2 positive answers to
the following 2 questions: (1) In the past 12 months, has your child
had a clogged or itchy nose when he or she did not have a cold? (2)
In the past 12 months, has your child had a clogged or itchy nose
accompanied by watery eyes?28
All subjects whowere not identiﬁed as having asthma or allergic
rhinitis and who did not have a positive bronchodilation response
during lung function testing (n¼ 29, 3.2%) were coded as being free
of allergic respiratory diseases.
In summary, the population was subdivided into 3 phenotypes
according to allergic respiratory disease: (1) without allergic
diseases (designated as apparently “lung healthy”), (2) with allergic
rhinitis (referred to as rhinitis in text) but no asthma, and (3) with
asthma only or with concomitant rhinitis. Missing data for ques-
tions that were relevant for phenotype group classiﬁcation led to
exclusion. Ultimately, 1,128 subjects had complete and available
information on allergic respiratory diseases.
Statistical Analysis
Medians and corresponding percentiles (25th, 75th) or per-
centages (%, n/N) were used to describe subject characteristics. The
Kruskal-Wallis test was used to analyze differences in lung function
among phenotypes (healthy, rhinitis, and asthma) and to assess
variances in spirometric parameters according to IgE sensitization
group (Fig 2) within each phenotype category. Group comparisons
were performed after stratiﬁcation for sex. If the Kruskal-Wallis test
showed a statistically signiﬁcant result, then the Wilcoxon rank-
sum test, adjusting for multiple testing through the Holm correc-
tion, was applied. Adjusted linear regression models were applied
to analyze associations between sensitization to inhalant allergens
according to the IgE groups (Fig 2) and lung function parameters.
The main model was adjusted for sex (if not already stratiﬁed),
study center (Munich vs Wesel), study group (control vs interven-
tion), and age, weight, and height assessed on the day of spiro-
metric examination (model 1). Model 2 was further adjusted for
parental education level, exclusive breastfeeding, maternal smok-
ing during pregnancy, and intake of rhinitis medication in the past
12 months. Regression models for standardized GLI z-scores,22
which are already adjusted for sex, ethnicity, age, and height,
were adjusted only for additional variables of models 1 and 2.
Regression analyses in subjects with asthma were adjusted for
rhinitis status but not for intake of rhinitis medication. Parental
educationwas categorized as high (>10 years), middle (10 years), or
low (<10 years) according to the highest education level of the
mother or father. Breastfeeding was classiﬁed as longer than 4
months, 1 to 4 months, or no exclusive breastfeeding.
Group comparisons and regression models were performed
for the lung function parameters FEV1, FVC, FEV1/FVC ratio, and
FEF25%e75% and the corresponding GLI z-scores. A P value less than
.05 was considered statistically signiﬁcant. All analyses were per-
formed with the statistical software package R 3.1.0.29
Results
The study population was comprised of 1,719 subjects with a
median age of 15.2 years (Table 1). Boys accounted for 48.6% of
subjects. The prevalence of rhinitis was 21.1% (n ¼ 347) and that of
asthma was 10.1% (n ¼ 119). The prevalences were higher in boys
comparedwith girls for the 2 diseases (22.9% vs 19.3% for rhinitis and
11.9% vs 8.5% for asthma, respectively). Subjects with rhinitis but not
asthma accounted for 12.6% (n ¼ 145). Of the 119 subjects with
asthma, 60.5% concurrently had rhinitis. Although 46.4% (n¼ 798) of
subjects had a positive screening test to inhalant allergens, only 11.9%
(n ¼ 204) were sensitized to food allergens.
Multiple group comparisons of lung function parameters among
the respiratory phenotypes showed signiﬁcantly decreased lung
function in boyswith asthma comparedwith healthy boys and boys
with rhinitis, except for z-score FVC, between the healthy and
asthma groups (P ¼ .31) and between the rhinitis and asthma
groups (P > .24 for absolute and z-score FVC values; Table 2). The
healthy and rhinitis groups did not differ in lung function. A similar
tendency was observed in girls, but associations failed to reach
statistical signiﬁcance.
Sensitization According to Phenotypes
In total, data from 1,128 subjects were analyzed, and most were
free of allergic respiratory disease (76.6%). Figure 3 shows the dis-
tribution of different grades of sensitization to inhalant allergens by
Table 1
Characteristics of study population
Median (25th, 75th percentile) or % (n/N)
Boys (n ¼ 836) Girls (n ¼ 883) Total (n ¼ 1,719)
Age (y) 15.2 (15.1, 15.4) 15.2 (15.1, 15.4) 15.2 (15.1, 15.4)
Weight (kg) 64 (57, 73) 58 (53, 63) 60 (54, 67)
Height (cm) 177 (172, 182) 167 (163, 171) 171 (166, 177)
Study center (%)
Munich 50.72 (424/836) 50.40 (445/883) 50.55 (869/1,719)
Wesel 49.28 (412/836) 49.60 (438/883) 49.45 (850/1,719)
Study group (%)
Control 48.68 (407/836) 49.72 (439/883) 49.21 (846/1,719)
Intervention 51.32 (429/836) 50.28 (444/883) 50.79 (873/1,719)
Parental education (%)
Low 8.01 (67/836) 6.47 (57/881) 7.22 (124/1,717)
Medium 30.14 (252/836) 26.22 (231/881) 28.13 (483/1,717)
High 61.84 (517/836) 67.31 (593/881) 64.65 (1,110/1,717)
Exclusive
breastfeeding (%)
No 24.30 (190/782) 23.23 (194/835) 23.75 (384/1,617)
1e4 mo 28.64 (224/782) 28.14 (235/835) 28.39 (459/1,617)
>4 mo 47.06 (368/782) 48.62 (406/835) 47.87 (774/1,617)
Smoking during
pregnancy, yes (%)
12.15 (92/757) 12.81 (99/773) 12.48 (191/1,530)
Rhinitis (%) 22.91 (184/803) 19.29 (163/845) 21.06 (347/1,648)
Rhinitis without
asthma (%)
13.70 (74/540) 11.68 (71/608) 12.63 (145/1,148)
Asthma (%) 11.89 (66/555) 8.45 (53/627) 10.07 (119/1,182)
Positive
bronchodilation
(%)
5.67 (42/741) 3.36 (27/804) 4.47 (69/1,545)
Speciﬁc IgE screening
test level
0.35 kU/L (%)
Inhalant allergens 52.87 (442/836) 40.32 (356/883) 46.42 (798/1,719)
Food allergens 12.92 (108/836) 10.87 (96/883) 11.87 (204/1,719)
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allergic respiratory disease status: (1) no sensitization, (2) a posi-
tive screening test for inhalant allergens only, and a positive
allergen-speciﬁc sensitization test to (3) at least 1 inhalant allergen
(>3.5 kU/L) and (4) at least 3 inhalant allergens (Fig 2). With
increasing sensitization grade, the percentage of subjects with
rhinitis or asthma increased from 5.8% in IgE group 1 (total n¼ 620)
to 69.4% in IgE group 4 (total n ¼ 144). A positive screening test for
inhalant allergens (IgE group 2, 3, or 4) was observed in 32.4% of
subjects without respiratory lung disease (n ¼ 864), in 93.8% of
subjects with rhinitis (n ¼ 145), and in 77.3% of subjects with
asthma (n ¼ 119). Of those with an increased allergen-speciﬁc IgE
concentration (>3.5 kU/L) to at least 1 inhalant allergen, 55.4% of
boys and 52.2% of girls in group 3 and 31.7% of boys and 29.0% of
girls in group 4 were classiﬁed as having no asthma or rhinitis.
Comparison of Spirometric Parameters in IgE Groups within
Phenotypes
In healthy subjects, analyses comparing all IgE groups with one
another using Kruskal-Wallis tests were not signiﬁcant for any lung
function parameter for boys or girls. Applying linear regression
model 1 (adjusted for age, height, weight, study group, and study
center) and model 2 (also adjusted for parental education level,
breastfeeding, maternal smoking during pregnancy, and intake of
rhinitis medication; data not shown) did not show a signiﬁcant
difference in lung function between IgE group 1 and groups 2, 3,
and 4 for healthy girls (Table 3). For healthy boys, only a signiﬁcant
difference between IgE groups 1 and 2 was observed for FEV1, GLI
z-score FEV1, and GLI z-score FVC whereas no differences were
found for IgE groups 3 and 4 compared with IgE group 1 (Table 3).
Owing to the small number of subjects with rhinitis in IgE
groups 1 and 2 (<10.4%), only IgE groups 3 and 4 were included in
group comparisons and linear regression models (Table 4). Never-
theless, increasing sensitization grade was not associated with any
of the spirometric parameters in those with rhinitis. Sensitivity
analyses applying the ISAAC deﬁnition of current allergic rhino-
conjunctivitis symptoms did not yield different results. The same
null ﬁndings were observed in subjects with asthma when lung
function parameters in subjects without any or a low sensitization
(IgE groups 1 and 2) were compared with those more highly
sensitized (IgE groups 3 and 4; Table 4). Sensitization to food
allergens also was not associated with lung function when
analyzing subjects without sensitization (IgE group 1), those with
high allergen-speciﬁc sensitization to inhalant allergens but no
food sensitization (IgE groups 3 and 4), and those with concurrent
sensitization to food allergens (IgE group 3 and 4 plus positive
screening test for food allergens; data not shown) stratiﬁed by
allergic respiratory disease.
Discussion
The present results did not show an association between lung
function assessed by spirometry and increasing sensitization grade
in healthy individuals or those with rhinitis or asthma. Although no
associations were found for polysensitized healthy boys, low
sensitized healthy boys had higher values of FEV1, GLI z-score FEV1,
and GLI z-score FVC compared with non-sensitized healthy boys.
However, conﬁdence intervals were wide and results were not
signiﬁcant for the FEV1/FVC ratio. Thus, this result should be
interpreted with caution and might not be clinically relevant.
Previous studies that have assessed associations between lung
function and allergen-speciﬁc IgE in serum in youth are highly
variable for the results and methods applied.14e17 With respect to
the methods, these studies differ in which lung function parame-
ters and allergens were considered and how the calculation of
the allergen-speciﬁc IgE was conducted (analyzing individual
allergen-speciﬁc IgE concentrations or summing all testedTa
b
le
2
Lu
n
g
fu
n
ct
io
n
p
ar
am
et
er
s
st
ra
ti
ﬁ
ed
by
al
le
rg
ic
re
sp
ir
at
or
y
d
is
ea
se
Ph
en
ot
yp
e
B
oy
s,
m
ed
ia
n
(2
5t
h
,7
5t
h
p
er
ce
n
ti
le
s)
G
ir
ls
,m
ed
ia
n
(2
5t
h
,7
5t
h
p
er
ce
n
ti
le
s)
To
ta
l,
m
ed
ia
n
(2
5t
h
,7
5t
h
p
er
ce
n
ti
le
s)
H
ea
lt
h
y
R
h
in
it
is
A
st
h
m
a
H
ea
lt
h
y
R
h
in
it
is
A
st
h
m
a
H
ea
lt
h
y
R
h
in
it
is
A
st
h
m
a
To
ta
l
(N
)
38
7
74
66
47
7
71
53
86
4
14
5
11
9
FE
V
1
(L
)
3.
90
(3
.4
7,
4.
29
)
3.
84
(3
.5
4,
4.
19
)
3.
55
b
,c
(3
.0
9,
3.
94
)
3.
19
(2
.9
3,
3.
44
)
3.
15
(2
.9
2,
3.
50
)
3.
12
(2
.8
5,
3.
47
)
3.
41
(3
.0
6,
3.
90
)
3.
53
(3
.1
,3
.9
3)
3.
33
(2
.8
7,
3.
72
)
FV
C
(L
)
4.
57
(4
.0
4,
5.
02
)
4.
53
(3
.9
8,
4.
76
)
4.
32
b
(3
.7
4,
4.
77
)
3.
58
(3
.2
7,
3.
92
)
3.
56
(3
.2
6,
3.
95
)
3.
68
(3
.2
8,
3.
96
)
3.
91
(3
.4
3,
4.
55
)
3.
99
(3
.5
,4
.5
6)
3.
93
(3
.5
,4
.4
3)
FE
V
1
/F
V
C
ra
ti
o
0.
86
(0
.8
2,
0.
90
)
0.
87
(0
.8
2,
0.
90
)
0.
82
b
,c
(0
.7
7,
0.
88
)
0.
89
(0
.8
5,
0.
93
)
0.
89
(0
.8
5,
0.
92
)
0.
86
(0
.8
2,
0.
93
)
0.
88
(0
.8
3,
0.
92
)
0.
87
(0
.8
3,
0.
92
)
0.
85
(0
.7
9,
0.
91
)
FE
F 2
5
%
e
7
5
%
(L
/s
)
4.
15
(3
.4
6,
4.
85
)
4.
25
(3
.5
7,
4.
60
)
3.
30
b
,c
(2
.6
5,
4.
23
)
3.
72
(3
.2
2,
4.
31
)
3.
69
(3
.1
5,
4.
32
)
3.
53
(2
.8
7,
4.
12
)
3.
90
(3
.3
1,
4.
56
)
4.
04
(3
.3
9,
4.
48
)
3.
40
(2
.7
8,
4.
16
)
Z-
sc
or
ea
FE
V
1
0
.5
6
(
1.
1,
0.
04
)
0
.3
3
(
0.
87
,0
.0
3)
1
.0
5b
,c
(
1.
73
,
0.
39
)
0
.5
7
(
1.
15
,0
.0
4)
0
.4
7
(
1.
18
,0
.1
2)
0
.8
7
(
1.
25
,
0.
26
)
0
.5
7
(
1.
14
,0
.0
4)
0
.4
2
(
1.
07
,0
.0
7)
0
.9
5
(
1.
51
,
0.
35
)
Z-
sc
or
ea
FV
C
0
.6
4
(
1.
17
,
0.
01
)
0
.5
7
(
1.
12
,0
.0
8)
0
.7
9
(
1.
44
,
0.
22
)
0
.5
3
(
1.
1,
0.
1)
0
.5
4
(
0.
99
,0
.1
5)
0
.5
4
(
0.
87
,
0.
09
)
0
.5
6
(
1.
12
,0
.0
6)
0
.5
6
(
1.
06
,0
.1
)
0
.6
1
(
1.
32
,
0.
14
)
Z-
sc
or
ea
FE
V
1
/F
V
C
ra
ti
o
0
.0
3
(
0.
62
,0
.6
4)
0.
04
(
0.
64
,0
.7
1)
0
.7
4b
,c
(
1.
43
,0
.2
8)
0
.0
3
(
0.
71
,0
.7
4)
0
.0
2
(
0.
71
,0
.5
6)
0
.4
1
(
1.
17
,0
.6
6)
0
.0
3
(
0.
67
,0
.6
9)
0.
03
(
0.
71
,0
.5
7)
0
.5
2
(
1.
25
,0
.4
8)
Z-
sc
or
ea
FE
F 2
5
%
e
7
5
%
0
.3
6
(
1.
07
,0
.2
5)
0
.3
1
(
0.
88
,0
.1
9)
1
.2
6b
,c
(
1.
82
,
0.
22
)
0
.3
4
(
0.
92
,0
.4
0)
0
.3
4
(
0.
95
,0
.3
5)
0
.6
0
(
1.
40
,0
.0
2)
0
.3
5
(
0.
99
,0
.3
3)
0
.3
4
(
0.
91
,0
.3
0)
0
.8
6
(
1.
62
,
0.
09
)
A
bb
re
vi
at
io
n
s:
FE
F 2
5
%
e
7
5
%
,f
or
ce
d
ex
p
ir
at
or
y
ﬂ
ow
at
25
%
to
75
%
of
fo
rc
ed
vi
ta
l
ca
p
ac
it
y;
FE
V
1
,f
or
ce
d
ex
p
ir
at
or
y
vo
lu
m
e
in
1
se
co
n
d
;
FV
C
,f
or
ce
d
vi
ta
l
ca
p
ac
it
y.
a Z
-s
co
re
s
fo
r
lu
n
g
fu
n
ct
io
n
p
ar
am
et
er
s
w
er
e
ad
ju
st
ed
fo
r
se
x,
et
h
n
ic
it
y,
ag
e,
an
d
h
ei
gh
t
ac
co
rd
in
g
to
th
e
G
lo
ba
l
Lu
n
g
Fu
n
ct
io
n
In
it
ia
ti
ve
.2
2
b
Si
gn
iﬁ
ca
n
t
d
if
fe
re
n
ce
by
th
e
W
ilc
ox
on
ra
n
k-
su
m
te
st
st
ra
ti
ﬁ
ed
by
se
x
be
tw
ee
n
h
ea
lt
h
y
an
d
as
th
m
at
ic
p
h
en
ot
yp
es
.
c S
ig
n
iﬁ
ca
n
t
d
if
fe
re
n
ce
by
th
e
W
ilc
ox
on
ra
n
k-
su
m
te
st
st
ra
ti
ﬁ
ed
by
se
x
be
tw
ee
n
rh
in
it
is
an
d
as
th
m
at
ic
p
h
en
ot
yp
es
.
A. Luzak et al. / Ann Allergy Asthma Immunol 115 (2015) 183e190 187
concentrations).14e17 The number of investigated allergens in
studies addressing a similar research question ranges from 1 (house
dust mites17) to 6 (Dermatophagoides farinae, Alternaria alternata,
dog, cat, timothy grass, and ragweed15). It also is debatable whether
it is more appropriate to use the quantitatively measured speciﬁc
IgE concentrations as the predictor or whether these concentra-
tions should be categorized into groups to assess the probability of
clinical symptoms. The present analytical strategy took high
speciﬁc IgE values and polysensitization into account by dividing all
inhalant allergen-speciﬁc IgE concentrations (cutoff 3.5 kU/L) and
Figure 3. Distribution and prevalence of sensitization. Numbers within columns represent the number of subjects per phenotype per IgE group (Fig 2). F, female; M, male;
spec. IgE, allergen-speciﬁc immunoglobulin E.
Table 3
Associations between lung function and sensitization group in healthy subjectsdResults of linear regression analysisa
Comparison IgE group Healthy boys, IgE group 1 vs 2, 3, 4 Healthy girls, IgE group 1 vs 2, 3, 4
b 95% CI P value b 95% CI P value
FEV1 2 0.18 0.04 to 0.31 .01 0.02 0.12 to 0.08 .67
3 0.04 0.07 to 0.15 .50 0.02 0.11 to 0.07 .66
4 0.00 0.18 to 0.17 .97 0.01 0.15 to 0.17 .87
FVC 2 0.14 0.01 to 0.29 .06 0.06 0.17 to 0.05 .27
3 0.00 0.12 to 0.12 .99 0.08 0.18 to 0.03 .15
4 0.02 0.21 to 0.17 .84 0.03 0.22 to 0.15 .70
FEV1/FVC ratio 2 0.01 0.01 to 0.03 .23 0.01 0.01 to 0.03 .29
3 0.01 0.01 to 0.02 .22 0.01 0.00 to 0.03 .10
4 0.00 0.02 to 0.03 .80 0.01 0.02 to 0.04 .45
FEF25%e75% 2 0.26 0.03 to 0.54 .08 0.06 0.17 to 0.28 .63
3 0.15 0.09 to 0.38 .22 0.09 0.12 to 0.30 .40
4 0.09 0.28 to 0.46 .64 0.24 0.12 to 0.61 .19
Z-scoreb FEV1 2 0.33 0.06 to 0.59 .01 0.01 0.26 to 0.23 .91
3 0.09 0.13 to 0.31 .42 0.03 0.27 to 0.20 .78
4 0.00 0.35 to 0.34 .99 0.01 0.40 to 0.41 .97
Z-scoreb FVC 2 0.27 0.01 to 0.53 .04 0.09 0.33 to 0.16 .48
3 0.01 0.20 to 0.23 .91 0.15 0.38 to 0.08 .21
4 0.02 0.36 to 0.32 .90 0.09 0.49 to 0.31 .65
Z-scoreb FEV1/FVC ratio 2 0.09 0.20 to 0.39 .55 0.13 0.15 to 0.42 .36
3 0.13 0.12 to 0.38 .30 0.19 0.08 to 0.46 .17
4 0.04 0.34 to 0.43 .82 0.22 0.24 to 0.68 .35
Z-scoreb FEF25%e75% 2 0.23 0.06 to 0.51 .12 0.08 0.19 to 0.35 .55
3 0.17 0.07 to 0.40 .17 0.13 0.13 to 0.38 .33
4 0.09 0.28 to 0.47 .62 0.26 0.18 to 0.70 .24
Abbreviations: CI, conﬁdence interval; FEF25%e75%, forced expiratory ﬂow at 25% to 75% of forced vital capacity; FEV1, forced expiratory volume in 1 second; FVC, forced vital
capacity.
aResults of linear regressionmodels in healthy subjects stratiﬁed by sex and adjusted for study center, study group, age, weight, height, and speciﬁc IgE that was categorized as
IgE group 1 (reference category) and IgE groups 2 to 4. The IgE groups are deﬁned in Figure 2. A change of b by 0.1 in FEV1 or FVC indicates a lung volume change of 100mL (not
applicable to b of z-scores).
bZ-scores for lung function parameters were adjusted for sex, ethnicity, age, and height according to the Global Lung Function Initiative.22
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summing up all positive concentrations (Figure 2). This high cutoff
value (3.5 kU/L) was chosen to allow subjects with low and high
probabilities of having symptoms to be distinguished. This
approach led to amore differentiated picture of sensitization to 1 or
2 allergens vs polysensitization without emphasizing extremely
high speciﬁc IgE values in the analysis. These high speciﬁc IgE
values are generally limited owing to the ImmunoCAP test quan-
titative range limit of 100 kU/L.
Thus far, results of other analyses have suggested a tendency
toward lower lung function in those highly sensitized. Rajendra
et al15 reported a negative correlation between the FEV1/FVC ratio
and the sum of allergen-speciﬁc IgE concentrations to 6 inhalant
allergens in 18- to 20-year-old womenwith current asthma (n¼ 32,
Pearson correlation coefﬁcient [r] ¼ 0.42, P ¼ .017). Matsui et al,16
who performed partial Pearson correlations for lung function in
12- to 20-year-old subjects with asthma and quantitative speciﬁc IgE
concentrations (log10), reported an inverse relation between FEV1
percent predicted and the FEV1/FVC ratio and the sum of speciﬁc IgE
concentrations of cockroach, dust mites, cat, and mouse.
House dust mite as a single allergen has been commonly
analyzed in previous studies.14,16,17 Correlation analyses in 10-year-
old children with asthma between house dust mite-speciﬁc IgE
(D pteronyssinus and D farinae) and FEV1 and FEF25%e75% percent
predicted were found to be signiﬁcant (FEV1: r ¼ 0.37 and 0.44,
respectively, P < .05) in a study by Choi et al.14 In contrast, no as-
sociation was reported for FEV1 by Silvestri et al17 (no P value
given, FEF25%e75% not investigated). In line with the ﬁnding
reported by Silvestri et al is the study by Matsui et al16 who found
no partial Pearson correlations between FEV1 percent predicted
and quantitative speciﬁc IgE (log10) for house dust mites (D
pteronyssinus andD farinae) after adjusting for income, study group,
sex, age, and race in 12- to 20-year-olds with asthma. For compa-
rability with these studies, the present study applied quantitative
correlation analysis and adjusted linear regression modeling
(model 1) to logarithmically transformed speciﬁc IgE values of D
pteronyssinus in subjects with asthma in this cohort. These analyses
showed a slight negative correlation with the GLI z-score FEV1
(r ¼ 0.18, P ¼ .08) and regression coefﬁcient (b ¼ 0.04, P ¼ .31).
However, applying quantitative analyses to the present data was
not appropriate, because the IgE concentrations were not normally
distributed (Fig 1).
Owing to the various statistical approaches used and the
different selections of studied allergens included in previous
studies, it is challenging to provide a general conclusion regarding
a potential association between allergen-speciﬁc sensitization and
lung function. The authors did not observe an association between
current sensitization to inhalant allergens and absolute spiro-
metric parameters or standardized GLI z-scores for spirometric
indices in their analysis using linear regression models adjusted
for potential confounders. Nevertheless, the positive ﬁndings
from others who have applied correlation analyses need to be
acknowledged.
The present results are limited to the selected study population.
To avoid misclassiﬁcation, only subjects who provided complete
phenotype information were included in the regression analyses.
High compliance to lung function measurement and in completing
questionnaires is likely to have led to some selection bias. The
classiﬁcation of subjects into phenotype groups was performed
using questionnaire-based information that was not veriﬁed by an
examination from a physician. Of subjects assigned to the rhinitis
subgroup, only 9 of 145 were not sensitized to the tested inhalant
allergens. For this reason, a comparison between polysensitized
subjects and non-sensitized subjects was not possible.
Despite these limitations, this study has several strengths. Data
on 8 common inhalant allergens and various spirometric parame-
ters, which cover parameters indicative of airway narrowing (FEV1,
FEV1/FVC ratio), lung volume and lung size (FVC), and ﬂow rates
(FEF25%e75%), were available. When summing the quantitative
values of speciﬁc IgE concentrations, high values for 1 allergen can
strongly inﬂuence the summed result. Higher allergen-speciﬁc IgE
values lead to a higher probability of having symptoms, but clear
cutoffs are not well deﬁned.23,30,31 The present classiﬁcation of
sensitization was independent of the exact quantitative IgE values.
For example, subjects in IgE group 4 were known to have at least 3
allergens with allergen-speciﬁc IgE levels higher than 3.5 kU/L and
therefore could conﬁdently be identiﬁed as polysensitized without
focusing entirely on exact values or allergen combinations.
Using this qualitative approach, the authors did not identify an
association between sensitization to inhalant allergens and lung
function parameters in their cohort. This study population was
nevertheless comparable to other epidemiologic respiratory
studies in lung function and sensitization pattern.11,12,26,32 Boys had
Table 4
Associations between lung function and sensitization group in subjects with rhinitis and asthmadResults of linear regression analysis
Comparison of IgE group RhinitisdIgE groups 3 vs 4a IgE group AsthmadIgE groups 1 þ 2 vs 3, 4b
b 95% CI P value b 95% CI P value
FEV1 3 0.09 0.12 to 0.31 .39
4 0.03 0.10 to 0.17 .63 4 0.09 0.33 to 0.16 .48
FVC 3 0.22 0.01 to 0.42 .04
4 0.03 0.13 to 0.19 .73 4 0.11 0.12 to 0.34 .34
FEV1/FVC ratio 3 0.03 0.07 to 0.02 .29
4 0.00 0.02 to 0.02 .67 4 0.05 0.10 to 0.01 .08
FEF25%e75% 3 0.09 0.64 to 0.46 .75
4 0.11 0.17 to 0.38 .44 4 0.41 1.03 to 0.22 .20
Z-scorec FEV1 3 0.04 0.46 to 0.54 .88
4 0.14 0.16 to 0.44 .35 4 0.40 0.97 to 0.16 .16
Z-scorec FVC 3 0.24 0.20 to 0.68 .28
4 0.18 0.15 to 0.51 .29 4 0.05 0.54 to 0.44 .85
Z-scorec FEV1/FVC ratio 3 0.38 1.05 to 0.29 .27
4 0.03 0.35 to 0.29 .86 4 0.67 1.43 to 0.09 .08
Z-scorec FEF25%e75% 3 0.25 0.88 to 0.39 .44
4 0.13 0.16 to 0.43 .38 4 0.66 1.37 to 0.05 .07
Abbreviations: CI, conﬁdence interval; FEF25%e75%, forced expiratory ﬂow at 25% to 75% of forced vital capacity; FEV1, forced expiratory volume in 1 second; FVC, forced vital
capacity.
aResults of linear regression models were adjusted for sex, study center, study group, age, weight, and height (reference category, IgE group 3).
bResults of linear regression models were adjusted for sex, study center, study group, age, weight, height, and having concurrent rhinitis (reference category, combined IgE
groups 1 and 2). The IgE groups are deﬁned in Figure 2.
cZ-scores for lung function parameters were adjusted for sex, ethnicity, age, and height according to the Global Lung Function Initiative.22
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higher spirometric parameters than girls, were more often sensi-
tized, and had a higher prevalence of rhinitis and asthma. Lung
function parameters in subjects with asthmawere lower compared
with those in healthy subjects.
In conclusion, neither sensitization to 1 or 2 inhalant allergens
nor polysensitization showed a relation to lung function in appar-
ently lung-healthy adolescents, those with asthma, or those with
rhinitis. These results nevertheless conﬁrm that polysensitization
contributes to the identiﬁcation of subjects at higher risk for
rhinitis and asthma.
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Lung development begins in early gestational age and
continues until early childhood, while lung growth
continues until 20–25 years, at which point a plateau in
lung function is reached [1, 2]. Several factors have the
potential to affect lung function during this process
[1–4]. Adverse events in early life may influence lung
function trajectories and lead to higher susceptibility
to lung diseases, such as asthma or chronic obstructive
lung disease [1, 5]. Recently published results among chil-
dren with asthma underline that the impairment of lung
function in childhood is a predictor of reduced lung-
function growth and abnormal decline over time [4].
There is an increasing focus on the influence of lung func-
tion deviations in early childhood on later life respiratory
morbidity [1, 4–7]. Numerous epidemiological studies
have investigated factors that might influence lung func-
tion or that are associated with allergic respiratory
diseases at different stages in life (Fig. 1). However, previ-
ous studies have mainly investigated only one factor or a
few factors at specific periods of life, and most are focused
on early life events [7–27]. In reality, it is likely that a com-
plex framework of several factors determines an individ-
ual’s lung function throughout life [1, 2, 5]. Therefore, an
approach that investigates the simultaneous effects of
several factors might have the potential to identify which
factors may be most influential at a certain stage of life. To
date, only one epidemiological study reported on the
effects of several factors (including early life events, socio-
economic status and environmental factors) on spirometricFig. 1 Covariates investigated for association with lung function in 15-yearlung function between 6 and 16 years of age in Tunisian
children [28]. Besides well-established factors (height,
weight, sex and age), this study found that type of
heating had the strongest effect on lung function in
healthy Tunisian children.
In the current study, we used two large, well charac-
terized, longitudinal German birth cohort studies to
investigate associations between numerous early life
events and current environmental and lifestyle factors,
as well as allergic diseases, with lung function assessed
by spirometry in adolescents aged 15 years. Our main
purpose was to identify factors associated with spiromet-
ric measures of central and peripheral airway function in
adolescents and further, to examine the relative import-
ance of early life events compared to current environ-
mental and lifestyle factors (Fig. 1).
Methods
Study population
We used data from two prospective German birth
cohorts with each 15 years of follow-up; the German
Infant study on the influence of Nutrition Intervention
plus air pollution and genetics on allergy development
(GINIplus) [29] and the study on Life-style related
factors on the development of the Immune System and
Allergies in East and West Germany plus the influence
of traffic emissions and genetics (LISAplus) [30]. The
inclusion criteria were the same for both cohorts,
German families with a full-term newborn and birth
weight of at least 2500 g were considered as eligible.old adolescents (definitions presented in Table 1)
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1995 and 1998 in the study centers Munich and Wesel
and surrounding areas. Parents who’s newborns had at
least one first degree family member with an atopic dis-
ease were asked to participate in the intervention study
arm, which investigated the effect of three different
hydrolyzed formulas on allergy development (N = 2252).
All others were asked to participate in the observation
study arm (N = 3739). At the 15-year follow-up, 1887
subjects participated in lung function measurements
(50.4% were from the intervention arm).
In LISAplus, 3094 full-term children were recruited
between 1997 and 1999 in the area of four German
cities: Munich, Wesel, Leipzig and Bad Honnef. Given
that air pollution concentrations (an important environ-
mental factor considered in the analysis) were only avail-
able for Munich and Wesel in GINIplus, the population
of LISAplus was restricted to these study areas, compris-
ing 1812 subjects, of which 563 participated in lung
function measurements at 15 years.
In GINIplus, parent-completed questionnaires were
collected at birth, yearly from 1 to 4, and at 6, 10 and
15 years of age. In LISAplus, follow-ups were at birth,
0.5, 1, 1.5, 2, 4, 6, 10 and 15 years of age. The 15-year
follow-up for both studies included a self-report ques-
tionnaire for the adolescents, lung function testing and
blood sample collection. Further information about the
cohorts’ design is described elsewhere [29–31]. Data
from the LISAplus and GINIplus birth cohorts were
pooled and are presented for the complete study popula-
tion considering study group and study center as poten-
tial confounders in the analyses.
Lung function measurements
Lung function measurements by spirometry were
performed in line with ATS/ERS recommendations [32].
Participants were asked not to change their asthma
medication prior to lung function testing. Among the
analyzed participants, 83 had asthma. Of these, 89.2%
reported asthma medication in the past 12 months. On
the day of lung function testing, 7.2% reported the intake
of short-acting beta agonists, 9.6% reported the intake of
inhaled corticosteroids, and 18.1% reported the intake
of both inhaled corticosteroids and beta adrenergic
agonists, of which most (86.7%) consisted of long-
acting beta agonists.
For the performance of spirometry assessments, the
technicians were equally trained and the equipment used
was the same in both study centers. Flow-volume curves
were obtained using a pneumotachograph-type spirometer
(EasyOne Worldspirometer, ndd, Zurich, Switzerland).
Subjects performed at least three and up to eight trials per
test. Trial results were visually inspected according to
ATS/ERS acceptability criteria [32]. Indices of the bestmanoeuvre, defined as the test with the largest sum of
the forced expiratory volume in one second (FEV1) and
the forced vital capacity (FVC), were used in analyses.
Further spirometric parameters obtained included the
peak expiratory flow (PEF), the forced expiratory flow
rates at 25% (FEF25), 50% (FEF50) and 75% (FEF75) of
exhaled FVC and the mean flow rate between 25% and
75% of FVC (FEF25–75).
These parameters could be viewed as indicative of
different lung regions or functions [33, 34]: lung volume
(FVC), airways and lung volume (FEV1), airflow limita-
tion (FEV1/FVC), flow rates for the larger conducting
(PEF, FEF25) and peripheral airways (FEF50, FEF75 and
FEF25–75). We focused our analyses and results primary
on four spirometric parameters (FVC, FEV1, FEV1/FVC
and FEF25–75) that represent lung volume and airway
function. We also report if the associations for the
primary parameters are supported by the results of the
additional secondary parameters, which represent flow
rates (PEF, FEF25, FEF50, FEF75). Results for the secondary
parameters are presented in the additional file only.
Definition of covariates
We selected factors for investigation based on a short
review of the literature, including former GINIplus and
LISAplus publications [8, 9, 35, 36], and after considering
the number of participants with available data in our
cohorts. An overview of investigated covariates is pre-
sented in Fig. 1. A detailed description was provided in
Table 1. Investigated covariates were divided in early life
events (e.g. parental atopy, maternal smoking during preg-
nancy, season of birth, birth weight), current environmen-
tal and lifestyle factors that were assessed at the 15-year
follow-up (e.g. air pollution, indoor second-hand smoke
exposure, BMI), and allergic diseases (e.g. asthma,
rhinitis). Besides study specific variables (study group and
center), sex, age and height, which are included in lung
function prediction equations [37], were considered as
basic covariates. The study population comprised only
Caucasians, so ethnicity was not included as covariate.
Statistical analysis
Differences between sexes and between participants in-
cluded and excluded in this analysis were assessed using
the t-test (normally distributed) or Wilcoxon rank-sum
test (non-normally distributed) for continuous variables.
The chi-square test was used for categorical variables.
Associations between study specific variables, early life
events, environmental and lifestyle factors, and allergic
diseases, with spirometric parameters were analyzed
using linear regression. In order to determine the rele-
vant factors, best subset selection was performed using
the Mallows’ Cp statistic (Cp) as the model selection
criterion. The Cp is based on least squares estimation
Table 1 Definition of early life events, environmental and lifestyle factors, and allergic diseases at age 15
Definition Assessment
Early life events
Parental atopy positive if the mother or father had asthma, eczema or hay fever asked at birth; questionnaire-based
Parental education three categories based on the highest number of education years
of either parent (high: >10 years; medium: 10 years; low: <10 years)
asked at birth; questionnaire-based
Maternal age at delivery dichotomized in ≤31 years and >31 years (mean age served as cut-off) asked at birth; questionnaire-based
Maternal smoking during pregnancy yes vs no asked at birth; questionnaire-based
Early second-hand smoke exposure at home positive if parents reported at least once that the child was exposed to
second-hand smoke at home
asked up to age 4 (at 4 months, 1 year (control arm only)
and yearly at 2 to 4 years in GINIplus; half-yearly from
birth to 2 years and at age 4 years for past 24
months in LISAplus); questionnaire-based
Season of birth dichotomized (December to February (winter) versus other seasons) Birth month derived from date of birth; questionnaire-based
Birth weight continuous, grams asked at birth in LISAplus and at 1 year in GINIplus;
questionnaire-based
Breastfeeding exclusive breastfeeding for at least four months asked separately for 1–6 months at 1 year in GINIplus and
at 6 months in LISAplus; questionnaire-based
Peak weight and peak height velocity maximum of the first derivative of the individual weight or height gain
curves obtained between birth and two years of age (calculated using
nonlinear random effects models) [9]
weight and height measurements obtained during the
children’s preventive medical check-ups to monitor growth
Early lower respiratory tract infections doctor’s diagnosis of pneumonia or obstructive bronchitis within the
first three years of life (hereon referred to as lung infections)
asked up to age 3 (yearly in GINIplus; half-yearly up to
age 2 years and up to age 3 years asked at the 4 year
follow-up in LISAplus); questionnaire-based
Environmental and lifestyle factors at age 15
Short-term air pollution exposure continuous, the average of the daily concentrations of NO2, PM2.5 mass
and PM10 mass (μg/m
3)
obtained for the seven days prior to lung function testing
from monitoring sites near the centers of Munich
and Wesel [8]
Long-term air pollution exposure continuous, long-term concentrations of NO2, PM2.5 mass and PM10
mass (μg/m3)
estimated to each participant’s home address at birth,
10- and 15-years, respectively [8]
Regular indoor second-hand smoke exposure positive if the adolescent reported indoor second-hand smoke
exposure at least once a week
asked at age 15 years; one question in GINIplus, two
questions for second-hand exposure: (1) at home and (2) in
other locations in LISAplus (positive if regular exposure was
reported in at least one question); questionnaire-based
Active smoking yes vs no asked at age 15 years, questionnaire-based
Vitamin D concentrations continuous; serum 25-hydroxyvitamin D [25(OH)D] concentrations
adjusted for seasonal variance using a generalized additive
model (nmol/l) [36]
measured at age 15 years using Roche’s vitamin D total test
(E170, Roche Diagnostics, Mannheim, Germany)
Body mass index continuous, kilogram per square meter (kg/m2) calculated using body height and weight obtained at
lung function testing
Current allergic diseases
Asthma defined based on the Global Allergy and Asthma European Network
(GA2LEN) definition [44]. Subjects were considered as currently having
parents were asked to provide yearly information on their
child’s doctor diagnosed allergic diseases throughout
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Table 1 Definition of early life events, environmental and lifestyle factors, and allergic diseases at age 15 (Continued)
asthma if they responded positively to at least two of the three
following questions: (1) Has a doctor diagnosed asthma in your child at
the age 3 to 15 years? (2) Has your child taken asthma medication
during the last 12 months? (3) Has your child had wheezing or
whistling in the chest in the last 12 months?
childhood; information on current allergic symptoms and
asthma medication in the last 12 months was derived
from the last follow-up questionnaire at age 15 years.
Current allergic rhinitis positive if one of the following questions was positive:
(1) Has a doctor diagnosed hay fever (i.e. seasonal allergic rhinitis)
in your child? (2) Has a doctor diagnosed perennial allergic
rhinitis in your child?
asked separately for ages 11 to 15, at the 15-year follow-up;
questionnaire-based
Sensitization to food or aeroallergens food allergen mixture including egg white, codfish, cow milk, wheat
flour, peanut, and soybean and aeroallergen mixture including cat, dog,
mugwort, birch, timothy, rye, Cladosporium herbarum, and
Dermatophagoides pteronyssinus; for both tests, a value >0.35 kU/L was
considered positive
measured by serum specific Immunoglobulin E (IgE) using
the ImmunoCAP Specific IgE system (Phadia GmbH,
Freiburg, Germany) at age 15 years
GINIplus: German Infant study on the influence of Nutrition Intervention plus air pollution and genetics on allergy development; LISAplus: Life-style related factors on the development of the Immune System and
Allergies in East and West Germany plus the influence of traffic emissions and genetics
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models with a subset of all the independent variables,
taking the number of predictors into consideration [38].
Best subset selection provides the model with the lowest
Cp for all possible model sizes of the set of all potential
independent variables. The model with the lowest Cp
among all model sizes was chosen. Categorical variables
were entered using dummy coding.
To strengthen the model selection approach, we
applied a two-step process. First, we performed the se-
lection in the total population. Second, to determine if
the same variables would have been selected in a sub-
population or if any variables might have been selected
by random, the model selection process was repeated
1000 times with two thirds (N = 884) of the population
randomly selected for inclusion each time. The fre-
quency of selecting a given variable in the regression
models with the lowest Cp (even if the variable was not
necessarily significant) was assessed and compared to
the variables included in the models derived using the
total population. To reduce model complexity, we
focused only on variables that remained in >70% of the
replication models for each particular spirometric
parameter. Regression models including these selected
variables (plus significant study specific variables) were
rerun in the total population (N = 1326). Multicollinear-
ity in the final models was assessed by the variance infla-
tion factor (VIF), which is a measure of how much of
the variance of an estimated regression coefficient is in-
fluenced by the correlation between independent vari-
ables. If correlations among variables exist, their relative
importance, meaning the partial contribution to the total
R2 of a regression model, is influenced by the order in
which the variables are entered in a model. To adjust for
possible correlations, we report the relative importance
of each variable as the sequential R2 contribution [39].
The sequential R2 is corrected for the dependence on
orderings by unweighted averaging of R2 contribution
over all possible orderings. The reported results of the
total sequential R2 per variable were normalized to sum
up to 100% to facilitate comparability [39].
In a sensitivity analysis, current asthmatics were ex-
cluded from the final models.
Analyses were run in the statistical program R, version
3.2.0 [40]. P-values <0.05 were considered statistically
significant.
Results
Study population
Valid lung function data and information on the investi-
gated factors (Fig. 1) was available for 1326 subjects
(63% from Munich, 51% male, mean age of 15.2 years;
Table 2). Due to non-random loss to follow-up over the
15-year period, participants differed from the initialcohort, e.g. higher educated parents, more breastfeeding,
lower BMI (Additional file 1: Table A1).
Mean lung function parameters were higher among
boys (p < 0.05), with the exception of FEV1/FVC, which
was higher among girls (Table 2). Of 2358 participants
with valid lung function measurements at the 15-year
follow-up, 43.8% were excluded due to missing informa-
tion on investigated factors. Lung function did not differ
between the population analyzed and the other subjects
with valid spirometry (Munich and Wesel) stratified by
sex, with the exception that participating males had a
slightly higher FEV1/FVC compared to non-participating
males (Additional file 1: Table A2).
Variable selection
Nearly all early life events and current environmental
and lifestyle factors that showed significant associa-
tions with lung function in the selection models based on
the total population remained in >70% of the models
(Additional file 1: Tables A3 and A4). Exceptions included
parental atopy (54% in FEV1/FVC model), parental educa-
tion (52% in FEV1 model), and regular indoor second-
hand smoke exposure at age 15 (66% in FEV1/FVC model,
and slightly <70% in FEF25–75 model), which were less
often included and therefore excluded from further ana-
lyses. Linear regression results for the included variables
are shown in Table 3. Results considering secondary flow
rates (PEF and FEF25 to FEF75) are shown in the additional
file 1: Tables A4 and A5. The VIF was <2 for all variables
in the final models, suggesting low multicollinearity.
Individual factors - sex, age and height
Sex and height at lung function testing showed stable as-
sociations with all spirometric parameters, except for the
association between FEF25–75 and sex and between FEV1/
FVC and height (Table 3). Associations for age were found
with FEV1 and FVC. Similar results were present consid-
ering further flow rates (Additional file 1: Table A5).
Early life events
Lower lung function was associated with higher peak
weight velocity and early lung infections (Table 3). Peak
weight velocity was negatively associated with FEV1/
FVC (β: -0.8%/IQR increase) and FEF25–75 (β: −88 ml/s/
IQR increase). An impact of peak weight velocity on
mainly the peripheral airways was also supported by
the negative associations found with FEF50 and FEF75
(Additional file 1: Table A5). Early lung infections were
also negatively associated with airway function as as-
sociations were found for FEV1 (β: −55 ml), FEV1/
FVC (β: −1.1%) and FEF25–75 (β: −159 ml/s), but not
for FVC. Furthermore, the larger and peripheral air-
ways appeared to be affected by early lung infections
Table 2 Population characteristics of analyzed subjects.
Total Males Females
% (N) 100 (1326) 51.1 (678) 48.9 (648)
Mean (SD) or % (n)
Age, years 15.2 (0.3) 15.2 (0.3) 15.2 (0.3)
Height*, cm 172 (8.2) 176 (7.4) 167 (6.0)
Study specific
Study
GINIplus control 38.3 (508) 38.2 (259) 38.4 (249)
GINIplus intervention 34.5 (457) 33.8 (229) 35.2 (228)
LISAplus 27.2 (361) 28.0 (190) 26.4 (171)
Study center
Munich 63.3 (840) 63.1 (428) 63.6 (412)
Wesel 36.7 (486) 36.9 (250) 36.4 (236)
Early life events
Parental atopy, yes 58.8 (780) 57.7 (391) 60.0 (389)
Parental education
low (< 10 years of school) 5.2 (69) 5.8 (39) 4.6 (30)
medium (= 10 years of school) 26.7 (354) 27.0 (183) 26.4 (171)
high (> 10 years of school) 68.1 (903) 67.3 (456) 69.0 (447)
Maternal age at delivery >31 years*, yes 49.9 (662) 46.3 (314) 53.7 (348)
Maternal smoking during pregnancy, yes 12.0 (159) 11.9 (81) 12.0 (78)
Early second-hand smoke exposure at home (up to age 4), yes 32.7 (433) 32.6 (221) 32.7 (212)
Season of birth, winter 25.6 (339) 24.5 (166) 26.7 (173)
Birth weight*, g 3483 (442.0) 3541 (443.5) 3422 (432.6)
Exclusive breastfeeding >4 months, yes 60.6 (804) 58.3 (395) 63.1 (409)
Peak weight velocity*, kg/month 1.1 (0.2) 1.2 (0.2) 1.0 (0.2)
Peak height velocity*, cm/month 3.6 (0.4) 3.8 (0.4) 3.5 (0.4)
Lung infections (up to age 3)*, yes 31.2 (414) 34.8 (236) 27.5 (178)
Environmental and lifestyle factors at age 15
Short-term air pollution
NO2 (μg/m3) 20.4 (6.9) 20.5 (7.0) 20.3 (6.7)
PM2.5 mass (μg/m3) 14.7 (7.3) 14.4 (6.7) 15.0 (7.9)
PM10 mass (μg/m3) 18.9 (7.8) 18.6 (7.2) 19.3 (8.4)
Long-term air pollution
NO2 (μg/m3) 21.2 (4.8) 21.2 (5.0) 21.2 (4.6)
PM2.5 mass (μg/m
3) 14.8 (2.1) 14.8 (2.2) 14.8 (2.1)
PM10 mass (μg/m
3) 22.1 (3.2) 22.0 (3.3) 22.1 (3.2)
Regular indoor second-hand smoke exposurea, yes 20.1 (266) 19.0 (129) 21.1 (137)
Active smoking, yes 5.4 (71) 5.6 (38) 5.1 (33)
Serum vitamin Db, nmol/l 68.4 (25.3) 67.5 (24.3) 69.3 (26.2)
Body mass index*, kg/m2 20.7 (3.0) 20.7 (3.2) 20.8 (2.8)
Allergic diseases at age 15
Asthma, yes 6.3 (83) 7.4 (50) 5.1 (33)
Rhinitis, yes 18.9 (251) 20.9 (142) 16.8 (109)
Sensitization to
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Aeroallergens*, yes 45.4 (602) 51.5 (349) 39.0 (253)
Food allergens, yes 11.2 (148) 12.8 (87) 9.4 (61)
Spirometric parameters at age 15
FVC, l* 4.08 (0.77) 4.50 (0.74) 3.64 (0.51)
FEV1, l* 3.52 (0.63) 3.83 (0.64) 3.19 (0.42)
FEV1/FVC, %* 86.7 (6.39) 85.3 (6.43) 88.1 (6.02)
PEF, l/s* 7.15 (1.28) 7.73 (1.3) 6.54 (0.93)
FEF25, l/s* 6.26 (1.17) 6.61 (1.27) 5.89 (0.92)
FEF50, l/s* 4.46 (1.05) 4.71 (1.14) 4.19 (0.87)
FEF75, l/s* 2.21 (0.72) 2.31 (0.78) 2.11 (0.63)
FEF25–75, l/s* 3.92 (0.92) 4.12 (1.01) 3.70 (0.77)
*Significant difference (p-value < 0.05) between males and females (t-test, Wilcoxon rank-sum test, or chi-square test)
aat least once a week or more. bseason-adjusted 25(OH)D concentration
FEV1: forced expiratory volume in 1 s. FVC: forced vital capacity. FEF25, FEF50, FEF75: forced expiratory flow rates at 25, 50 and 75% of exhaled FVC. FEF25–75: mean
flow rate between 25 and 75% of FVC. PEF: peak expiratory flow. SD: standard deviation
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all flow rates (Additional file 1: Table A5).
While clear associations indicative of airway function
and not for lung volume (FVC) were observed for peak
weight velocity and early lung infections, no or only
unstable associations were found for parental education,
parental atopy, maternal age at delivery, maternal smoking
during pregnancy, early second-hand smoke exposure at
home, season of birth, birth weight, exclusive breastfeeding
for at least four months and peak height velocity.Table 3 Coefficients (95%-confidence intervals) of regression models
Spirometric parameter indicative of Lung volume
FVC, ml
Sex, male 347 (289, 405)
Age, IQR years 47 (26, 69)
Height, IQR cm 637 (598, 676)
Early life events
Peak weight velocity, IQR kg/month
Lung infections (up to age 3), yes
Environment & lifestyle at age 15
Regular indoor second-hand smoke exposurea, yes
Serum vitamin Db, IQR nmol/l 65 (34, 96)
Body mass index, IQR kg/m2 222 (194, 250)
Allergic diseases at age 15
Asthma, yes −118 (−216, −21)
Study specific
Study (LISAplus vs GINIplus) 68 (12, 124)
Study center (Wesel vs Munich) −66 (−119, −13)
All associations were statistically significant (p-value < 0.05). Estimates for continuou
(0.26 years), height (11 cm), peak weight velocity (0.28 kg/month), vitamin D (32.35
aat least once a week or more. bseason-adjusted 25(OH)D concentration. FEV1: force
between 25 and 75% of FVCEnvironmental and lifestyle factors at age 15
Regular indoor second-hand smoke exposure was nega-
tively associated with FEV1 (β: −59 ml) (Table 3), as well
as PEF and FEF75 (Additional file 1: Table A5), which sup-
ports the notion of a potential effect on the airways.
Vitamin D concentrations were positively associated with
FVC (β: 65 ml/IQR increase) and FEV1 (β: 32 ml/IQR
increase), while the association with FEV1/FVC was nega-
tive (β: -0.6%/IQR increase). BMI was positively associated
with FVC (β: 222 ml/IQR increase), FEV1 (β: 144 ml/IQRadjusted for covariates that remained stable in replication analyses
Airways & volume Airflow limitation Airways
FEV1, ml FEV1/FVC, % FEF25–75, ml/s
220 (167, 274) −2.2 (−2.9,-1.4)
30 (11, 50)
517 (481, 553) 508 (438, 577)
−0.8 (−1.3, −0.3) −88 (−155, −20)
−55 (−102, −7) −1.1 (−1.8,-0.3) −159 (−258, −60)
−59 (−114, −5)
32 (3, 61) −0.6 (−1, −0.2)
144 (118, 171) −1.2 (−1.6,-0.8) 85 (31, 140)
−177 (−268, −86) −1.8 (−3.1,-0.4) −304 (−494, −115)
−135 (−182, −88) −1.6 (−2.3,-0.9) −256 (−352, −161)
s variables are presented per interquartile range (IQR) increase (IQR: age
nmol/l), body mass index (3.56 kg/m2))
d expiratory volume in 1 s. FVC: forced vital capacity. FEF25–75: mean flow rate
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negatively associated with FEV1/FVC (β: -1.2%/IQR in-
crease). Positive associations between BMI and PEF, FEF25
and FEF50 were also found (Additional file 1: Table A5).
Spirometric parameters indicative of lung volumes were
positively associated with vitamin D concentrations and
BMI, while regular indoor second-hand smoke exposure
showed some associations with flow rates, but no clear
pattern. No associations were found with short-term or
long-term air pollution exposure or active smoking at age
15 (prevalence for smoking 5.4%).
Allergic diseases at age 15
Asthma was negatively associated with all lung function
measures (Table 3), while no associations were found
with current allergic rhinitis, or sensitization to food or
aeroallergens. This was also true considering second-
ary parameters for airway function, except for PEF
(Additional file 1: Table A5). Exclusion of subjects
with asthma from the final models did not substantially
modify the associations reported for early life events and
environmental and lifestyle factors at age 15.
Relative importance of factors in regression models
The total R2 was moderate in all models (R2 < 0.2),
except for when FVC and FEV1 were the modelled out-
comes, in which case it was higher (R2 = 0.68 and
R2 = 0.59, respectively). As expected, the contribution to
the total R2 of each model was highest for height (61.6–
75.3%) and sex (23.9–27.2%) for almost all considered
indices (Table 4, Additional file 1: Table A6). Due to the
varying contribution of factors to different spirometric
parameters, a direct comparison of all factors and
parameters is not possible. The influence of early life
events was primarily detectable for airway function. The
highest contribution was found for FEV1/FVC with
22.4% and 7.2% for peak weight velocity and early lung
infections, respectively. However, these two early life
factors contributed less than 5% to the explained vari-
ance of the other lung function parameters of airway
function (FEV1, FEF25–75). Among the current envir-
onmental and lifestyle factors, vitamin D concentra-
tions (≤2.1%, maximum in FEV1/FVC) and regular
indoor second-hand smoke exposure (0.2% in FEV1)
contributed less than BMI, which contributed to
almost all parameters (range 3.2% in FEF25–75 to
23.7% in FEV1/FVC).
Discussion
Early life events, such as peak weight velocity and early
lung infections, as well as current lifestyle factors, such
as BMI, indoor second-hand smoke exposure and serum
vitamin D concentrations, were associated with several
spirometric parameters at age 15 years. The results ofour study also confirm the well-established evidence
supporting a role of sex, height and asthma status on
lung function.
Among the early life events, a higher peak weight vel-
ocity was associated with airflow limitation and lower
peripheral flow rates. Further, early lung infections were
negatively associated with all lung function parameters
except lung volume, suggesting that early lung infections
may lead to low, long-term airflow limitation. A study
by Svanes et al. reported an association of early child-
hood disadvantage factors, e.g. respiratory infections,
maternal smoking and others, with lower lung function
in adults and also a larger decline in lung function over
time [6]. Early structural and functional changes on the
developing or growing lung might lead to an impaired
lung function and a higher susceptibility to lung dis-
eases, but possible underlying mechanisms are not fully
understood yet [1, 5, 6].
Regular indoor second-hand smoke exposure at age
15 years was associated with somewhat poorer airway
function. The relative contribution of indoor second-
hand smoke exposure was relatively low and no clear
pattern with the lung function parameters could be
determined. Higher vitamin D concentrations were
primarily associated with volumetric indices, and with
some airflow limitation, but with relatively small effects
(<2.5% of R2). After height and sex, BMI contributed the
most to the explained variance for nearly all spirometric
parameters. BMI was positively associated with all lung
function parameters indicative of lung volume and
airway function, but also with airflow limitation. Similar
associations have been reported in other studies among
youth [15, 21].
Except for BMI, the relative importance of early life
events and environmental and lifestyle factors was rela-
tively low, in comparison to the contribution of sex and
height. Nevertheless, early life events were primarily
negatively associated with parameters indicative of air-
way function, while no associations were found for lung
volume. This suggests that early life factors should be
considered in studies focusing on airway function. Regu-
lar indoor second-hand smoke exposure at age 15, an
environmental and lifestyle factor, showed the same
tendency. On the contrary, positive associations were
detected for vitamin D concentration with volumetric
parameters and for BMI with both, volumes and airway
function. Given the associations between higher weight
gain in the first 2 years of life and current BMI with the
spirometric indices, it appears that body weight at
several points in life is important for lung function.
Associations of lung function with peak weight vel-
ocity [26, 27], lower respiratory infections [10, 14, 41],
BMI [15, 21], vitamin D concentrations [16, 17] and
second-hand smoke exposure [18, 20] have been also
Table 4 Relative importance of variables in final regression models (averaged R2contribution)
Relative importance of variables in regression models adjusted for covariates that remained stable in replication analyses are displayed as normalized percent of
R2contribution averaged (unweighted) over variable orderings.
1at least once a week or more. 2season-adjusted 25(OH)D concentration. FEV1: forced expiratory volume in 1 s. FVC: forced vital capacity. FEF25–75: mean flow rate
between 25 and 75% of FVC
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gated associations between several early life events and
current lifestyle factors with lung function [28]. This cross-
sectional study investigated Tunisian children with an age
range of 6–16 years (92 participants were 14–16 years old
and would be comparable to our population). Similar to
our results, associations between lung function with sex,
height and weight were found. Strong associations with
age were also reported [28], whereas the more narrow age
distribution in our analysis was only associated with some
spirometric parameters. As in our study, no associations
between normal birth weight and lung function were
observed in this previous publication [28]. Kotecha et al.
reported an association between birth weight and lung
function at age 8–9 years, but not at age 14–17 years,
suggesting that the importance of early factors on lung
function might differ by age [13].
As a complex framework of factors influences lung
function [1, 2], we considered several early life andcurrent environmental and lifestyle factors in adolescence
to identify factors associated with lung function and their
relative importance at age 15. Correlations, interactions or
modulating effects between some investigated factors are
very likely and study specific population characteristics
might influence the impact and contribution of single
factors. Study center was shown to be associated with lung
function in our cohort but might partially stand as a
surrogate for other factors not captured by our data. For
example, there might be differences in lifestyle and envir-
onmental factors between the included rural (Wesel) and
urban (Munich) areas.
Due to loss to follow-up, the prevalence of low educa-
tion (<10 years of school) among the participants’
parents was only 5.2%, which may partially explain why
socioeconomic status did not remain in the main
models. In contrast to our results, a review covering
different countries and age ranges showed that low
socioeconomic status was associated with reduced lung
Luzak et al. Respiratory Research  (2017) 18:138 Page 11 of 13function [42]. The underrepresentation of less educated
families in our study might have also led to a lack of
association with some factors that are correlated with
socioeconomic status, such as maternal smoking during
pregnancy (prevalence 12%), which otherwise, has been
shown to have a negative effect in previous studies
[18, 20]. Furthermore, results of a study among school-
children in Canada suggested a modifying effect of socio-
economic status on the association of air pollution and
traffic exposure with respiratory symptoms and lung func-
tion [43]. In this study, a tendency for a higher risk of
respiratory symptoms and lower lung function associated
with traffic or air pollution exposure was seen in less edu-
cated households, although most associations were not
statistically significant [43].
Strengths and limitations
A major strength of this study is the investigation of a
full range of standardized measured and visually
inspected spirometric lung function parameters indica-
tive of lung volume, as well as less often investigated
lung function measures of larger conducting and periph-
eral airways, in two prospective birth cohorts. Further-
more, information on a broad range of early life events,
environmental and lifestyle factors, and allergic diseases
at age 15 was available for 1326 German adolescents,
enabling this rarely applied comprehensive approach.
Further factors that were available only in a subset of
our population (986 subjects (74%)) e.g. having <2 or ≥2
siblings at age 15 (one variable for older, another for
younger siblings), using gas for cooking and having mold
at home, both asked in the first year of life, and daycare
center attendance during the first three years of life
would not have been included in the final models (based
on best subset selection in this reduced population).
This result and the limited data availability for these
factors led to their exclusion from the main analysis.
The inclusion of physical activity assessed by accelero-
metry would also have diminished our sample size to
721 subjects (54%) and was not shown to be associated
with lung function in our cohort [35].
A major limitation of this study is selective loss to
follow-up. For example, participants included in the ana-
lysis had higher parental education, more breastfeeding
and less maternal smoking during pregnancy (Additional
file 1: Table A1). Our results might therefore not be
generalizable to all German adolescents. It is possible
that covariates that were not associated with lung func-
tion in our population could play a role in others, point-
ing out a need for replication in other, larger studies.
Further, study center (Munich/Wesel) was associated
with lung function in our study population, which might
suggest regional environmental and lifestyle differences
not captured by the considered factors.Our use of the Cp statistic as a selection criterion for
automatic model selection might have resulted in the
selection of a group of variables that would not have been
selected using a different selection criterion (e.g. adjusted
R2). To reduce model complexity, we chose to use the Cp
statistic because it penalizes the number of included vari-
ables. Further, we replicated our analysis (N = 1000) in
randomly chosen subpopulations to reduce potential
selection bias attributable to influential cases.
Conclusions
In addition to well-known measures included in lung
function prediction equations (sex and height), as well as
current asthma and BMI, our study showed that among
a variety of factors considered in our analysis, weight
gain and pulmonary infections during infancy were
prevalent factors associated with lung function in 15-
year-olds. While the early life factors were primarily as-
sociated with airway function, factors at age 15 showed
associations with airway function as well as lung volume.
Although our findings require replication in independent
studies, they nevertheless highlight the need to include
specific early life events and current lifestyle factors in
studies on lung health among adolescents and suggest
that effective health promotion should exist at all ages.
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Appendix 1 
 
Additional file – Tables A1 to A6 
Table A1 Population characteristics of analyzed participants in comparison to the initial 
study population for the Munich and Wesel study centers 
 Study population 
analyzed 
(N=1326) 
Study population 
excluded 
(N=6477)
A
 
p-value* 
 Mean (SD) or n/N (%) 
Sex    
male 678/1326 (51) 3267/6316 (52) 0.72 
female 648/1326 (49) 3049/6316 (48)  
 Age at lung function measurement, years 15.2 (0.3) 15.3 (0.3) < 0.01 
 Height at lung function measurement, cm 171.5 (8.2) 171.6 (8.5) 0.86 
Study specific    
 Study     
  GINIplus control 508/1326 (38) 3231/6477 (50) < 0.01 
  GINIplus intervention 457/1326 (34) 1795/6477 (28)  
  LISAplus 361/1326 (27) 1451/6477 (22)  
 Study center    
  Munich 840/1326 (63) 3573/6477 (55) < 0.01 
  Wesel 486/1326 (37) 2904/6477 (45)  
Early life events    
 Parental atopy, yes 780/1326 (59) 3194/6276 (51) < 0.01 
 Parental education     
  low (< 10 years of school) 69/1326 (5) 827/6413 (13) < 0.01 
  medium ( = 10 years of school) 354/1326 (27) 1775/6413 (28)  
  high (> 10 years of school) 903/1326 (68) 3811/6413 (59)  
 Maternal age at delivery >31 years, yes 662/1326 (50) 2897/6461 (45) < 0.01 
 Maternal smoking during pregnancy, yes 159/1326 (12) 1069/5657 (19) < 0.01 
 Early second-hand smoke exposure at home 
 (up to age 4), yes 433/1326 (33) 2117/4448 (48) < 0.01 
 Season of birth, winter 339/1326 (26) 1702/6477 (26) 0.61 
 Birth weight, g 3482.7 (442.0) 3463.7 (461.3) 0.17 
Exclusive breastfeeding > 4 months, yes 804/1326 (61) 2498/4957 (50) < 0.01 
 Peak weight velocity, kg/month 1.06 (0.22) 1.09 (0.23) < 0.01 
 Peak height velocity, cm/month 3.62 (0.42) 3.67 (0.42) < 0.01 
 Lung infections (up to age 3), yes 414/1326 (31) 1371/4230 (32) 0.44 
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 Study population 
analyzed 
(N=1326) 
Study population 
excluded 
(N=6477)
A
 
p-value* 
 Mean (SD) or n/N (%) 
Environmental and lifestyle factors at age 15    
 Short-term air pollution at lung function 
measurement    
  NO2 (μg/m
3
) 20.4 (6.9) 20.4 (6.7) 0.83 
  PM2.5 mass (μg/m
3
)  14.6 (7.3) 15.7 (7.2) < 0.01 
  PM10 mass (μg/m
3
) 18.9 (7.8) 20.1 (7.8) < 0.01 
Long-term air pollution at participant’s home 
address    
  NO2 (μg/m
3
) 21.2 (4.8) 22.0 (4.4) < 0.01 
  PM2.5 mass (μg/m
3
)  14.8 (2.1) 15.5 (2.2) < 0.01 
  PM10 mass (μg/m
3
) 22.1 (3.2) 22.9 (3.3) < 0.01 
Regular indoor second-hand smoke 
exposure
1
, yes 266/1326 (20) 438/2242 (20) 0.74 
 Active smoking, yes 71/1326 (5) 165/2246 (7) 0.02 
 Serum vitamin D concentration
2
, nmol/l 68.4 (25.3) 66.3 (24.1) 0.07 
 Body mass index, kg/m
2
 20.7 (3) 21.2 (3.5) < 0.01 
Allergic diseases at age 15    
 Asthma, yes 83/1326 (6) 145/2938 (5) 0.09 
 Rhinitis, yes 251/1326 (19) 491/2839 (17) 0.21 
 Sensitization to    
  Aeroallergens, yes 602/1326 (45) 560/1199 (47) 0.54 
  Food allergens, yes 148/1326 (11) 144/1199 (12) 0.55 
AOnly participants from the Munich and Wesel study centers.*t-test, Wilcoxon rank-sum test or 
Pearson’s chi-square test. 1at least once a week or more. 2season-adjusted 25(OH)D concentration. 
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Table A2 Characteristics of lung function parameters of analyzed participants in comparison 
to all other subjects with valid lung function measurements at age 15 in the Munich and 
Wesel study centers 
 Males  Females  
 Study population 
analyzed 
(N=678) 
Study population 
excluded 
(N=470)
A
 
Study population 
analyzed 
(N=648) 
Study population 
excluded 
(N=562)
A
 
Spirometric parameter Mean (SD) Mean (SD) 
FVC, l  4.50 (0.74) 4.53 (0.77) 3.64 (0.51) 3.65 (0.49) 
FEV1, l 3.83 (0.64) 3.82 (0.67) 3.19 (0.42) 3.22 (0.42) 
FEV1/FVC, %  85.33 (6.43)* 84.46 (6.37) 88.12 (6.02) 88.39 (5.99) 
FEF25-75, l/s 4.12 (1.01) 4.03 (1.04) 3.70 (0.77) 3.77 (0.82) 
PEF, l/s 7.73 (1.3) 7.64 (1.34) 6.54 (0.93) 6.55 (0.98) 
FEF25, l/s 6.61 (1.27) 6.46 (1.32) 5.89 (0.92) 5.92 (0.99) 
FEF50, l/s 4.71 (1.14) 4.58 (1.14) 4.19 (0.87) 4.29 (0.94) 
FEF75, l/s 2.31 (0.78) 2.26 (0.80) 2.11 (0.63) 2.15 (0.64) 
*Significant difference in lung function parameter between participants analyzed and those 
excluded, stratified by sex (t-test, p<0.05). AParticipants with valid lung function measurements at 
age 15 from the Munich and Wesel study centers. 
FEV1: forced expiratory volume in 1 second. FVC: forced vital capacity. FEF25, FEF50, FEF75: forced 
expiratory flow rates at 25, 50 and 75% of exhaled FVC. FEF25-75: mean flow rate between 25 and 75% 
of FVC. PEF: peak expiratory flow. SD: standard deviation. 
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  Table A3 Coefficients (95% confidence intervals) of regression models with the lowest Mallows’ Cp, determined by best subset selection in the total   
  population  
Spirometric parameter  
indicative of  
Lung volume Airways & 
volume  
Airflow 
limitation 
 Airways Function of  
larger conducting airways        
  
peripheral airways 
  FVC, ml FEV1, ml FEV1/FVC, % FEF25-75, ml/s PEF, ml/s FEF25, ml/s FEF50, ml/s FEF75, ml/s 
Sex, male  349 (291, 406) 217 (164, 270) -2 (-2.8, -1.1) 118 (1, 234) 607 (473, 740) 274 (140, 409) 229 (99, 360)  
Age, IQR years 49 (27, 70) 34 (14, 54)  31 (-10, 71) 45 (-4, 93)  72 (22, 123) 42 (-4, 88)  
Height, IQR cm 646 (606, 687) 519 (483, 555) -0.4 (-1, 0.1) 467 (389, 545) 709 (619, 799) 560 (469, 651) 482 (394, 571) 330 (274, 385) 
Early life events 
Parental atopy, yes   -0.7 (-1.4, -0.1) -77 (-172, 18) -124 (-238, -10)   -67 (-142, 9) 
Parental education
#
         
 high  -51 (-100, -2)  -90 (-193, 12) -154 (-282, -25) -118 (-243, 7) -114 (-229, 2)  
 low     -193 (-454, 67)    
Early second-hand smoke 
exposure at home (up to age 4), 
yes       133 (7, 258)   
Season of birth, winter 46 (-8, 100)        
Birth weight, IQR g -33 (-66, 1)        
Peak weight velocity, IQR 
kg/month   -0.7 (-1.2, -0.2) -110 (-180, -40)   -120 (-200, -41) -89 (-143, -35) 
Lung infections (up to age 3), yes  -54 (-101, -6) -1.0 (-1.7, -0.3) -161 (-260, -62) -131 (-249, -12) -143 (-263, -23) -169 (-281, -57) -117 (-196, -38) 
Environment & lifestyle at age 15 
Long term air pollution  
NO2, IQR μg/m
3
   -0.4 (-0.9, 0.1)     -43 (-98, 12) 
PM2.5 mass, IQR μg/m
3
 86 (-29, 201)        
Regular indoor second-hand 
smoke exposure
1
, yes  -65 (-120, -10) -0.8 (-1.6, 0) -132 (-246, -17) -177 (-315, -40) -137 (-278, 5) -124 (-254, 6) -126 (-217, -35) 
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Spirometric parameter  
indicative of  
Lung volume Airways & 
volume  
Airflow 
limitation 
 Airways Function of  
larger conducting airways        
  
peripheral airways 
  FVC, ml FEV1, ml FEV1/FVC, % FEF25-75, ml/s PEF, ml/s FEF25, ml/s FEF50, ml/s FEF75, ml/s 
Serum vitamin D concentration
2
, 
IQR nmol/L  63 (32, 94) 31 (3, 60) -0.6 (-1, -0.2)      
Body mass index, IQR kg/m
2
  226 (197, 254) 142 (116, 169) -1.2 (-1.6, -0.8) 93 (38, 149) 261 (195, 327) 227 (161, 294) 149 (86, 211)  
Allergic diseases at age 15         
Asthma, yes  -119 (-216, -22) -178 (-269, -88) -2 (-3.4, -0.6) -346 (-538, -154) -198 (-434, 38) -398 (-627, -168) -405 (-620, -190) -193 (-346, -40) 
Rhinitis, yes      119 (-28, 265)    
Aeroallergen sensitization, yes   0.6 (-0.1, 1.3) 78 (-17, 172)    70 (-5, 144) 
Study specific         
Study group
#
         
 GINIplus (intervention) 49 (-7, 105)        
 LISAplus 97 (34, 160) 45 (-6, 97)    121 (-9, 252)   
Study center, Wesel -145 (-276, -15) -138 (-188, -87) -1.3 (-2.1, -0.6) -266 (-368, -164) -325 (-446, -204) -334 (-462, -206) -282 (-396, -168) -179 (-263, -95) 
Significant associations are shown in bold (p<0.05). Estimates for continuous variables are presented per interquartile range (IQR) increase (IQR: age (0.26 years), 
height (11 cm), birth weight (587.5 g), peak weight velocity (0.28 kg/month), long term NO2 (6.64 μg/m
3), long term PM 2.5 mass (4.00 μg/m3), vitamin D 
concentration (32.35 nmol/l), body mass index (3.56 kg/m2). 
#Factor entered using dummy coding. 1at least once a week or more. 2season-adjusted 25(OH)D concentration.  
FEV1: forced expiratory volume in 1 second. FVC: forced vital capacity. FEF25, FEF50, FEF75: forced expiratory flow rates at 25, 50 and 75% of exhaled FVC. FEF25-75: 
mean flow rate between 25 and 75% of FVC. PEF: peak expiratory flow.
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 Table A4 Distribution of the frequency of inclusion of each factor in 1000 replication analyses (%) 
Spirometric parameter  FVC FEV1 FEV1/FVC FEF25-75 PEF FEF25 FEF50 FEF75 
Sex, male  100 100 100 62 100 100 98 2 
Age, years 100 98 14 35 51 90 54 23 
Height, cm 100 100 42 100 100 100 100 100 
Early life events         
Parental atopy, yes 10 26 54 38 72 11 31 36 
Parental education
#
         
high 12 52 20 50 57 52 49 34 
low 15 10 3 3 31 8 8 3 
Maternal age at delivery >31 years, yes 7 3 20 17 12 8 13 16 
Maternal smoking during pregnancy, yes 29 23 3 1 5 6 3 1 
Early second-hand smoke exposure at home  
(up to age 4), yes  16 10 2 1 31 66 2 1 
Season of birth, winter 43 18 1 2 10 9 2 10 
Birth weight, g 44 8 5 4 18 11 20 10 
Exclusive breastfeeding > 4 months, no 3 2 2 3 19 4 6 2 
Peak weight velocity, kg/month 3 22 93 92 1 25 95 97 
Peak height velocity, cm/month 23 18 3 4 12 3 4 11 
Lung infections (up to age 3), yes 6 73 94 98 74 80 95 95 
Environment & lifestyle at age 15         
Short-term air pollution         
 NO2 (μg/m
3
) 2 4 17 24 7 4 41 13 
 PM2.5 mass (μg/m
3
)  4 4 11 9 4 3 12 3 
 PM10 mass (μg/m
3
) 9 1 39 12 3 2 17 10 
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Spirometric parameter  FVC FEV1 FEV1/FVC FEF25-75 PEF FEF25 FEF50 FEF75 
Long-term air pollution          
 NO2 (μg/m
3
) 6 19 31 27 19 6 28 24 
 PM2.5 mass (μg/m
3
)  36 31 24 10 21 8 10 9 
 PM10 mass (μg/m
3
) 8 4 8 9 16 3 13 20 
Regular indoor second-hand smoke exposure
1
, yes 21 80 66 70 86 54 51 95 
Active smoking, yes 9 12 7 7 21 8 6 9 
Serum vitamin D concentration
 2
, nmol/l  100 74 85 1 16 2 4 32 
Body mass index, kg/m
2
  100 100 100 97 100 100 100 8 
Allergic diseases at age 15         
Asthma, yes  79 99 84 97 39 97 99 79 
Rhinitis, yes  7 5 6 8 31 3 10 5 
Sensitization to         
 Aeroallergens, yes 1 11 41 44 4 2 32 45 
 Food allergens, yes 3 2 4 4 3 8 5 2 
Study specific         
Study group
#
         
 GINIplus (intervention) 53 17 7 6 13 6 3 4 
 LISAplus 90 54 16 3 4 53 7 10 
Study center, Wesel 82 99 63 86 99 99 83 78 
Factors that were included in >70% of replication analyses are shaded in gray.  
#Factor entered using dummy coding. 1at least once a week or more. 2season-adjusted 25(OH)D concentration. FEV1: forced expiratory volume in 1 second. 
FVC: forced vital capacity. FEF25, FEF50, FEF75: forced expiratory flow rates at 25, 50 and 75% of exhaled FVC. FEF25-75: mean flow rate between 25 and 75% of 
FVC. PEF: peak expiratory flow.
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Table A5 Coefficients (95% confidence intervals) of regression models of flow rates adjusted 
for covariates that remained stable in replication analyses 
Spirometric parameter 
indicative of airway function of larger conducting airways              peripheral airways 
 PEF, ml/s FEF25, ml/s FEF50, ml/s FEF75, ml/s 
Sex, male 602 (470, 735) 285 (150, 420) 227 (97, 358)  
Age, IQR years  63 (14, 112)   
Height, IQR cm 713 (623, 803) 555 (464, 646) 488 (399, 576) 328 (272, 383) 
Early life events     
Parental atopy, yes  -123 (-236, -11)     
Peak weight velocity, IQR 
kg/month    -122 (-202, -43) -82 (-136, -28) 
Lung infections (up to age 3), yes   -140 (-258, -23) -150 (-270, -29) -171 (-283, -58) -118 (-198, -39) 
Environment & lifestyle at age 15 
Regular indoor second-hand 
smoke exposure
 1
, yes -164 (-301, -27)    -130 (-220, -39) 
Serum vitamin D concentration
2
, 
IQR nmol/l      
Body mass index, IQR kg/m
2
  265 (200, 331) 231 (165, 297)  149 (87, 212)  
Allergic diseases at age 15 
Asthma, yes   -391 (-621,-161)  -392 (-607,-177) -171 (-323, -20) 
Study specific     
Study center (Wesel vs Munich)   -314 (-430,-198) -303 (-419,-186) -266 (-375,-157) -201 (-277,-125) 
All associations were statistically significant (p<0.05). Estimates for continuous variables are 
presented per interquartile range (IQR) increase (IQR: age (0.26 years), height (11 cm), peak weight 
velocity (0.28 kg/month), vitamin D (32.35 nmol/l), body mass index (3.56 kg/m2)).  
1at least once a week or more. 2season-adjusted 25(OH)D concentration.  
FEF25, FEF50, FEF75: forced expiratory flow rates at 25, 50 and 75% of exhaled forced vital capacity. 
PEF: peak expiratory flow.   
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Table A6 Relative importance of variables in final regression models of flow rates (averaged 
R2 contribution)  
Spirometric parameter indicative of airway 
function of larger conducting airways              peripheral airways 
 PEF FEF25 FEF50 FEF75 
Total R
2
 of the model 0.38 0.24 0.18 0.13 
Sex 32.9 21.8 18.2  
Age  2.6   
Height 55.0 54.8 55.5 68.3 
Early life events 
Parental atopy 0.7    
Peak weight velocity    4.0 4.1 
Lung infections (up to age 3)  0.4 1.3 3.3 5.1 
Environment & lifestyle at age 15 
Regular indoor second-hand smoke exposure
1
 0.6   5.1 
Serum vitamin D concentration
2
      
Body mass index  8.2 12.1 6.9  
Allergic diseases at age 15 
Asthma  3.0 5.5 3.9 
Study specific 
Study center (Wesel vs Munich)  2.1 4.4 6.7 13.5 
< 1% < 3% < 5% < 10% < 15% ≥ 15% 
Relative importance of variables in regression models adjusted for covariates that remained stable in 
replication analyses are displayed as normalized percent of R2contribution averaged (unweighted) 
over variable orderings.  
1at least once a week or more. 2season-adjusted 25(OH)D concentration.  
FEF25, FEF50, FEF75: forced expiratory flow rates at 25, 50 and 75% of exhaled forced vital capacity. 
PEF: peak expiratory flow. 
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Abstract
Background
Intensity and duration of physical activity are associated with the achievement of health ben-
efits. Our aim was to characterize physical activity behavior in terms of intensity, duration
pattern, and adherence to theWHO physical activity recommendations in a population-
based sample of adults from southern Germany. Further, we investigated associations
between physical activity and sex, age, and body mass index (BMI), considering also com-
mon chronic diseases.
Methods
We analyzed 475 subjects (47%males, mean age 58 years, range 48–68 years) who wore
ActiGraph accelerometers for up to seven days. Measured accelerations per minute
obtained from the vertical axis (uniaxial) and the vector magnitude of all three axes (triaxial)
were classified as sedentary, light or moderate-to-vigorous physical activity (MVPA) accord-
ing to predefined acceleration count cut-offs. The average minutes/day spent in each activity
level per subject served as outcome. Associations of sex, age, BMI, and seven chronic
diseases or health limitations, with the activity levels were analyzed by negative binomial
regression.
Results
Most of the wear time was spent in sedentarism (median 61%/day), whereas the median
time spent in MVPA was only 3%, with men achieving more MVPA than women (35 vs. 28
minutes/day, p0.05). Almost two thirds of MVPA was achieved in short bouts of less than 5
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minutes, and 35% of the subjects did not achieve a single 10-minute bout. Hence, only 14%
adhered to theWHO recommendation of 2.5 hours of MVPA/week in at least 10-minute
bouts. Females, older subjects and obese subjects spent less time in MVPA (p0.05), but
no clear association with hypertension, asthma, diabetes, chronic obstructive pulmonary
disease, anxiety/depression, pain or walking difficulties was observed in regression analy-
ses with MVPA as outcome.
Conclusions
Activity behavior among middle-aged German adults was highly insufficient, indicating a fur-
ther need for physical activity promotion in order to gain health benefits.
Background
Being physically active is linked to several health benefits, including the improvement of func-
tional ability, cardiorespiratory fitness, metabolic health, and the prevention of premature
death [1–4]. Although every bit of physical activity (PA) counts towards health benefits, the
frequency, intensity and duration have great impact on these benefits [1–3]. Existing evidence
supports a dose-response relationship of PA and reduced risk of chronic conditions like type 2
diabetes, cardiovascular disease, or stroke [3]. Therefore, the World Health Organization
(WHO) recommends that adults without mobility-related chronic diseases should accumulate
at least 2.5 hours of moderate-intensity PA per week spent in bouts of at least 10 minutes [1].
In order to improve adherence and to establish PA promotion, it is important to collect evi-
dence on the pattern of PA behavior, however assessing PA is challenging [5–7]. Various
approaches exist that rely either on self-reports or objective motion sensors [5, 6]. A systematic
review comparing self-reported and objectively measured activity in adults found that correla-
tions were generally low-to-moderate [6]. This is illustrated by the results of the fitness health
survey for England in 2008 in which, based on self-report, 39% of men and 29% of women
aged>16 years achieved at least moderate activity for a minimum of 30 minutes at five or
more days a week; while, based on accelerometer data, only 6% of men and 4% of women met
this threshold in at least 10 minute bouts [8]. Self-report tends to overestimate the time spent
physically active at high intensity levels, whereas activity gained through lifestyle activities, e.g.
during house work or active transportation, might be underestimated [6, 9]. Accelerometry
provides the possibility to measure PA in a more standardized manner regardless of the cur-
rent fitness level that might influence the subjectively perceived and reported intensity of PA
[6, 9, 10]. Therefore, the number of studies that investigate objectively measured PA is increas-
ing [11]. However, to date few population-based studies that objectively investigate the adher-
ence to PA recommendations for moderate to vigorous activity (MVPA) in adults exist [8, 9,
12–14]. In the United States, data from the National Health and Nutrition Examination Survey
(NHANES) revealed that if at least 30 minutes of MVPA on 5 out of 7 days, in bouts of at least
8–10 minutes, was considered as the recommended threshold, the adherence was less than 5%
among adults [9]. Further, European data for adults from England, Norway, Sweden and Por-
tugal revealed a generally low achievement of PA recommendations (1% to 20%) [8, 12–14].
Large scale, population-based data on PA in German adults was provided from the health
monitoring system at the Robert Koch Institute based only on self-reports. Among 7671 par-
ticipants, aged 18–79 years, 20% reported to achieve the WHO threshold of at least 2.5 hours
of MVPA/week [15]. Furthermore, investigations of objectively measured PA in Germany
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were performed in 168 participants aged 65–89 years. Of those, 12% reached 2.5 hours of
MVPA/week in bouts lasting at least 10 minutes [16]. To our knowledge further data on PA
from population-based studies assessing PA with accelerometers in German adults are
missing.
The aim of the present study was to determine the PA levels and PA duration pattern
assessed by accelerometry in a German adult cohort aged 48–68 years. Duration patterns of
interest were the time spent in MVPA assessed in various bouts and the adherence to the
WHO PA recommendations for adults categorized by sex and age. A further goal was to ana-
lyze the associations of sex, age, and BMI with activity levels serving as outcome. Since evi-
dence indicates that subjects with chronic health issues engage less in PA [16, 17], we further
addressed, if common chronic diseases or health limitations such as hypertension, asthma or
physical complaints were associated with PA in a population-based sample of German adults.
Methods
Study population
The present analysis was based on a follow-up study of the KORA (Cooperative Health
Research in the Region of Augsburg) S4 cohort comprising 4261 adults examined in 1999–
2001. The primary study design has been described previously [18]. Between June 2013 and
September 2014, 2279 subjects (age range 38 to 88 years) participated in the KORA FF4 fol-
low-up of whom 1043 were designated to participate in the “Lung health & physical activity”
section, which involved spirometric lung function measurements and PA assessment by accel-
erometry (Fig 1). The study was approved by the responsible ethics committee of the Bavarian
Medical Association. The investigations were carried out in accordance with the Declaration
of Helsinki and written informed consent was obtained from all participants.
Baseline information on sociodemographic variables, self-reported physician diagnosis of
common chronic diseases such as asthma or diabetes, and medication use was obtained during
a standardized interview, also including questionnaires such as the EuroQol—5 Dimensions
(EQ-5D) questionnaire and the shortened medical outcome survey (SF-12) which are assess-
ment tools for health status and health-related quality of life. Further, participants underwent a
standardized medical examination. Height and weight were assessed while subjects were wear-
ing light clothes without shoes. After a rest of at least 5 minutes in a sitting position, blood
pressure was measured three times on the right arm and determined by the mean of the second
and third measurement.
In the present analysis, diabetes was defined based on self-reported physician diagnosis or
use of antidiabetic agents. Hypertension was defined as blood pressure greater or equal to 140/
90 mmHg or if the subject reported the use of antihypertensive medication given that the sub-
ject was aware of being hypertensive. Subjects who reported a doctor’s diagnosis of chronic
bronchitis or chronic obstructive pulmonary disease (COPD) were classified as having COPD.
Information on mobility, pain/physical complaints and anxiety/depression was derived from
the EQ-5D, and on overall health from the SF-12 questionnaire.
Physical activity assessment
The subjects received the accelerometer, instructions on its use, and a diary sheet at the study
center. Participants were asked to start wearing the monitor on the following morning imme-
diately after getting out of bed, and to complete a daily diary (S1 Methods) which included the
time of getting up, going to work, getting back from work, start and end of specific sport epi-
sodes, type of sport performed, and going to sleep. Non-wear time was also included along
with an explanation e. g. taking a shower or swimming. The measurement of PA was obtained
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from ActiGraph GT3X (Pensacola, Florida) accelerometers with the use of the ActiLife soft-
ware (version 6.11.2, firmware 4.4.0). The accelerometer was attached to an elastic belt and
worn over a one week period at the hip on the side of the dominant hand.
Measured accelerations primarily sampled at 30 Hz and stored at 1 Hz were resampled in
one minute epochs for further data analysis. As recommended by ActiGraph, data filtering
was set to default (‘normal’). 1-minute epochs were chosen to allow for comparisons with
other population-based studies [8, 9, 12–14] and for applicability of available activity level cali-
bration studies that were performed based on accelerometer counts and oxygen consumption
per minute [20, 21]. Since it is debated whether the triaxial assessment of PA might be able to
capture more complex movement than uniaxial and therefore might derive a better estimation
of PA, we used both information for our analysis [22, 23].
According to the recorded acceleration value per minute, each minute was classified into
one of three activity levels (sedentary, light, MVPA) using two approaches: the uniaxial count
cut-offs of the vertical axis were based on the commonly used Freedson et al. [20] cut-offs and
the triaxial vector magnitude cut-offs referred to Sasaki et al. [21]. In our analysis the uniaxial
cut-offs for sedentary, light and MVPA were set to100,>100, and1952 counts/minute
and the triaxial cut-offs to<200,2690, and>2690 counts/minute, respectively. Further, the
minutes per person obtained in each single activity level were summed and divided by the
number of recorded days; resulting in the average minutes per day per subject spent in
sedentary, light, or MVPA. Several steps were applied to assure high quality data, which are
Fig 1. Participant recruitment and data handling. 1After exclusion of 3 outliers. 2Multiple reasons possible (detailed description in S1 Methods).
NHANES algorithm: National Health and Nutrition Examination Survey algorithm [19].
doi:10.1371/journal.pone.0172503.g001
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described in detail in the additional file–S1 Methods. Days were excluded if the difference
between the non-wear time algorithm, which was based on the NHANES algorithm [19], and
the diary non-wear time was>120 minutes (if the accelerometer indicated a non-wear time)
or>60 minutes (if the non-wear time was reported in the diary). Further reasons for exclusion
were missing information on time spent awake, no reported non-wear time over the whole
reporting period, and an incorrect handling of the accelerometer. MVPA for non-wear time
<2 hours during sport was imputed using the percent of time spent in MVPA during PA of
each subject or, if not available, through sex specific averages [24]. Through imputation, a
mean of 3 minutes of MVPA/day (about 11%) was added to the recorded MVPA of 56 sub-
jects. Valid days were required to have at least 10 hours of recording time, or>7 hours if the
subjects reported day length was<10 hours. To account for differences in PA between week-
days and weekends that were shown in previous studies [25, 26], subjects were included in the
analysis only if they had at least 3 valid weekdays and 1 valid weekend day.
Statistical analyses
Pearson’s Chi-square test, Fishers exact test (if cell count<5), and Wilcoxon rank-sum test
(adjusting for multiple testing using the Holm correction, if necessary) were used to assess
sex specific differences, group differences in the analyzed study population, and differences
between subjects designated to participate in the “Lung health & physical activity” section and
those who participated in the PA assessment. Time counts of all three activity levels were aver-
aged over the reporting period for each subject and described by median and the 25th and 75th
percentiles.
Among the study population, age, ranging from 48 to 68 years, was grouped into three age
tertiles (low:<55 years; intermediate: 55–61, and advanced:>61 years). BMI (kg/m2) was cal-
culated using values of height and weight obtained by physical examination in the study center.
Subjects were categorized as normal weight (BMI 18–25 kg/m2), overweight (BMI25 kg/
m2), and obese (BMI30 kg/m2) [27].
Mean minutes of MVPA/subject showed a skewed distribution, with a great variance. Nega-
tive binomial regression, which accounts for overdispersion, was applied to investigate the
associations between time spent in each PA level (sedentary, light, or MVPA) with sex, age and
BMI.
Sedentary, light and MVPA served as outcome in all analyses. Each outcome was expressed
in minutes averaged over the recording period for each subject and rounded to the nearest
integer. For each outcome, a basic model was applied, which was adjusted for sex, age and
BMI. Stepwise selection (combined forward and backward selection), using the lowest Akaike
information criterion (AIC) as stopping rule, was performed to determine a model for each
activity level considering several covariates. Besides sex, age and BMI, the following covariates
were assessed: (1) season, categorized as winter (start of measurement: December to February),
spring (March to May), summer (June to August), and autumn (September to November), (2)
education, categorized as low (<10 years of school), middle (10 years of school) and high (>10
years of school), (3) hypertension, (4) diabetes, (5) asthma, (6) COPD, (7) difficulties with
walking, (8) pain or physical complaints, and (9) anxiety or depression. All models with seden-
tary and light activity as outcome were additionally adjusted for average wear time/day. Our
study population comprised Caucasians only, so ethnicity was not considered as a covariate.
A potential interaction effect of sex was tested in the final models. Sensitivity analyses were
performed through exclusion of subjects reporting fair/poor overall health (N = 49) and exclu-
sion of subjects who reported myocardial infarction (N = 14) and/or stroke (N = 8), to avoid
possible bias towards a lower PA due to these diseases. All analyses were performed with
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uniaxial cut-offs. To assess the impact of uni- vs. triaxial motion monitoring and to ensure bet-
ter comparability to other studies, we replicated all aforementioned analyses using triaxial cut-
offs.
Adherence to the WHO PA recommendation was defined as achieving at least 2.5 hours of
MVPA/week in bouts of at least 10 minutes. Therefore, hours of MVPA/day spent in bouts of
at least 10 minutes were averaged across the recording period for each subject and multiplied
by seven.
For all analyses the statistical program R, version 3.2.0 [28], was used and p-values below
0.05 were considered statistically significant.
Results
Of 562 subjects who provided accelerometer data, 478 had valid data that passed the quality
control (Fig 1, S1 Methods). Three subjects were excluded from the analyses; one male due to
extremely high total measured uniaxial MVPA values (averaged 223 minutes/day compared to
the median 35 minutes/day in all males), one female due to extremely high MVPA values in
the triaxial measurement (averaged 252 minutes/day compared to the median 43 minutes/day
in all females) and a second male due to severe obesity (BMI of 62 kg/m2). The final study pop-
ulation comprised of 475 subjects with a mean age of 58 years (Table 1). At least 6 valid days
were recorded by 89% of the subjects while 2% had 4 valid days. Males accounted for 47% of
the subjects. The prevalence of overweight and obesity was 80% in males and 63% in females,
respectively, and differed significantly between sexes. Subjectively reported overall health was
good to excellent in 90% of subjects. 53% reported at least one chronic morbidity when consid-
ering hypertension, diabetes, asthma, COPD, walking difficulties, pain/physical complaints or
anxiety/depression. In comparison to all other participants designated to the “Lung health &
physical activity” section of the KORA FF4 follow up (N = 481) participants in PA (N = 562)
reported more often a very good overall health. All other population characteristics did not dif-
fer (Table A in S1 Tables).
Activity levels
The overall median recorded wear time averaged per subject was about 15 h/day (Fig 2). The
daily median time spent sedentary was higher in males than in females (586 vs. 529 minutes,
respectively, p<0.05), whereas females engaged in more light activity (303 vs. 343 minutes,
respectively, p<0.05) (Fig 2, Table B in S1 Tables). The daily median time spent in MVPA was
35 minutes (25-75th percentile: 21–49 minutes) for males and 28 minutes for females (25-75th
percentile: 17–47 minutes) (p<0.05). In the total population, of the daily recorded time, a
median of 61% (25-75th percentile: 54–67%) was spent in sedentary behavior, whereas the
median time spent in light and MVPA was 35% (25-75th percentile: 30–42%) and 3% (25-75th
percentile: 2–5%), respectively.
Age comparisons revealed that subjects aged<55 years spent more minutes in MVPA/day
than those aged>61 years, irrespective of sex (median: 35 and 26 minutes in males, and 31
and 21 minutes in females, respectively, p<0.05). Normal and overweight men and women
spent more time in MVPA/day compared to obese subjects (median: 44, 36 and 28 minutes in
males, and 34, 28, and 20 minutes in females, respectively (p<0.05); Table C in S1 Tables).
Investigation of covariates
Whilst in sedentary and light activity no associations were seen with age and BMI in the basic
models, negative associations were present between MVPA and the highest age tertile (ratio
0.75; 95% confidence interval (CI) 0.65, 0.87)) as well as obesity (ratio 0.67; CI: 0.57, 0.78)
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(Table 2). Exclusion of subjects with myocardial infarction and/or stroke (N = 21) did not sub-
stantially alter the results. Models with the lowest AIC after stepwise selection (combined for-
ward and backward selection) considering sex, age, BMI, seven chronic morbidities or health
limitations, season and education as covariates are shown in Table 2. Associations of sex, the
highest age tertile and obesity with MVPA remained significant.
In our cohort, no or only unstable associations of morbidity with PA levels could be deter-
mined. Pain or physical complaints were negatively associated with MVPA in the best fit
model obtained by stepwise selection, but were not significant after exclusion of subjects with
myocardial infarction and those with stroke (p<0.1). Results were only slightly altered after
exclusion of subjects who reported fair/poor overall health. Due to an interaction effect
between sex and diabetes, we stratified the models of sedentary and light activity by sex.
After stratification, diabetes showed a negative association with light activity and a positive
Table 1. Characteristics of the study population (% (N)).
Males Females Total
47.2% (224) 52.8% (251) 100% (475)
Age, years (mean: 58; range: 48–68)
55 34.8 (78) 30.7 (77) 32.6 (155)
55–61 31.7 (71) 38.6 (97) 35.4 (168)
!61 33.5 (75) 30.7 (77) 32.0 (152)
Working, yes* 75.9 (170) 64.9 (163) 70.1 (333)
Education
Low (10 years of school) 46.0 (103) 45.8 (115) 45.9 (218)
Medium (= 10 years of school) 25.0 (56) 32.7 (82) 29.1 (138)
High (!10 years of school) 29.0 (65) 21.5 (54) 25.1 (119)
Body mass index, kg/m2*
Normal (25) 19.6 (44) 37.1 (93) 28.8 (137)
Overweight (25, 30) 50.9 (114) 35.5 (89) 42.7 (203)
Obese (30) 29.5 (66) 27.5 (69) 28.4 (135)
Overall health (reported)
Excellent/very good 32.1 (72) 25.1 (63) 28.4 (135)
Good 60.3 (135) 62.2 (156) 61.3 (291)
Fair/poor 7.6 (17) 12.7 (32) 10.3 (49)
Hypertension, yes* 39.3 (88) 29.1 (73) 33.9 (161)
Diabetes, yes 6.2 (14) 7.2 (18) 6.7 (32)
Asthma ever, yes 8.0 (18) 11.6 (29) 9.9 (47)
COPD, yes 7.1 (16) 10.4 (26) 8.8 (42)
Difﬁculties in walking
Not at all/slight 95.1 (213) 93.2 (232) 94.1 (445)
Moderate/hard 4.9 (11) 6.8 (17) 5.9 (28)
Pain or physical complaints*
Not at all/slight 90.2 (202) 81.3 (204) 85.5 (406)
Moderate/hard 9.8 (22) 18.7 (47) 14.5 (69)
Feeling anxious/depressed*
Not at all/slight 96.9 (216) 90.0 (226) 93.2 (442)
Moderate/strong 3.1 (7) 10.0 (25) 6.8 (32)
*p0.05 in Chi-square test (males vs. females).
COPD: Chronic obstructive pulmonary disease.
doi:10.1371/journal.pone.0172503.t001
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association with time spent sedentary in females only (p<0.05; Table 2). Further, an unstable
interaction effect was found between sex and the highest age tertile (>61 years), suggesting a
positive association of advanced age with sedentary and a negative association with light activ-
ity in men, while no association was shown in females (data not shown).
Duration pattern of time spent in MVPA
The majority of time spent in MVPA was accumulated in short bouts i.e. less than 5 minutes
(Fig 3, Table D in S1 Tables). Overall, the median time spent in bouts of at least 1 minute was
3.52 hours/week, 1.11 hours in bouts of at least 5 minutes and only 0.45 hours in bouts of at
least 10 minutes. The median decrease of time spent in MVPA per subject lasting at least 1
minute was 66% when the bout was raised to at least 5 minutes and 86% when the bout was
further raised to at least 10 minutes. MVPA bouts of at least 10 minutes did not differ between
age tertiles for either sex.
We found that 168 subjects in our population did not achieve a single episode of MVPA
lasting at least 10 minutes. While 26% of normal weight subjects did not reach at least one
episode of MVPA spent in at least 10 minutes, this amount was almost double in obese sub-
jects (45%) (Table E in S1 Tables). The highest proportion of subjects who did not meet this
10 minute threshold was found among those with difficulties in walking or pain/physical
complaints.
Fig 2. Total wear time and time spent in sedentary, light andmoderate to vigorous (MVPA) activity in minutes/day averaged
per subject. *p0.05 in Wilcoxon rank-sum test (males vs. females).
doi:10.1371/journal.pone.0172503.g002
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Adherence to WHO physical activity recommendation
As recommended by the WHO adults should accumulate a minimum of 2.5 hours of at least
moderate intensity PA/week spent in bouts of 10 minutes or greater. In our population, only
14% met this recommendation; 36 men and 30 women, respectively. While 15% of subjects
aged<55 years adhered to the WHO recommendation, 11% reached this threshold in the
advanced age category (>61 years). The highest prevalence of adherence was found within the
Table 2. Count ratios (95% confidence intervals) of uniaxial averageminutes/day of moderate-to-vigorous physical activity (MVPA), sedentary or
light activity estimated by negative binomial regression.
Outcome Sedentary Light MVPA
Variables Model Basic1 Stepwise1 Basic1 Stepwise1 Basic Stepwise
Sex Female - - - - - -
Male 1.06
(1.03;
1.10)
1.06 (1.03; 1.09) 0.88
(0.84;
0.92)
0.89 (0.85; 0.93) 1.24
(1.10;
1.39)
1.23 (1.09;
1.38)
Age, years 55 - - - - - -
55–61 0.97
(0.94;
1.01)
0.97 (0.93; 1.00) 1.05
(1.00;
1.11)
1.06 (1.00; 1.11) 0.99
(0.86;
1.13)
0.99 (0.86;
1.14)
!61 1.04
(1.00;
1.07)
1.04 (1.00; 1.08) 0.97
(0.91;
1.02)
0.96 (0.91; 1.01) 0.75
(0.65;
0.87)
0.76 (0.65;
0.87)
BMI (kg/m2) Normal (25) - - - - - -
Overweight (25,
30)
0.99
(0.96;
1.03)
1.00 (0.97; 1.04) 1.02
(0.97;
1.08)
x 0.85
(0.74;
0.98)
0.87 (0.76;
1.00)
Obese (30) 1.03
(0.99;
1.07)
1.04 (1.00; 1.08) 0.99
(0.94;
1.05)
x 0.67
(0.57;
0.78)
0.71 (0.60;
0.83)
Education Low (10 years of
school)
- - - - - -
Medium (= 10
years of school)
- 1.05 (1.01; 1.08) - 0.93 (0.88; 0.98) - x
High (!10 years
of school)
- 1.09 (1.06; 1.13) - 0.87 (0.82; 0.92) - x
Pain/physical
complaints
Not at all/slight - - - - - -
Moderate/hard - x - x - 0.83 (0.70;
0.98)
Hypertension No - - - - - -
Yes - x - x - 0.91 (0.80;
1.04)
Diabetes No - - - - - -
Yes - 1.07 (1.01; 1.13) - 0.89 (0.82; 0.97) - x
[stratiﬁed by sex: 1.12 (1.04;
1.21) females; 0.99
(0.91;1.08) males]
[stratiﬁed by sex: 0.80 (0.72;
0.88) females; 1.00
(0.87;1.16) males]
Signiﬁcant associations (p0.05) are shown in bold. Basic model was adjusted for sex, age, and body mass index (BMI). Besides sex, age, and BMI,
considered variables in the stepwise selection model (combined forward and backward selection) were: season, education, hypertension, diabetes, asthma,
chronic obstructive pulmonary disease (COPD), difﬁculties with walking, pain or physical complaints, and anxiety/depression. Models with the lowest Akaike
information criterion (AIC) are shown.
1Model additionally adjusted for average recorded wear time/day.
xCovariate did not remain in main model.
doi:10.1371/journal.pone.0172503.t002
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middle aged group with 55 to 61 years (16%). Among subjects adhering to the WHO recom-
mendation the prevalence of having hypertension, diabetes, asthma, COPD, walking difficul-
ties, pain/physical complaints or anxiety/depression ranged from 3% (walking difficulties) up
to 24% (hypertension) (Table E in S1 Tables), while 50% presented none of these morbidities.
Comparison of triaxial to uniaxial results
When applying triaxial cut-offs, subjects were less inactive and spent more time in light activity
or MVPA compared to uniaxial cut-offs (median 469 vs. 552 minutes sedentary, 397 vs. 324
minutes light, and 46 vs. 30 minutes MVPA, respectively), whereas group comparisons consid-
ering sex, age and BMI showed similar trends. Males, younger subjects and subjects with a
lower BMI spent more time in MVPA (Tables B and C in S1 Tables). As observed for uniaxial
data, the strongest associations in regression analyses were also present between MVPA
and advanced age (ratio 0.77; CI: 0.67, 0.87) or obesity (ratio 0.79; CI: 0.69, 0.91) (Table F in
Fig 3. Time spent in moderate to vigorous activity (MVPA) in at least 1, 5, and 10minute bouts categorized by age and adherence to
WHO physical activity recommendations.Hours/day spent in MVPA are averaged over the recording period of each subject and multiplied
by seven. MVPA cut-off set at 1952 counts/minute (uniaxial). Green dashed circles: Subjects whomet theWHO physical activity
recommendation of 2.5 hours of MVPA/week in at least 10 minute bouts. 1Median percent decrease in time spent in MVPA after excluding
bouts shorter than 5 and 10 minutes, respectively.
doi:10.1371/journal.pone.0172503.g003
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S1 Tables). Obesity was negatively associated with light activity (ratio 0.91; CI: 0.86, 0.96) and
positively with sedentary behavior (ratio 1.11; CI: 1.05, 1.16). Considering 1 minute, 5 minute
and 10 minute bouts of time spent in MVPA showed a similar pattern as with uniaxial cut-offs
(S1 Fig). In line with increased time spent in MVPA observed by triaxial assessment the num-
ber of subjects meeting the WHO recommendation increased from 66 to 81. Comparable to
uniaxial, the adherence was 17.1% (41 males and 40 females) (Table D in S1 Tables), with 18%
of subjects aged<55 years, 19% aged 55–61 years and 14% aged>61 meeting the threshold.
Among subjects not achieving at least one episode of time spent in MVPA in a 10 minute
bout, the highest prevalence of the investigated morbidities was still present among subjects
with difficulties in walking (Table G in S1 Tables).
Discussion
The time spent in MVPA was generally low among adults aged 48–68 years from southern
Germany, while men engaged more in MVPA than women. MVPA was significantly lower
among obese subjects and those aged>61 years. Only a median of 14% of MVPA was accumu-
lated in bouts of at least 10 minutes, which would count towards meeting theWHO PA recom-
mendations. This is why only 66 subjects (14%) met the threshold of at least 2.5 hours of
MVPA/week in bouts of at least 10 minutes.
The low prevalence of adherence to the WHO PA recommendation is comparable to other
European studies. In Norway, 20% of the study population (N = 3267), aged 20–85 years, accu-
mulated at least 30 minutes of daily MVPA in bouts of 8–10 minutes [12]. Of 1114 Swedish
participants (age range 18–79 years), 52% accumulated at least 30 minutes/day of MVPA, but
only 1% reached 30 minutes/day in 3 periods of 10 minute bouts [13]. In Portugal, 7–9%
participants aged 40–64 years and 3% aged 65 years or older, accumulated at least 30 minutes
MVPA/day in periods of at least 10 minutes [14]. Similar to our study, all three studies used
ActiGraph accelerometers, which is a commonly used device for objective PA assessment [11],
but varied slightly in terms of cut-offs (1952 to 2020 counts/minute for MVPA), number of
measured days (4 to 7) as well as application of international PA recommendations (e.g. allow-
ing 1–2 minutes of non-movement throughout the 10 minute bout) and population character-
istics such as age. Nevertheless, in general the adherence to the WHO PA recommendation
among all studies was widely below 50%.
In our analysis, in both, men and women, the majority of wear time was spent sedentary,
being higher in males than in females. A meta-analysis has recently reported that the risk for
all-cause mortality is increased for subjects with high amounts of sedentary behavior, assessed
as sitting time, but that this effect seems to be mitigated through PA [29]. Subjects in the high-
est quartile of PA and sitting time for>8h showed a lower mortality risk than those in the least
active quartile and<4h sitting time. The highly active subjects achieved about 60–75 minutes
moderate PA/day which was even higher than the recommendedWHO threshold [29]. In con-
trast, not meeting the WHO PA recommendations was found to account for about 6% of the
burden of coronary heart disease, 7% of type 2 diabetes, and 10% of colon cancers worldwide,
which would be addressed by increasing PA [30].
German large scale population-based data, based on self-reports, reported an adherence to
WHO PA recommendation of 18%, both in the 50–59 years and the 60–69 years age groups
[15]. This prevalence was only slightly higher than the prevalence found in our cohort (14%
uniaxial and 17% triaxial). However, despite the similar trend, no direct comparisons are pos-
sible, as the correlation between self-reported and directly measured PA was found to be only
low-to-moderate [6].
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Our data showed that the median number of daily minutes of MVPA decreased across age
and BMI categories, and further, that males achieved more minutes of MVPA, which is in line
with other studies [8, 9, 13, 14]. A similar pattern was shown in the health survey for England
in 2008, where participants in the normal weight category spent on average fewer minutes in
sedentary time and more time in MVPA than those who were in the overweight or obese cate-
gory, showing also a declining gradient of averaged minutes spent in MVPA with age [8]. In
contrast, we found that within all three age tertiles (<55, 55–61 and>61 years) the median
decrease of averaged hours spent in MVPA/week per subject was around 66% when raising
the consecutive MVPA counts to 5 minutes, and around 87% when raising this threshold to at
least 10 minutes. While the highest amount of subjects not achieving a single MVPA bout of at
least 10 minutes was seen among subjects reporting difficulties in walking (61%) and pain or
physical complaints (58%), the majority of subjects reporting any other investigated morbidity
reached at least one 10 minute bout of MVPA. A study investigating German adults aged
between 65–89 years reported a similar tendency, showing a stronger association between dis-
ability and PA than between multimorbidity and PA [16].
No stable association of hypertension, asthma, diabetes, COPD, walking difficulties, pain/
physical complaints, or anxiety/depression with time spent in MVPA was found. This result
should be interpreted with caution due to the low prevalence of morbidities such as COPD
(9%) or diabetes (7%) and probably mainly mild disease stages in our study population.
Despite the possibility that more active subjects participated in the PA assessment, our results
indicate that there is an urgent need to improve PA among adults in southern Germany, given
that subjects spent a median of 61% of the time sedentary, and in contrast only 3% in MVPA/
day. Furthermore, only 14% met the WHO PA recommendation.
The present results, including subjects aged 48–68 years resident in the region of Augsburg
in southern Germany, are limited to the selected study population which had a relatively low
response of 54%, likely leading to a potential risk of selection bias. Further, our results are
based on cross-sectional data, which does not allow generalizations about long term PA behav-
ior. Within our study population, the prevalence of morbidities was low and probably at early
stages. Furthermore, these were assessed by questionnaires only and were not verified by an
examination from a physician. The assessment of pain or physical complaints, and walking dif-
ficulties was based on self-report without precise definition of the cause.
Despite these limitations, this study has several strengths revealing new insights into PA lev-
els and duration pattern of German adults assessed by accelerometry. Data on objectively mea-
sured PA among German adults is rare. Despite the inability to measure all PA engagement
equally well, the advantage of the use of accelerometers is the ability to analyze the intensity
and duration of consecutive minutes of PA, while minimizing the risk of reporting bias occur-
ring in self-reports [5, 6, 9, 10].
There is a lot of methodological diversity among studies investigating PA with accelerome-
ters [22]. This is partly due to the use of different devices, the investigation of uni- or triaxial
movement measures as well as the chosen cut-points [11, 21–23]. Thus we provided data
based on different approaches to illustrate the potential impact on the measured PA of adults
in our study and to provide data for comparability with other studies published.
Conclusions
In conclusion, the prevalence of being physically active was found to be generally low among
adults from southern Germany. Overall, time spent in MVPA was accumulated mainly in very
short bouts and one third of the population did not achieve a single 10 minute bout of MVPA
contributing towards the WHO PA recommendation. Furthermore, only one in eight subjects
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achieved the WHO threshold, indicating a further need for PA promotion in Germany, partic-
ularly among older and obese subjects.
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Methods 1 
 
S1 Methods: Detailed description of diary, quality control and data 
imputation. 
Diary 
Participants were asked to fill out a detailed course of the day diary for seven consecutive 
days. For a better understanding, a one day example was provided. The diary was provided 
in German language to the participants and was translated to English for publication only. 
Course of the day Example 
Date 13.04.2012 
Getting up: Sensor from wrist to hip (time) 6:15 
How well did you sleep? (1: Very good to 6: 
Poor) 3 
How do you get to work? Car 
(e. g. by car, bus)   
Time you leave the house - to work 7:30 
Starting time of work 8:00 
End time of work 18:00 
Arrival time at home 18:45 
Have you taken a nap? 13:00 -  
(if yes, time from … to)  13:45 
Type of physical activity e.g. soccer, basketball, 
hiking, cycling Soccer 
Was this activity performed as member of a sports 
club or gym? Yes 
Start         …………… 19:30 
Finish        ………….. 21:15 
Going to bed time 23:30 
  How did you feel today?          →  2 
 
   
Time and reason for removing the accelerometer   
  Example 
Time and duration 6:20 - 6:40 
Reason  Showering 
Time and duration 
19:45 - 
21:00 
Reason Swimming 
Methods 2 
 
Quality control 
We performed several steps to assure the best possible data quality. The number of non-
valid days was 635 (16.4%). Wearing days were excluded if one or more of the below 
described exclusion criteria were met. Days were excluded if:  
 differences occurred by comparison of the wear time between the diary report and 
the accelerometric data. Therefore, an algorithm based on the algorithm derived 
from the National Health and Nutrition Examination Survey 
(http://riskfactor.cancer.gov/tools/nhanes_pam) was applied. Non-wear time periods 
were defined as at least 60-minute time intervals of consecutive zero counts, 
allowing up to two consecutive minutes with nonzero counts less than or equal to 
100 counts. Differences between this non-wear time algorithm and the reported wear 
time were calculated in minutes for each event. Because of the uncertainty of 
misclassification of wear periods as non-wear time and the other way round, we 
based our limits for exclusion of time intervals near the 3th and 97th percentile of the 
difference distribution. The limits were set to > |- 120| min difference between 
algorithm and diary, if algorithm reported non-wear time, and > 60 minutes, if the 
subject reported non-wear time, but the accelerometer showed counts of wear time 
 317 days 
 time of getting up or going to sleep could not be assessed or were missing > 4 times 
throughout the measuring period  212 days 
 the wear time was < 10 hours according to the diary (exception: if the total time 
spent awake was only between 8 to 10 hours than this day was excluded if the 
reported wear time in the diary was < 7 hours)  74 days 
 non wear-time was not at all reported through the whole wear time period, despite 
the fact that the accelerometer is not waterproof  71 days 
 reported sport activities without wearing the accelerometer lasted > 2 hours, e.g. 
during a competition or skiing  43 days  
 the sensor was defective or worn incorrectly (upside down or on hand instead of hip) 
 13 days 
 the subject reported to be sick (excluding headache or cold) on 2 or more days in a 
row (exclusion of days from the second day on)  13 days 
 the subject reported to be sick on most of the reporting days  10 days 
 the subject reported to be on a trip – meaning non-regular hole day activity -  on 2 or 
more days in a row (exclusion of days from the second day on)  1 day 
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Imputation of non-wear time periods during sport 
To account for MVPA obtained through sport activities lasting < 2 hours when the 
accelerometer was not worn, e.g. during swimming or material arts, we imputed non-wear 
time MVPA. If the reported non-wear time period lasted between 30 and 120 minutes, we 
subtracted 15 minutes before imputation accounting for preparing for PA, e.g. changing 
clothes. The efficiency (e.g. % of time spent in MVPA during PA) of each subject as well as 
sex specific averages were calculated. If the subject had a period of reported PA while 
wearing the accelerometer, MVPA of non-wear time sport was imputed through multiplication 
of time spent in PA without wearing the accelerometer by his or her efficiency and added to 
the subjects total MVPA on this particular day. If no PA activities were reported where the 
accelerometer was worn, sex specific efficiency averages were used for imputation. 
S1 Fig. Time spent in moderate to vigorous activity (MVPA) (triaxial cut-offs) in at least 1, 5, and 
10 minute bouts categorized by age and adherence to WHO physical activity recommendations. 
 
Hours/day spent in MVPA are averaged over the recording period of each subject and multiplied 
by seven.MVPA cut-off set at 2690 counts/minute (triaxial). - - - Subjects who met the WHO 
physical activity recommendation of  2.5 hours of MVPA/week in at least 10 minute bouts. 
ᬅMedian percent decrease in time spent in MVPA after excluding bouts shorter than 5 and 10 
minutes, respectively.
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S1 Tables: Tables A-G. 
Table A. Comparison of subjects participating in accelerometry compared to all other 
participants designated to participate in the “Lung health & physical activity” section of the 
KORA FF4 follow-up (n/N (%)). 
Participating in accelerometry Yes 
(N=562) 
No  
(N=481) 
Sex, male 264/562 (47) 224/481 (47) 
Age, years   
 < 55 189/562 (34) 145/481 (30) 
 55-61 201/562 (36) 159/481 (33) 
 > 61 172/562 (31) 177/481 (37) 
Working, yes 400/561 (71) 317/481 (66) 
Education   
 Low (< 10 years of school)  261/561 (47) 238/479 (50) 
 Medium (= 10 years of school) 153/561 (27) 117/479 (24) 
 High (> 10 years of school) 147/561 (26) 124/479 (26) 
Body mass index, kg/m2   
 Normal (< 25) 156/562 (28) 154/481 (32) 
 Overweight (< 30) 245/562 (44) 181/481 (38) 
 Obese (≥ 30) 161/562 (29) 146/481 (30) 
Overall health (reported)*   
 Excellent/very good 155/562 (28) 102/479 (21) 
 Good 346/562 (62) 304/479 (63) 
 Fair/poor 61/562 (11) 73/479 (15) 
Hypertension, yes 185/561 (33) 184/481 (38) 
Diabetes, yes 37/561 (7) 37/481 (8) 
Asthma ever, yes 54/562 (10) 47/481 (10) 
COPD, yes 48/562 (9) 34/480 (7) 
Myocardial infarction, yes 17/561 (3) 14/481 (3) 
Stroke, yes 12/562 (2) 11/477 (2) 
Difficulties in walking   
 Not at all/slight  523/559 (94) 439/479 (92) 
 Moderate/hard  36/559 (6) 40/479 (8) 
Pain or physical complaints   
 Not at all/slight 476/562 (85) 388/479 (81) 
 Moderate/hard 86/562 (15) 91/479 (19) 
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Participating in accelerometry Yes 
(N=562) 
No  
(N=481) 
Feeling anxious/depressed    
 Not at all/slight 519/560 (93) 439/478 (92) 
 Moderate/strong 41/560 (7) 39/478 (8) 
*p < 0.05 in Chi-square test. COPD: Chronic obstructive pulmonary disease. 
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Table B. Median time spent in the three activity levels – sedentary, light and moderate to 
vigorous (MVPA) stratified by sex.  
  Uniaxial  Triaxial  
  
Males 
47.2 % (224) 
Females 
52.8 % (251) 
Males 
47.2 % (224) 
Females 
52.8 % (251) 
Median (25th, 75th percentile) of minutes per day averaged per subject 
 Sedentary 586 (520, 646)* 529 (473, 587) 504 (434, 577)* 435 (376, 498) 
 Light 303 (253, 369)* 343 (291, 396) 370 (308, 437)* 416 (362, 471) 
 MVPA 35 (21, 49)* 28 (17, 47) 49 (33, 71)* 43 (28, 62) 
Median % (25th, 75th percentile) of recorded time spent in each level per day averaged 
per subject 
 Sedentary 63 (56, 69)* 58 (52, 65) 54 (47, 62)* 48 (42, 55) 
 Light 32 (27, 40)* 38 (33, 44) 40 (34, 48)* 46 (40, 52) 
 MVPA 4 (2, 5)* 3 (2, 5) 5 (4, 8) 5 (3, 7) 
*p < 0.05 in Wilcoxon rank-sum test (males vs. females). 
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Table C. Median time spent in moderate to vigorous activity stratified either by age tertile or 
body mass index (BMI) for males and females.  
  Uniaxial  Triaxial  
  Males  Females  Males Females 
Median (25th, 75th percentile) of minutes per day averaged per subject 
Age, years < 55 35 (24, 57)1 31 (21, 52)1 57 (32, 80)1 45 (32, 65)1 
 55 - 61 40 (29, 54)2 28 (17, 46) 56 (41, 74)2 43 (32, 67) 
 > 61 26 (15, 43) 21 (10, 42) 39 (26, 55) 38 (17, 58) 
BMI, kg/m2 Normal (< 25) 44 (30, 59)3 34 (20, 54)3 55 (39, 79) 50 (30, 72)3 
 Overweight (≥ 25) 36 (21, 51)4 28 (18, 40)4 49 (32, 70) 40 (32, 58) 
 Obese (≥ 30) 28 (17, 41) 20 (11, 33) 43 (32, 63) 35 (21, 57) 
Significant difference (p < 0.05) by pairwise Wilcoxon rank-sum test stratified by sex 
between the categories: 
1 age < 55 and age > 61  
2 age 55-61 and age > 61 
3 normal and obese 
4 overweight and obese
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Table D. Bout-length of median hours/week spent in moderate to vigorous activity stratified 
by sex and age.  
*p < 0.05 (pairwise) Wilcoxon rank-sum test between (A) males and females, and (B) age 
categories stratified by sex.  
 
  Uniaxial  Triaxial  
  Males Females Males Females 
Median hours (25th, 75th percentile) of MVPA/week  
A ≥ 1 min bouts 4.00 (2.43, 5.68)* 3.22 (1.92, 5.4) 5.76 (3.78, 8.12)* 5.02 (3.22, 7.21) 
 ≥ 5 min bouts 1.27 (0.53, 2.95) 0.99 (0.35, 2.45) 1.75 (0.83, 3.42) 1.38 (0.64, 2.98) 
 ≥ 10 min bouts 0.59 (0, 1.75) 0.35 (0, 1.36) 0.70 (0.17, 2.01) 0.52 (0, 1.76) 
Median % (25th, 75th percentile) of MVPA/week spent in ≥ 5 and ≥ 10 minute bouts of total 
MVPA/week  
B ≥ 5 min bouts     
 Age, years     
 < 55 32 (20, 49) 39 (17, 55) 32 (21, 42) 32 (19, 46) 
 55 - 61 30 (19, 55) 34 (17, 54) 29 (20, 50) 28 (17, 46) 
 > 61 37 (15, 59) 34 (12, 54) 33 (15, 49) 32 (16, 51) 
 ≥ 10 min bouts     
 Age, years     
 < 55 13 (0, 33) 12 (0, 38) 14 (2, 25) 13 (4, 37) 
 55 - 61 15 (0, 34) 17 (0, 31) 11 (4, 29) 12 (4, 28) 
 > 61 17 (0, 37) 9 (0, 32) 16 (0, 30) 10 (0, 32) 
% (n) reached WHO recommendation 
  16.1 (36) 12.0 (30) 18.3 (41) 15.9 (40) 
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Table E. Achieved bout-length applying uniaxial cut-offs. 
% (N) achieved bout of MVPA  < 10 minutes1 
(N=168) 
 ≥ 10 minutes2  
(N=241)  
≥ 10 minutes  
+ adherence to WHO3 
(N=66) 
Sex    
 Male  32.1 (72) 51.8 (116) 16.1 (36) 
 Female 38.2 (96) 49.8 (125) 12.0 (30) 
Age, years (range: 48 - 68)     
 < 55 32.9 (51) 52.3 (81) 14.8 (23) 
 55-61 31.5 (53) 52.4 (88) 16.1 (27) 
 > 61 42.1 (64) 47.4 (72) 10.5 (16) 
Body mass index, kg/m2 *    
 Normal (< 25) 25.5 (35) 50.4 (69) 24.1 (33) 
 Overweight (≥ 25) 35.5 (72) 53.7 (109) 10.8 (22) 
 Obese (≥ 30) 45.2 (61) 46.7 (63) 8.1 (11) 
Education*    
Low (< 10 years of school)  45.4 (99) 45.9 (100) 8.7 (19) 
Medium (= 10 years of 
school) 
32.6 (45) 48.6 (67) 18.8 (26) 
High (> 10 years of school) 20.2 (24) 62.2 (74) 17.6 (21) 
Hypertension*    
 No 30.3 (95) 53.8 (169) 15.9 (50) 
 Yes 45.3 (73) 44.7 (72) 9.9 (16) 
Diabetes     
 No 34.5 (153) 51.5 (228) 14.0 (62) 
 Yes 46.9 (15) 40.6 (13) 12.5 (4) 
Asthma     
 No 34.1 (146) 51.4 (220) 14.5 (62) 
 Yes 46.8 (22) 44.7 (21) 8.5 (4) 
COPD    
 No 34.6 (150) 51.5 (223) 13.9 (60) 
 Yes 42.9 (18) 42.9 (18) 14.3 (6) 
Difficulties in walking*    
 Not at all/slight 33.7 (150) 52.1 (232) 14.2 (63) 
 Moderate/hard  60.7 (17) 32.1 (9) 7.1 (2) 
Pain or physical complaints*     
 Not at all/slight 31.5 (128) 53.2 (216) 15.3 (62) 
 Moderate/hard 58.0 (40) 36.2 (25) 5.8 (4) 
Feeling anxious/depressed     
 Not at all/slight 34.6 (153) 52.0 (230) 13.3 (59) 
 Moderate/strong 43.8 (14) 34.4 (11) 21.9 (7) 
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 1subjects who did not achieve moderate to vigorous activity (MVPA) in bouts of at least 10 
minutes. 2subjects who achieved bouts of at least 10 minutes, but less than 2.5 hours per 
week. 3subjects who met the WHO recommendation of 2.5 hours a week in bouts of at least 
10 minutes. *p < 0.05 Chi-square test or Fisher's Exact Test (if cell counts < 5). COPD: 
Chronic obstructive pulmonary disease.
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Table F. Count ratios (95% confidence intervals) of triaxial average minutes per day of moderate-to-vigorous physical activity (MVPA), 
sedentary or light activity estimated by negative binomial regression. 
Outcome Sedentary  Light  MVPA  
                                          Model  
Variables   
Basic
1
  Stepwise
1
  Basic
1
  Stepwise
1
  Basic  Stepwise  
Sex Female - - - - - - 
 Male 1.09 (1.05; 1.13) 1.09 (1.05; 1.13) 0.89 (0.85; 0.92) 0.89 (0.85; 0.92) 1.18 (1.06; 1.31) 1.18 (1.06; 1.31) 
Age < 55 - - - - - - 
 55-61 0.96 (0.92; 1.00) 0.95 (0.91; 0.99) 1.05 (1.00; 1.10) 1.05 (1.01; 1.10) 1.01 (0.89; 1.15) 1.02 (0.90; 1.15) 
  > 61 1.03 (0.98; 1.08) 1.04 (0.99; 1.08) 0.99 (0.94; 1.04) 0.99 (0.94; 1.04) 0.77 (0.67; 0.87) 0.76 (0.67; 0.87) 
BMI Normal - - - - - - 
 Overweight 1.04 (0.99; 1.08) 1.05 (1.00; 1.09) 0.97 (0.93; 1.02) 0.96 (0.92; 1.01) 0.88 (0.78; 1.00) 0.88 (0.77; 0.99) 
  Obese 1.11 (1.05; 1.16) 1.12 (1.07; 1.18) 0.91 (0.86; 0.96) 0.90 (0.85; 0.95) 0.79 (0.69; 0.91) 0.78 (0.68; 0.90) 
Education Low  - - - - - - 
 Medium - 1.07 (1.02; 1.11) - 0.93 (0.89; 0.98) - 0.97 (0.86; 1.10) 
 High - 1.12 (1.07; 1.17) - 0.90 (0.86; 0.94) - 0.85 (0.75; 0.97) 
Pain/physical 
complaints 
Not at all/slight - - - - - - 
 Moderate/hard - 
x
 - 
x
 - 0.87 (0.75; 1.01) 
Diabetes No - - - - - 
-
 
 Yes - 1.10 (1.02; 1.18) 
[stratified by sex: 
1.18 (1.07; 1.30) 
females; 0.99 (0.89; 
1.11) males] 
- 0.90 (0.83; 0.97) 
[stratified by sex: 
0.81 (0.74; 0.89) 
females; 1.02 (0.90; 
1.16) males] 
- 
x
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Significant associations (p < 0.05) are shown in bold. Basic model was adjusted for sex, age, and body mass index (BMI). Besides sex, age, 
and BMI considered variables in the stepwise selection model were: season, education, hypertension, diabetes, asthma, chronic obstructive 
pulmonary disease (COPD), difficulties with walking, pain or physical complaints, and anxiety/depression. Models with the lowest Akaike 
information criterion (AIC) are shown. 1Model additionally adjusted for average recorded wear time/day. xCovariate did not remain in main 
model.
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Table G. Achieved bout-length applying triaxial cut-offs.  
% (N) achieved bout of MVPA  < 10 minutes1 
(N=116) 
 ≥ 10 minutes2  
(N=278)  
≥ 10 minutes  
+ adherence to WHO3 
(N=81) 
Sex    
 Male  23.2 (52) 58.5 (131) 18.3 (41) 
 Female 25.5 (64) 58.6 (147) 15.9 (40) 
Age, years (range: 48 - 68)     
 < 55 23.9 (37) 58.1 (90) 18.1 (28) 
 55-61 19.6 (33) 61.3 (103) 19.0 (32) 
 > 61 30.3 (46) 55.9 (85) 13.8 (21) 
Body mass index, kg/m2 *    
 Normal (< 25) 17.5 (24) 54.7 (75) 27.7 (38) 
 Overweight (≥ 25) 26.6 (54) 59.6 (121) 13.8 (28) 
 Obese (≥ 30) 28.1 (38) 60.7 (82) 11.1 (15) 
Education*    
Low (< 10 years of school)  29.8 (65) 57.3 (125) 12.8 (28) 
Medium (= 10 years of 
school) 
24.6 (34) 53.6 (74) 21.7 (30) 
High (> 10 years of school) 14.3 (17) 66.4 (79) 19.3 (23) 
Hypertension,     
 No 22.3 (70) 58.3 (183) 19.4 (61) 
 Yes 28.6 (46) 59.0 (95) 12.4 (20) 
Diabetes,     
 No 23.3 (103) 59.6 (264) 17.2 (76) 
 Yes 40.6 (13) 43.8 (14) 15.6 (5) 
Asthma,     
 No 23.4 (100) 59.1 (253) 17.5 (75) 
 Yes 34.0 (16) 53.2 (25) 12.8 (6) 
COPD,    
 No 23.6 (102) 59.4 (257) 17.1 (74) 
 Yes 33.3 (14) 50.0 (21) 16.7 (7) 
Difficulties in walking*    
 Not at all/slight 22.9 (102) 59.6 (265) 17.5 (78) 
 Moderate/hard  50.0 (14) 42.9 (12) 7.1 (2) 
Pain or physical complaints*     
 Not at all/slight 22.4 (91) 58.6 (238) 19.0 (77) 
 Moderate/hard 36.2 (25) 58.0 (40) 5.8 (4) 
Feeling anxious/depressed    
 Not at all/slight 24.2 (107) 59 (261) 16.7 (74) 
 Moderate/strong 25.0 (8)    53.1 (17) 21.9 (7) 
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 1subjects who did not achieve moderate to vigorous activity (MVPA) in bouts of at least 10 
minutes. 2subjects who achieved bouts of at least 10 minutes, but less than 2.5 hours per 
week. 3subjects who met the WHO recommendation of 2.5 hours a week in bouts of at least 
10 minutes. *p < 0.05 Chi-square test or Fisher's Exact Test (if cell counts < 5). COPD: 
Chronic obstructive pulmonary disease. 
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Abstract
Background: In lung disease, physical activity (PA) yields beneficial health effects, but its association with the function
of healthy lungs has rarely been studied. We investigated the association of accelerometer-based PA with spirometric
indices, maximal inspiratory mouth pressure (PImax) and lung diffusion capacity in lung-healthy adults.
Methods: In total, 341 apparently lung-healthy participants from the population-based KORA (Cooperative Health
Research in the Region of Augsburg) FF4 cohort study (45% male, aged 48-68 years, 47% never smokers) completed
lung function testing and wore ActiGraph accelerometers over a one week period at the hip. In adjusted regression
analyses, moderate to vigorous PA (MVPA) was characterized as: sex-specific activity quartiles, achieving ≥ 10 consecutive
minutes (yes vs. no), and meeting the WHO PA recommendations (yes vs. no).
Results: Positive associations of MVPA-quartiles with forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC),
and corresponding Global Lung Function Initiative z-scores were found. Subjects in the most active quartile (> 47 or >
50 min/day for females and males, respectively) had 142 ml [95% CI: 23, 260] higher FEV1 and 155 ml [95% CI: 10, 301]
higher FVC than those in the least active quartile (< 17 or < 21 min/day for females and males, respectively); however
these associations were stronger among ex−/current smokers. Achieving at least once 10 consecutive minutes of
MVPA was only associated with higher PImax [β-estimate: 0.57 kPa; 95% CI: 0.04, 1.10], remaining significant among
never smokers. No associations were found with diffusion capacity or for reaching the WHO-recommended 150 min of
MVPA/week in 10-min bouts.
Conclusions: Although the effects were small, active subjects showed higher spirometric results. The observed
associations were more pronounced among ever smokers suggesting a higher benefit of PA for subjects being at a
higher risk for chronic lung diseases.
Keywords: Lung function, Spirometry, Activity behavior, Accelerometer
Background
Physical activity (PA) reduces the risk of premature mor-
tality and chronic diseases like cardiovascular disease or
diabetes mellitus [1]. Benefits of activity apply also to
persons with chronic lung diseases such as asthma or
chronic obstructive pulmonary disease (COPD), who are
therefore encouraged to engage in regular PA [2, 3].
Studies have shown that higher PA was associated with a
lower risk of hospital admissions and all-cause mortality
in COPD patients [3, 4]. Furthermore, the diffusion cap-
acity of the lung for carbon monoxide was shown to be
a predictor of a decline in 6-min-walking distance in
COPD patients [5]. Moreover, exercise training in COPD
patients was associated with improved ventilatory
muscle function and showed positive effects on the
forced vital capacity (FVC) [6, 7]. Due to the positive
health effects of PA in patients with chronic lung
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diseases, PA has been incorporated into pulmonary
rehabilitation programs [8].
In population-based studies, PA was shown to be asso-
ciated with slower age-related decline of the forced ex-
piratory volume in 1 s (FEV1) in adults [9, 10]. Results
from a longitudinal study among middle-aged men
showed that those with higher levels of PA experienced
slower lung function decline over 25 years [11]. How-
ever, all these studies assessed PA by questionnaires,
which was found to correlate only low-to-moderately
with activity objectively assessed by motion sensors in
adults [12, 13].
Only a few studies have investigated the association of
accelerometer-based PA with lung function. Moreover,
the association between PA and lung function in lung-
healthy persons is unclear. In lung-healthy adolescents,
no associations were found between accelerometer-
based PA and a broad range of spirometric parameters
[14]. In adults, results of a study among 62 smokers
showed that lung function between inactive participants,
defined as those who engaged in less than 150 min/week
of moderate to vigorous PA (MVPA), and active ones
did not differ [15]. Thus, the evidence is inconclusive.
Furthermore, studies among athletes suggest that
endurance exercise is associated with higher FVC and
improved lung diffusion capacity [16, 17]. A study
among 25 healthy men showed an improvement of max-
imal inspiratory pressure after 5 weeks of inspiratory
muscle training [18], as observed in COPD patients after
exercise training [6], whereas the increase in respiratory
muscle endurance of marathon runners was described as
a consequence of differences in breathing pattern devel-
oped during running rather than respiratory muscle
strength [19].
Considering the limited evidence on the association
between PA and lung function in lung-healthy popula-
tions, our aim was to investigate the association of
accelerometer-based PA with lung function in apparently
lung-healthy German adults from a population-based
sample. Therefore, we addressed different aspects of
lung function i.e. lung volume, airflow limitation,
pulmonary gas exchange (TLCO/VA) and inspiratory
muscle strength (PImax).
Methods
Study population
The present analysis was based on a follow-up study of the
KORA S4 (KORA: Cooperative Health Research in the Re-
gion of Augsburg) cohort comprising 4261 adults (51.0%
female) examined in 1999 – 2001. A description of the
primary study design has been published previously [20].
The selection of the study population is displayed in
detail in Fig. 1. In the KORA FF4 follow-up study 2279
participants (51.6% female) aged 38-88 years were exam-
ined between June 2013 and September 2014. Covering
only the age range 48-68 years, 1043 of these partici-
pants were selected for the “Lung health & physical ac-
tivity” study, which comprised spirometry, assessment of
Fig. 1 Selection of participants. KORA: Cooperative Health Research in the Region of Augsburg. ATS: American Thoracic Society. ERS: European
Respiratory Society. COPD: chronic obstructive pulmonary disease. FEV1: forced expiratory volume in 1 s. FVC: forced vital capacity. TLCO/VA:
transfer factor of the lung for carbon monoxide adjusted for hemoglobin and divided by alveolar volume. PImax: maximum inspiratory mouth pressure
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inspiratory muscle strength (PImax), measures of
pulmonary gas exchange, and accelerometer-based
assessment of habitual PA over one week. Information
on sociodemographic variables, and current medication
intake seven days before examination was obtained from
standardized interviews and questionnaires. For the
assessment of common diseases such as stroke or myo-
cardial infarction, subjects were asked for each disease
separately if a doctor has ever diagnosed this particular
disease. Further, information on mobility and pain/dis-
comfort was obtained from the EuroQol five dimensions
questionnaire (EQ-5D 5 L) [21].
Of 1010 subjects who participated in spirometry, spi-
rometric data of 990 participants were considered as
valid based on international recommendations [22]. In
accelerometry, two males with values greater than the
mean plus seven times the standard deviation for weight
and MVPA, respectively, were excluded during data
management after quality control, resulting in 477
subjects with valid accelerometric data out of 562 who
initially participated. For the selection of lung-healthy
subjects, 465 subjects who had both, valid spirometry
and accelerometry were considered. Subjects who re-
ported a doctor’s diagnosis of asthma, emphysema,
chronic bronchitis or COPD, or used pulmonary medi-
cation including antileukotrienes, inhaled sympathomi-
metics, anticholinergics, and/or steroids were excluded
from this analysis (N = 71). Furthermore, subjects with
FEV1/FVC < 0.7 (indication of airflow limitation) were
excluded (N = 53) [23]. Finally, 341 apparently lung-
healthy subjects were available for the present analysis.
Among these, PImax results were available for 331 sub-
jects (54.7% female) and results for the transfer factor of
the lung for carbon monoxide divided by alveolar
volume (TLCO/VA) for 322 subjects (54.3% female).
Physical activity assessment
A detailed description of the procedure, data handling,
quality control and inclusion criteria has been reported
previously [24]. In brief, participants were asked to wear
an ActiGraph GT3X accelerometer (Pensacola, Florida)
over a one week period at the hip from getting up until
going to bed time and to complete a daily diary which
included the time of getting up, going to sleep, and rea-
sons for and duration of non-wear time. Non-wear time
according to the accelerometer data was assessed based
on the algorithm derived from the National Health and
Nutrition Examination Survey [25]. Days were consid-
ered as not valid, if the difference between the non-wear
time algorithm applied to the accelerometer data and
the diary non-wear time was greater than 60 min (if the
non-wear time was reported in the diary) or greater than
120 min (if the accelerometer indicated a non-wear
time). Subjects were excluded in case of no reported
non-wear time over the whole 7 day reporting period
although the accelerometer should have been removed
during water activities e.g. showering. Further exclusion
criteria for single days were missing information on time
spent awake, day length < 10 h/day, non-wear time dur-
ing sport activities lasting > 2 h, or incorrect handling of
the accelerometer e.g. hand instead of hip. Further
details of all exclusion criteria have been previously pub-
lished [24]. Subjects were only included in the analysis if
they had at least 3 valid weekdays and 1 valid weekend
day. 89% of the subjects included in our analysis re-
corded at least 6 days, 9% had 5 days and 2% provided
4 days only. Measured accelerations of the vertical axis
were stored at 1 Hz and converted into 1-min epochs
classifying a moderate to vigorous PA (MVPA) level as
≥ 1952 counts per minute, as proposed by Freedson et
al. [26]. Non-wear time during sport was imputed as
described here [14, 24].
Since the relationship between MVPA and lung function
measures adjusted for sex, age, and height was non-linear,
MVPA was divided into sex-specific quartiles. In addition,
two further binary PA variables were built based on the
World Health Organization (WHO) recommendation
stating that adults should accumulate at least 150 min
of MVPA/week in bouts of at least 10 min [27].
PA was quantified as exposure in three ways: (1) sex-
specific MVPA quartiles; (2) achieving at least one 10-min
bout of MVPA over the whole measurement period (yes
vs. no); (3) reaching the WHO threshold of 150 min
MVPA/week in at least 10-min bouts (yes vs. no). Cut-offs
for sex-specific MVPA quartiles were set as follows: cut-
off for males: 1st ≤ 21.6 min/day, 2nd > 21.6-35.2 min/day,
3rd > 35.2-49.9 min/day, 4th > 49.9 min/day; and cut-offs
for females: 1st ≤ 17.2 min/day, 2nd > 17.2-28.3 min/day,
3rd > 28.3-46.7 min/day, 4th > 46.7 min/day, respectively.
Lung function assessment
Lung function assessment was performed in line with
the American Thoracic Society (ATS) and European Re-
spiratory Society (ERS) statements [22, 28, 29].
Flow-volume curves were obtained using a pneumo-
tachograph-type spirometer (MasterScope, Jaeger, Hoech-
berg, Germany). Subjects were guided to perform at least
3 and up to 8 spirometric maneuvers per test in order to
obtain acceptable and reproducible values. During the ma-
neuvers both flow-volume and volume-time curves were
monitored online by a trained examiner. After each test,
the curves were visually inspected, artifacts e.g. coughing
were excluded and the results were selected and evaluated
according to the ATS/ERS recommendations [22], includ-
ing a good start with extrapolated volume < 0.5% of FVC
or 0.15 l, an exhalation of ≥ 6 s or a plateau in volume-
time curve. Spirometric parameters included FEV1, FVC,
FEV1/FVC, and forced expiratory flow between 25% and
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75% of exhaled FVC (FEF25-75). Standardized z-scores
were calculated using reference equations for spirometry
from the Global Lung Function Initiative (GLI) [30].
TLCO was determined using the single-breath technique.
Subjects were asked to perform a maximum of 5 trials in
order to achieve acceptable and reproducible values with
an inspired volume > 85% of the largest vital capacity in
<4 s, and an effective breath hold time within 8 to 12 s ac-
cording to ATS/ERS recommendations [28]. TLCO results
were adjusted for hemoglobin obtained from blood sam-
ples collected on the day of the physical examination in
the study center [28]. For determination of PImax, subjects
were instructed to exhale to residual volume followed by a
maximal voluntary inspiration against an obstructed
mouth piece with a small leak to prevent glottic closure
using a flanged mouth piece [29]. The highest peak
inspiratory pressure achieved during a minimum of 3 and
a maximum of 15 maneuvers was used for analysis
(MasterScreen PFT, Jaeger, Hoechberg, Germany).
Statistical analyses
Sex-specific differences were assessed using Pearson’s
Chi-squared test (categorical variables), the t-test (nor-
mal distribution), and Wilcoxon rank-sum test
(skewed distribution). Mean and corresponding standard
deviation or percentages (%, N) were used to describe
subject characteristics and categorized PA. Due to a
non-normal distribution, median and 1st and 3rd
quartiles were reported for continuous MVPA.
Adjusted linear regression models were applied to
analyze associations between PA and lung function pa-
rameters. Since spirometric parameters (FEV1, FVC, and
FEF25-75) were correlated (r = 0.61 to 0.98), the results of
regression analyses were not adjusted for multiple test-
ing. For each spirometric parameter, the mean plus/
minus 4 times the standard deviation was calculated for
each sex to determine sex-specific outliers. According to
this definition one subject was excluded in the analyses
using z-scores for FEV1 and FVC and another in FEF25-
75 models. The main model was adjusted for sex, age,
height, weight, smoking status categorized as never, ex-,
or current smokers, education level categorized as low
(<10 years of school, i. e. “Hauptschule” in Germany),
middle (10 years of school, i.e. “Realschule”) and high
(>10 years of school, i.e. “Gymnasium”), and a doctor’s
diagnosis of hay fever (ever). Regression models for stan-
dardized GLI z-scores [30] that are already adjusted for
ethnicity, sex, age, and height, were adjusted only for
additional variables. Covariates remained in the model
independent of statistical significance. As the mean body
mass index (BMI) was 27.7 kg/m2 we included a
sensitivity analysis, replacing weight with BMI in the
main analysis.
To assess if the association might be modified through
other covariates potentially associated with lung func-
tion, sensitivity analyses were done. Since smoking be-
havior has an impact on lung function and might modify
potential associations, we calculated the main regression
model with stratification into never and ex−/current
smokers. In further analyses, the main model was
additionally adjusted for moderate to extreme problems
in walking about and/or pain or discomfort, season cate-
gorized as winter (start of measurement: December to
February), spring (March to May), summer (June to
August), and autumn (September to November), or for
self-reported acute respiratory infections in the last three
weeks prior to lung function testing. All participants
were Caucasian therefore ethnicity was not included as a
covariate. Interaction effects between MVPA and sex
were tested in the main model. In case of significant
interaction effects (p < 0.05), stratified results were
reported additionally.
To eliminate a possible impact of myocardial infarc-
tion and/or stroke (N = 15), subjects with a history of
these events were excluded from the main model as a
further sensitivity analysis.
The statistical program R, version 3.3.3 [31], was used
for all analyses and p-values below 0.05 were considered
statistically significant.
Results
The study population consisted of 341 (45% male) appar-
ently lung-healthy subjects (i.e. no chronic lung diseases
or pulmonary medication intake, and FEV1/FVC ≥ 0.7)
with a mean age of 57 years (Table 1). The prevalence of
current smoking was 14%, while 47% of the participants
reported to be never smokers. Despite a lower prevalence
of females among all ex−/current smokers than among
never smokers (50.0% and 61.6%, respectively), 70.2% of
current smokers were female. BMI was comparable be-
tween never and ex−/current smokers. Mean z-scores
were lower among ex−/current smokers compared to
never smokers, being statistically significant for z-score
FEF25-75. Nevertheless, smoking status did not affect PA
(Additional file 1: Table S1). Included subjects were
slightly younger (mean age of 57 years vs. 58 years,
respectively) and more often never smokers (46.6% vs.
37.8%, respectively) compared to all other subjects
performing spirometry (Additional file 1: Table S2).
Overall, participants spent a median of 31 min/day in
MVPA with a range from 1 to 111 mean min/day, being
lower for females than for males (median 28 vs. 35 min,
respectively). In total, 66% of subjects achieved at least
one 10-min bout of MVPA, and 15% achieved the rec-
ommended 150 min of MVPA/week in at least 10-min
bouts (Table 1).
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Table 1 Population characteristics, lung function and physical activity measurements
Males (n = 152) Females (n = 189)
Age
mean years (SD) 57.1 (5.8) 57.5 (5.3)
Height *
mean cm (SD) 177.0 (6.0) 162.1 (6.0)
Weight *
mean kg (SD) 88.8 (13.5) 71.5 (14.4)
BMI*
n normal (BMI < 25) (%) 27 (17.8) 79 (41.8)
n overweight (≥ 25 BMI <30) (%) 83 (54.6) 61 (32.3)
n obese (BMI ≥ 30) (%) 42 (27.6) 49 (25.9)
Smoking status*
n never smokers (%) 61 (40.1) 98 (51.9)
n ex-smokers (%) 77 (50.7) 58 (30.7)
n current smokers (%) 14 (9.2) 33 (17.5)
Education*
n low (< 10 years of school) (%) 68 (44.7) 84 (44.4)
n medium (10 years of school) (%) 34 (22.4) 66 (34.9)
n high (> 10 years of school) (%) 50 (32.9) 39 (20.6)
Hay fever
n yes (%) 22 (14.5) 43 (22.8)
Problems in walking about, and/or pain or discomfort
n not at all/slight (%) 135 (88.8) 154 (81.9)
n moderate/extreme (%) 17 (11.2) 34 (18.1)
Lung function
FEV1*
mean l (SD) 3.76 (0.57) 2.66 (0.42)
FVC*
mean l (SD) 4.88 (0.71) 3.39 (0.56)
FEV1/FVC*
mean % (SD) 77.08 (3.93) 78.5 (4.14)
FEF25-75*
mean l/s (SD) 3.16 (0.91) 2.37 (0.63)
Z-score FEV1
mean (SD) 0.25 (0.86) 0.32 (0.91)
Z-score FVC
mean (SD) 0.29 (0.80) 0.35 (0.87)
Z-score FEV1/FVC
mean (SD) −0.12 (0.58) −0.15 (0.63)
Z-score FEF25-75
mean (SD) −0.01 (0.78) −0.01 (0.80)
TLCO, hemoglobin adjusted*
mean mmol/min/kPa (SD) 9.88 (1.50) 6.90 (1.07)
TLCO/VA*
mean mmol/min/kPa/l (SD) 1.45 (0.16) 1.38 (0.18)
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Physical activity and spirometric parameters
In the total population, being in the most active MVPA
quartile was associated with higher FEV1, FVC, FEV1 z-
score and FVC z-score (Table 2, Additional file 1: Table
S3). FEV1 was 142 ml higher in the most active subjects,
i.e. females that engaged > 47 min/day and males that
engaged > 50 min/day in MVPA, than in the least active
quartile, i.e. < 17 min/day for females or < 21 min/day
for males. Stratified analyses revealed that these associa-
tions remained in ex−/current smokers, but not in never
smokers (Table 2).
The results for FVC were comparable to those observed
for FEV1, except for an interaction effect between the
third MVPA quartile and sex that was present for FVC
only. After stratification an association was found for fe-
males only (Additional file 1: Table S4). Sensitivity ana-
lyses, e.g. further adjustment for walking difficulties and/
or discomfort, and exclusion of subjects with stroke and/
or myocardial infarction did not substantially change our
results. Adjusting for BMI instead of weight led to the very
similar results (Additional file 1: Table S5).
When MVPA was quantified as achieving at least
one 10-min bout, an association with lung function
was found in sex-stratified analyses for FEV1, FVC, z-
scores for FEV1 and FVC in females only
(Additional file 1: Tables S4 and S6). Reaching the
recommended 150 min of MVPA/week in at least 10-
min bouts was negatively associated with FEV1, FVC,
Table 1 Population characteristics, lung function and physical activity measurements (Continued)
Males (n = 152) Females (n = 189)
PImax*
mean kPa (SD) 9.77 (2.53) 6.67 (2.12)
Physical activity
MVPA*
median of mean min/day (1st; 3rd quartile) 35.2 (21.6; 49.9) 28.3 (17.2; 46.7)
10-min bout of MVPA achieved
n yes (%) 104 (68.4) 120 (63.5)
WHO threshold achieved
n yes (%) 24 (15.8) 26 (13.8)
SD standard deviation, BMI body mass index, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, FEF25-75 forced expiratory flow between 25% and 75%
of FVC, TLCO/VA transfer factor of the lung for carbon monoxide adjusted for hemoglobin and divided by alveolar volume, PImax maximum inspiratory mouth
pressure, MVPA moderate to vigorous physical activity
*p < 0.05 (males vs. females)
Table 2 Association of physical activity with spirometric parameters
MVPA Total population
(n = 341)
Never smokers
(n = 159)
Ex- and current smokers
(n = 182)
Quartilea β (95% CI) p-value β (95% CI) p-value β (95% CI) p-value
FEV1, ml 2 72 (−44, 188) 0.22 44 (−129, 218) 0.62 81 (−78, 240) 0.32
3 124 (7, 242) 0.04 167 (−7, 341) 0.06 60 (−104, 224) 0.47
4 142 (23, 260) 0.02 84 (−89, 257) 0.34 195 (29, 360) 0.02
FVC, ml 2 91 (−52, 235) 0.21 48 (−160, 256) 0.65 114 (−87, 316) 0.27
3 107 (−38, 251) 0.15 190 (−18, 398) 0.08 11 (−196, 219) 0.92
4 155 (10, 301) 0.04 75 (−132, 282) 0.48 227 (18, 437) 0.04
FEV1/FVC, % 2 0.01 (−1.18, 1.21) 0.98 −0.03 (−1.86, 1.80) 0.97 −0.10 (−1.72, 1.51) 0.90
3 0.87 (−0.34, 2.07) 0.16 0.33 (−1.50, 2.17) 0.72 1.07 (−0.59, 2.74) 0.21
4 0.64 (−0.57, 1.85) 0.30 0.70 (−1.12, 2.52) 0.45 0.56 (−1.12, 2.24) 0.51
FEF25-75, ml/s 2 100 (−120, 319) 0.37 61 (−266, 388) 0.71 101 (−201, 403) 0.51
3 277 (56, 499) 0.01 239 (−89, 566) 0.16 246 (−65, 558) 0.12
4 161 (−63, 384) 0.16 106 (−220, 433) 0.52 213 (−102, 527) 0.19
MVPA moderate to vigorous physical activity, CI confidence interval, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, FEF25-75 forced expiratory flow
between 25% and 75% of FVC
aLeast active MVPA quartile (1st quartile) was used as reference. All models were adjusted for sex, age, height, weight, education level, a doctor’s diagnosis of hay
fever and depending on the population analyzed also by smoking status (never, ex- or current)
Statistically significant associations (p < 0.05) are shown in bold
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and z-scores for FEV1 and FVC in males only
(Additional file 1: Tables S4 and S7).
Physical activity and inspiratory muscle strength
Subjects who engaged in at least one 10-min bout of
MVPA had an estimated increase of PImax by 0.6 kPA
(Table 3). However, in analyses stratified by smoking sta-
tus, this association was significant only in never
smokers (Additional file 1: Table S8).
Physical activity and pulmonary gas exchange
PA was not associated with TLCO/VA in any analysis,
except for a negative association found with the third
MVPA quartile among never smokers (Table 3,
Additional file 1: Table S8).
Discussion
The present analyses revealed weak positive associations
between the most active subjects and volumetric indices
in adults without lung function limitation. These associ-
ations were primarily observed among ex−/current
smokers, but not in never smokers, suggesting that the
effect might be driven by smoking behaviour. While PA
showed no association with TLCO/VA, PImax was higher
in subjects who engaged in at least one 10-min bout of
MVPA during the recording period, compared to those
who did not.
Compared to current recommendations PA was ra-
ther low in our population-based cohort. Median
daily MVPA was 31 min, and only 15% of subjects
met the WHO PA recommendation. This finding,
however, is comparable to results obtained through
the questionnaire-based German Health Interview and
Examination Survey for Adults where 18% of 50-
69 year old participants achieved the WHO activity
threshold [32].
Still, weak associations with lung function were
present in our analyses.
An association between PImax and the achievement of
at least one 10-min bout of MVPA was found in our
population, remaining significant in never smokers only.
In COPD, twitch mouth pressure has previously been
shown to decrease with increasing disease severity and
PImax could be improved by exercise training [6, 33]. A
study among marathon athletes compared to sedentary
controls reported a higher respiratory muscle endurance
in the athletes - probably as a result of breath technique,
but a similar PImax [19].
In our population, those who reached at least one 10-
min bout spent in MVPA showed a higher PImax, while
reaching the WHO PA recommendation showed no in-
crease. It might be that the threshold of engaging for at
least 10 consecutive minutes in habitual MVPA, i.e. sep-
arating subjects with short bouts of activity and those
with at least sporadic activity for 10 min, might repre-
sent a plateau. However, this result should be interpreted
with caution due to the weak associations found and the
potentially minor clinical relevance.
While TLCO has previously been shown to be a clinic-
ally relevant predictor of exercise capacity determined
by 6-min-walking distance test in COPD patients [5], PA
was not found to be a predictor of TLCO/VA in our ap-
parently lung-healthy population. The lack of findings
might be due to the possibly small effects that could not
be detected in habitual PA of middle-aged adults
without lung function limitation.
Our results show a weak, but positive association of
PA and volumetric lung function indices, primarily seen
among ex−/current smokers. Compared to the least ac-
tive subjects, subjects engaging on average more than
about 48 min/day in MVPA had a 142 ml higher FEV1.
Considering an annual decline of around 25 ml of FEV1
Table 3 Association of physical activity with pulmonary gas exchange and inspiratory muscle strength
Pulmonary gas exchange (TLCO/VA), 10−1 mmol/min/kPa/l Maximum inspiratory mouth pressure (PImax), kPa
β (95% CI) p-value β (95% CI) p-value
MVPA quartiles,
1st – least active (reference) – – – –
2nd 0.01 (−0.47, 0.49) 0.98 0.39 (−0.32, 1.10) 0.28
3rd −0.30 (−0.80, 0.19) 0.23 0.23 (−0.48, 0.94) 0.53
4th – most active 0.25 (−0.25, 0.75) 0.33 0.05 (−0.68, 0.78) 0.90
10-min bout of MVPA achieved,
yes vs. no −0.03 (−0.39, 0.34) 0.88 0.57 (0.04, 1.10) 0.04
WHO threshold achieved,
yes vs. no 0.36 (−0.13, 0.84) 0.15 0.00 (−0.71, 0.71) 1.00
The models were adjusted for sex, age, height, weight, smoking status categorized as never, ex-, or current smokers, education level, and a doctor’s diagnosis of
hay fever
TLCO/VA transfer factor of the lung for carbon monoxide adjusted for hemoglobin and divided by alveolar volume, PImax maximum inspiratory mouth pressure, CI
confidence interval, MVPA moderate to vigorous physical activity
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in adults [34, 35], our results would correspond to an
age-related decline of about 5 years. No causal relation-
ships or long-term effects can be drawn from our cross-
sectional analysis, but our results are in line with those
from a longitudinal study observing that current
smokers with moderate and high PA had a decreased de-
cline in FEV1 and FVC compared with smokers with low
PA [36]; and as in our study, this association was not ob-
served in never smokers. A study including only
smokers did not find an association between the
achievement of at least 150 min/week of MVPA and spi-
rometric parameters [15]. However, observed differences
may be related to diverse designs, population character-
istics and definitions of being active [15, 36]. PA was
suggested to promote an anti-inflammatory status and
to potentially protect against chronic diseases associated
with low-grade systemic inflammation [37]. Smokers are
at a higher risk for COPD and other smoking-related
diseases typically experiencing a low-grade systemic in-
flammation [38]. In our analysis, the positive associa-
tions between being active and volumetric indices were
more pronounced among ex−/current smokers, suggest-
ing a higher benefit of PA for subjects being at a higher
risk for chronic lung diseases.
Strength and limitations
A major strength of this study is the investigation of a
range of standardized lung function parameters obtained
by spirometry, as well as less often investigated measures
of gas exchange and respiratory muscle strength in
apparently lung-healthy adults. We objectively assessed
PA by accelerometry, which is rare, as most available
studies assessed PA by questionnaires [9–11, 36].
Evidence for the association between PA and lung
function in the general population without chronic lung
diseases is likewise rare.
Due to the cross-sectional design of our analysis, it is
not possible to draw conclusions about long-term effects
or causal relations. Although associations were found,
these results should be interpreted with caution due to
the small effects seen with partly wide confidence
intervals. Further, the present results are limited to the
pre-selected lung-healthy study population, comprising
48-68 year old residents in the region of Augsburg in
southern Germany. Information on chronic lung
diseases was assessed via self-report and was not indi-
vidually verified by a physician.
Conclusions
Objective measurements of physical activity showed a
weak, but positive association with slightly higher
volumetric lung function indices in lung-healthy adults
from southern Germany. This association was mainly
observed among ex−/current smokers. Further, engaging
in MVPA for at least 10 consecutive minutes was associ-
ated with higher PImax, remaining significant in never
smokers only. No associations were found for TLCO/
VA. Although the effects were small, our results suggest
a positive association of PA with lung function of lung-
healthy subjects from a population-based cohort.
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Table S1 Population characteristics stratified by smoking status 
  Never smokers 
(n=159) 
Ex- and current 
smokers 
(n=182) 
Sex* n females (%) 98 (61.6) 91 (50.0) 
Age mean years (SD) 57.6 (5.5) 57.2 (5.5) 
Height* mean cm (SD) 167.5 (9.7) 169.9 (9.3) 
Weight* mean kg (SD) 77.3 (16.6) 80.9 (16.2) 
BMI n normal (BMI <25 BMI) (%) 54 (34.0) 52 (28.6) 
 n overweight (≥25 BMI <30) (%) 68 (42.8) 76 (41.8) 
 n obese (BMI ≥30) (%) 37 (23.3) 54 (29.7) 
Education n low (<10 years of school) (%)  62 (39.0) 90 (49.5) 
 n medium (=10 years of school) (%) 54 (34.0) 46 (25.3) 
 n high (>10 years of school) (%) 43 (27.0) 46 (25.3) 
Hay fever n yes (%) 33 (20.8) 32 (17.6) 
Problems in walking 
about/pain/discomfort 
 
n not at all/slight (%) 
 
133 (84.2) 
 
156 (85.7) 
 n moderate/extreme (%) 25 (15.8) 26 (14.3) 
Lung function   
Z-score FEV1  mean (SD) 0.34 (0.92) 0.24 (0.86) 
Z-score FVC  mean (SD) 0.33 (0.84) 0.32 (0.85) 
Z-score FEV1/FVC  mean (SD) -0.07 (0.61) -0.20 (0.60) 
Z-score FEF25-75*  mean (SD) 0.08 (0.82) -0.09 (0.76) 
TLCO/VA*  mean mmol/min/kPa/l (SD) 14.39 (1.68) 13.85 (1.82) 
PImax*  mean kPa (SD) 7.75 (2.86) 8.36 (2.68) 
Physical activity   
MVPA among females median of mean minutes/day  
(1st; 3rd quartile) 
 
28.7 (17.2; 49.6) 
 
28.0 (17.5; 46.3) 
MVPA among males median of mean minutes/day 
(1st; 3rd quartile) 
 
36.6 (23.1; 52.0) 
 
33.0 (21.0; 48.7) 
MVPA quartiles n 1st – least active (%) 38 (23.9) 47 (25.8) 
 n 2nd (%) 37 (23.3) 48 (26.4) 
 n 3rd (%) 41 (25.8) 44 (24.2) 
 n 4th – most active (%) 43 (27.0) 43 (23.6) 
10-minute bout of 
MVPA achieved 
 
n yes (%) 
 
109 (68.6) 
 
115 (63.2) 
WHO threshold 
achieved 
 
n yes (%) 
 
26 (16.4) 
 
24 (13.2) 
*p<0.05 between never and ex-/current smokers.  
2 
 
 
SD: standard deviation. BMI: body mass index. FEV1: forced expiratory volume in 1 second. FVC: forced 
vital capacity. FEF25-75: forced expiratory flow between 25% and 75% of FVC. TLCO/VA: transfer factor of 
the lung for carbon monoxide adjusted for hemoglobin and divided by alveolar volume. PImax: maximum 
inspiratory mouth pressure. MVPA: moderate to vigorous physical activity. WHO: World Health 
Organization. 
 
 Table S2 Comparison of subjects included in the present analysis compared to all other participants of the   
 “Lung Health & physical activity” study performing spirometry 
  Analyzed 
population 
(n=341) 
“Lung Health & physical 
activity” study participants 
with spirometry 
(n=669) 
Sex n female (%) 189 (55.4) 346 (51.7) 
Age*  mean years (SD) 57.4 (5.5) 58.4 (5.8) 
Height mean cm (SD) 168.7 (9.6) 169.3 (9.3) 
Weight mean kg (SD) 79.2 (16.4) 81.0 (18.4) 
BMI n normal (BMI <25 BMI) (%) 106 (31.1) 194 (29.0) 
 n overweight (≥25 BMI <30) (%) 144 (42.2) 273 (40.8) 
 n obese (BMI ≥30) (%) 91 (26.7) 202 (30.2) 
Smoking status* n never smokers (%) 159 (46.6) 253 (37.8) 
 n ex-smokers (%) 135 (39.6) 280 (41.9) 
 n current smokers (%) 47 (13.8) 136 (20.3) 
Education n low (<10 years of school) (%)  152 (44.6) 325 (48.8) 
 n medium (=10 years of school) (%) 100 (29.3) 164 (24.6) 
 n high (>10 years of school) (%) 89 (26.1) 177 (26.6) 
Hay fever n yes (%) 65 (19.1) 140 (20.9) 
Asthma n yes (%) - 98 (14.6) 
COPD or emphysema n yes (%) - 83 (12.4) 
Problems in walking 
about/pain/discomfort* 
 
n not at all/slight (%) 
 
289 (85.0) 
 
530 (79.3) 
 n moderate/extreme (%) 51 (15.0) 138 (20.7) 
 *p<0.05 between study population analyzed and all other subjects participating in spirometry. 
 SD: standard deviation. BMI: body mass index. COPD: chronic obstructive pulmonary disease. 
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Table S3 Association of physical activity with GLI z-scores for spirometric parameters  
 MVPA Total populationa  
(n=341) 
Never smokers  
(n=159) 
Ex- and current smokersb 
(n=182) 
 Quartile β (95% CI) p-value β (95% CI) p-value β (95% CI) p-value 
Z-score FEV1 2 0.17 (-0.10, 0.43)  0.21 0.08 (-0.34, 0.49)  0.72 0.26 (-0.08, 0.60)  0.14 
 3 0.27 (0.01, 0.53)  0.05 0.35 (-0.06, 0.76)  0.10 0.20 (-0.15, 0.55)  0.26 
 4 0.34 (0.07, 0.60)  0.01 0.20 (-0.20, 0.60)  0.33 0.48 (0.12, 0.83)  0.01 
Z-score FVC 2 0.18 (-0.06, 0.43)  0.14 0.10 (-0.27, 0.47)  0.60 0.27 (-0.06, 0.60)  0.11 
 3 0.21 (-0.04, 0.46)  0.10 0.34 (-0.02, 0.71)  0.07 0.09 (-0.24, 0.43)  0.59 
 4 0.31 (0.06, 0.56)  0.01 0.18 (-0.18, 0.54)  0.33 0.45 (0.10, 0.80)  0.01 
Z-score FEV1/FVC 2 -0.04 (-0.22, 0.14)  0.65 -0.04 (-0.32, 0.23)  0.76 -0.04 (-0.27, 0.20)  0.77 
 3 0.09 (-0.09, 0.26)  0.35 -0.01 (-0.29, 0.26)  0.93 0.17 (-0.07, 0.41)  0.18 
 4 0.04 (-0.14, 0.22)  0.63 0.03 (-0.24, 0.30)  0.85 0.06 (-0.19, 0.31)  0.64 
Z-score FEF25-75 2 0.08 (-0.16, 0.31)  0.52 -0.01 (-0.38, 0.37)  0.97 0.16 (-0.14, 0.46)  0.31 
 3 0.25 (0.01, 0.48)  0.04 0.21 (-0.16, 0.57)  0.27 0.27 (-0.04, 0.58)  0.09 
 4 0.18 (-0.06, 0.41)  0.15 0.01 (-0.27, 0.46)  0.61 0.26 (-0.06, 0.58)  0.11 
All models were adjusted for weight, education level, and a doctor’s diagnosis of hay fever.  
aadditionally adjusted for smoking status categorized as never, ex-, or current smokers.  
badditionally adjusted for smoking status categorized as ex- or current smokers.  
GLI: Global Lung Function Initiative. MVPA: moderate to vigorous physical activity. CI: confidence interval. 
FEV1: forced expiratory volume in 1 second. FVC: forced vital capacity. FEF25-75: forced expiratory flow 
between 25% and 75% of FVC.  
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Table S4 Sex-stratified results of linear regression models 
  Males (n=152) Females (n=189) 
  β (95% CI) p-value β (95% CI) p-value 
MVPA  Quartile     
FEV1, ml 2 44 (-160, 248) 0.68 113 (-22, 247) 0.10 
 3 45 (-158, 248)  0.66 202 (66, 339) 0.00 
 4 60 (-148, 268) 0.57 209 (73, 345) 0.00 
FVC, ml 2 52 (-192, 297) 0.67 144 (-26, 314)  0.10 
 3 -72 (-315,171)  0.56 255 (83, 428)  0.00 
 4 88 (-161, 337)  0.49 210 (38, 381)  0.02 
FEV1/FVC, %  2 -0.10 (-1.81, 1.6)  0.90 0.16 (-1.48, 1.80)  0.85 
 3 2.04 (0.34, 3.75)  0.02 0.15 (-1.52, 1.82)  0.86 
 4 -0.21 (-1.96, 1.53)  0.81 1.35 (-0.31, 3.01)  0.11 
Z-score FEV1/FVC 2 -0.02 (-0.27, 0.24)  0.90 -0.04 (-0.28, 0.21)  0.77 
 3 0.31 (0.05, 0.56)  0.02 -0.05 (-0.30, 0.20)  0.69 
 4 -0.05 (-0.3, 0.21)  0.73 0.17 (-0.08, 0.41)  0.20 
10-minute bout of MVPA achieved, yes vs. no 
FEV1, ml  -70 (-229, 90)  0.39 154 (49, 259)  0.00 
FVC, ml  -121 (-312, 70)  0.22 157 (23, 290)  0.02 
Z-score FEV1  -0.11 (-0.42, 0.20)  0.48 0.36 (0.08, 0.64)  0.01 
Z-score FVC  -0.15 (-0.43, 0.14)  0.31 0.30 (0.04, 0.57)  0.03 
WHO threshold achieved, yes vs. no 
FEV1, ml  -196 (-387, -5)  0.05 105 (-39, 249)  0.15 
FVC, ml  -242 (-472, -12)  0.04 79 (-103, 261)  0.39 
Z-score FEV1  -0.38 (-0.75, 0.00)  0.05 0.33 (-0.05, 0.71)  0.09 
Z-score FVC  -0.35 (-0.70, -0.01)  0.05 0.25 (-0.12, 0.61)  0.18 
The models were adjusted for sex, age, height, weight, smoking status, education level, 
and a doctor’s diagnosis of hay fever.  
MVPA: moderate to vigorous physical activity. CI: confidence interval. FEV1: forced 
expiratory volume in 1 second. FVC: forced vital capacity. WHO: World Health 
Organization. 
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Table S5 Association of physical activity with spirometric parameters with adjustment for BMI instead of weight 
 MVPA  Total populationa  
 (n=341) 
 Never smokers  
 (n=159) 
 Ex- and current smokersb 
 (n=182) 
 Quartile  β (95% CI)  p-value  β (95% CI)  p-value  β (95% CI)  p-value 
FEV1, ml 2  71 (-45, 187)  0.23   43 (-131, 216)  0.63   81 (-79, 240)  0.32  
 3  124 (7, 242)  0.04   163 (-11, 337)  0.07   61 (-103, 225)  0.47  
 4  141 (22, 259)  0.02   79 (-94, 252)  0.37   197 (31, 363)  0.02  
FVC, ml 2  89 (-54, 233)  0.22   45 (-162, 252)  0.67   113 (-89, 315)  0.27  
 3  106 (-39, 251)  0.15   183 (-25, 391)  0.09   13 (-195, 222)  0.90  
 4  154 (8, 300)  0.04   68 (-139, 275)  0.52   231 (21, 441)  0.03  
FEV1/FVC, %  2  0.03 (-1.16, 1.22)  0.96   -0.01 (-1.84, 1.82)  0.99   -0.09 (-1.71, 1.53)  0.91  
 3  0.87 (-0.33, 2.07)  0.16   0.36 (-1.48, 2.19)  0.70   1.06 (-0.61, 2.73)  0.21  
 4  0.65 (-0.56, 1.86)  0.29   0.73 (-1.09, 2.56)  0.43   0.55 (-1.13, 2.23)  0.52  
All models were adjusted for sex, age, height, body mass index, education level, and a doctor’s diagnosis of hay 
fever. 
aadditionally adjusted for smoking status categorized as never, ex-, or current smokers.  
badditionally adjusted for smoking status categorized as ex- or current smokers. 
BMI: body mass index. MVPA: moderate to vigorous physical activity. CI: confidence interval. FEV1: forced 
expiratory volume in 1 second. FVC: forced vital capacity. FEF25-75: forced expiratory flow between 25% and 75% of 
FVC.  
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Table S6 Association of at least one 10-minute bout of MVPA achieved with spirometric parameters 
 10-minute bout of MVPA achieved, yes vs. no 
 Total populationa 
(n=341) 
Never smokers 
(n=159) 
Ex- and current smokersb 
(n=182) 
 β (95% CI) p-value β (95% CI) p-value β (95% CI) p-value 
FEV1, ml 36 (-52, 125)  0.42 74 (-59, 207)  0.28 22 (-98, 141)  0.72 
FVC, ml 27 (-82, 136)  0.62 44 (-116, 203)  0.59 33 (-118, 185)  0.67 
FEV1/FVC, %  0.39 (-0.51, 1.29) 0.40 1.19 (-0.18, 2.57) 0.09 -0.23 (-1.43, 0.98)  0.71 
FEF25-75, ml/s 49 (-118, 216)  0.57 157 (-92, 405)  0.22 -28 (-253, 197)  0.81 
Z-score FEV1 0.13 (-0.07, 0.33) 0.21 0.16 (-0.16, 0.47)  0.33 0.12 (-0.15, 0.38)  0.39 
Z-score FVC 0.11 (-0.08, 0.30) 0.24 0.08 (-0.20, 0.36)  0.58 0.15 (-0.11, 0.41) 0.25 
Z-score FEV1/FVC 0.03 (-0.10, 0.17) 0.63 0.12 (-0.09, 0.33)  0.26 -0.04 (-0.22, 0.14) 0.64 
Z-score FEF25-75 0.08 (-0.10, 0.26) 0.38 0.17 (-0.11, 0.45) 0.23 -0.01 (-0.24, 0.22) 0.94 
The models were adjusted for sex, age, height, weight, education level, and a doctor’s diagnosis of hay 
fever. 
aadditionally adjusted for smoking status categorized as never, ex-, or current smokers.  
badditionally adjusted for smoking status categorized as ex- or current smokers.  
MVPA: moderate to vigorous physical activity. CI: confidence interval. FEV1: forced expiratory volume in 1 
second. FVC: forced vital capacity. FEF25-75: forced expiratory flow between 25% and 75% of FVC.
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  Table S7 Association of the achievement of WHO threshold with spirometric parameters 
 WHO threshold achieved, yes vs. no 
 Total populationa 
(n=341) 
Never smokers 
(n=159) 
Ex- and current smokersb 
(n=182) 
 β (95% CI) p-value β (95% CI) p-value β (95% CI) p-value 
FEV1, ml -35 (-153, 82)  0.56 60 (-107, 226) 0.48 -142 (-312, 27)  0.10 
FVC, ml -69 (-214, 75)  0.35 56 (-143, 254) 0.58 -220 (-434, -6)  0.05 
FEV1/FVC, %  0.45 (-0.75, 1.65) 0.46 0.42 (-1.31, 2.15)  0.64 0.65 (-1.07, 2.37)  0.46 
FEF25-75, ml/s -31 (-255, 193)  0.79 18 (-299, 335) 0.91 -62 (-383, 260)  0.71 
Z-score FEV1 0.01 (-0.25, 0.28) 0.93 0.24 (-0.15, 0.63)  0.23 -0.24 (-0.61, 0.13) 0.20 
Z-score FVC -0.01 (-0.26, 0.24) 0.91 0.21 (-0.14, 0.55)  0.24 -0.26 (-0.62, 0.10) 0.16 
Z-score FEV1/FVC 0.04 (-0.14, 0.22)  0.66 0.01 (-0.25, 0.27)  0.94 0.07 (-0.18, 0.33)  0.57 
Z-score FEF25-75 0.01 (-0.22, 0.25) 0.92 0.08 (-0.27, 0.43)  0.66 -0.06 (-0.39, 0.26)  0.70 
The models were adjusted for sex, age, height, weight, education level, and a doctor’s diagnosis of hay 
fever.  
aadditionally adjusted for smoking status categorized as never, ex-, or current smokers.  
badditionally adjusted for smoking status categorized as ex- or current smokers.  
WHO: World Health Organization. CI: confidence interval. FEV1: forced expiratory volume in 1 second. FVC: 
forced vital capacity. FEF25-75: forced expiratory flow between 25% and 75% of FVC. 
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Table S8 Association of physical activity with pulmonary gas exchange and inspiratory muscle strength according to smoking status  
 Pulmonary gas exchange (TLCO/VA),  
10-1 mmol/min/kPa/l 
Maximum inspiratory mouth pressure (PImax), 
kPa 
 Never smokers 
(n=151) 
Ex- and current smokersa 
(n=171) 
Never smokers 
(n=155) 
Ex- and current smokersa 
(n=176) 
 β (95% CI) p-value β (95% CI) p-value β (95% CI) p-value β (95% CI) p-value 
MVPA quartilesa 
1st – least active vs.         
2nd   -0.26 (-0.93, 0.42)  0.45 0.22 (-0.47, 0.91)  0.53 0.85 (-0.21, 1.92)  0.12 0.01 (-0.96, 0.98)  0.98 
3rd  -0.81 (-1.50, -0.13)  0.02 0.12 (-0.61, 0.85)  0.75 0.84 (-0.22, 1.91)  0.12 -0.20 (-1.20, 0.80)  0.70 
4th – most active -0.05 (-0.73, 0.64) 0.90 0.47 (-0.27, 1.20)  0.21 0.17 (-0.90, 1.23)  0.76 -0.01 (-1.05, 1.02)  0.98 
10-minute bout of MVPA 
achieved, yes vs. no 0.00 (-0.54, 0.53)  0.99 -0.09 (-0.61, 0.42)  0.72 0.93 (0.11, 1.74) 0.03 0.37 (-0.35, 1.09)  0.32 
WHO threshold achieved,  
yes vs. no 0.12 (-0.55, 0.79)  0.72 0.56 (-0.16, 1.28)  0.13 0.50 (-0.51, 1.51)  0.33 -0.51 (-1.55, 0.53)  0.33 
All models were adjusted for sex, age, height, weight, education level, and a doctor’s diagnosis of hay fever.  
aadditionally adjusted for smoking status categorized as ex- or current smokers. 
TLCO/VA: transfer factor of the lung for carbon monoxide adjusted for hemoglobin and divided by alveolar volume. PImax: maximum inspiratory 
mouth pressure. CI: confidence interval. MVPA: moderate to vigorous physical activity. WHO: World Health Organization. 
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Research, Max-Lebsche-Platz 31, 81377 Munich, Germany 
Abstract  
Purpose: Among patients with lung disease, decreased lung function is associated with lower 
health-related quality of life. However, whether this association is detectable within the 
physiological variability of respiratory function in lung-healthy populations is unknown. We 
analyzed the association of each EQ-5D-3L dimension (mobility, self-care, usual activities, 
pain/discomfort, anxiety/depression), and self-reported physical inactivity with spirometric 
indices in lung-healthy adults. Modulating effects between inactivity and EQ-5D dimensions 
were considered.  
Methods: 1132 non-smoking, apparently lung-healthy participants (48% male, aged 64±12 
years) from the population-based KORA F4L and Age surveys in Southern Germany were 
analyzed. Associations of each EQ-5D dimension and inactivity with spirometric indices 
serving as outcomes (forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), 
FEV1/FVC, and mid-expiratory flow) were examined by linear regression, considering possible 
confounders. Interactions between EQ-5D dimensions (no problems/any problems) and 
inactivity (four categories of time spent engaging in exercise: inactive to most active) were 
assessed. 
Results: Amongst all participants 42% reported no problems in any EQ-5D dimension, 24% 
were inactive and 32% exercised >2 hours/week. After adjustment, FEV1 was -99 ml (95%CI: 
-166; -32) and FVC was -109 ml (95%CI: -195; -24) lower among subjects with mobility 
problems. Comparable estimates were observed for usual activities. Inactivity was negatively 
associated with FVC (β-coefficient: -83 ml, 95%CI: -166; 0), but showed no interactions with 
EQ-5D.  
Conclusions: Problems with mobility or usual activities, and inactivity were associated with 
slightly lower spirometric parameters in lung-healthy adults, suggesting a relationship between 
perceived physical functioning and volumetric lung function.  
 
Key words: quality of life, EQ-5D, Physical activity, Spirometry, FEV1, FVC  
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Introduction 
Health-related quality of life (HRQL) is reduced in patients with chronic lung diseases such as 
chronic obstructive pulmonary disease (COPD) [1-3]. While various factors, including impaired 
lung function, can lead to a decrease in HRQL with increasing disease severity, physical 
activity has been found to be associated with better HRQL, as well as with less hospital 
admissions in COPD [1, 4-6]. Among subjects with asthma, the mean decline in forced 
expiratory volume in 1 second (FEV1) differed between inactive and active participants by -5 
ml/year (95% confidence interval (CI): -13; 3) [7]. Based on these findings in patients with 
respiratory diseases, it is possible that HRQL or being physically inactive may already be 
associated with lung function among apparently lung-healthy subjects or among those in 
transition to lung disease. Physiological variation of lung function is mainly related to age, 
height, gender and ethnicity in lung-healthy subjects, but is modulated by the continuous 
interplay between adverse and protective biological, environmental and lifestyle factors [8-11]. 
These factors contribute to the considerable inter-individual variability of lung function 
measures observed during lung development and age-related decline [9-11]. This is also 
indicated by the increasing variability of the coefficients of variation for lung function 
parameters with age, e.g. for FEV1 and forced vital capacity (FVC) from about 11% at age 15 
to nearly 18% at age 80 years [12].  
While the association between lung function and HRQL is well established in patients with 
manifest disease [1-3], the relation between respiratory function variability and HRQL in lung-
healthy subjects is less studied.  
At a population level, two studies from the United Kingdom investigated the association 
between FEV1 and a 36-item questionnaire on general health status (Short Form-36, SF-36) 
in adults aged 40-79 years and 50-74 years, respectively [13, 14]. In both studies, positive 
associations of self-reported physical functioning based on the SF-36 with FEV1 were found. 
Subjects were more likely to report a good functional health if they were among the top 20% 
of the FEV1 distribution of the study population [13].  
To our knowledge, no study so far has examined the relationship between the EuroQol 5 
dimensions (EQ-5D) questionnaire as a generic health-related quality of life instrument, and 
lung function in a lung-healthy, population-based cohort with a comprehensive set of 
spirometric measures.  
The EQ-5D has been widely used to assess or compare health status across different 
populations [2, 15-19]. It covers five dimensions of health: mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression. As a short and practical preference-based measure, 
it offers the possibility to assess each dimension of health separately, or as an index-based 
utility score ranging from 0 to 1 (EQ-5D utility) with higher scores meaning 
better health [15]. Results from a comprehensive review revealed a range of EQ-5D utility from 
0.42 to 0.93 in asthma and 0.52 to 0.84 in COPD studies, decreasing with increasing disease 
severity [2]. As expected, HRQL is higher in the general population; a survey among 1966 
German participants reported a mean utility score of 0.94 in males and 0.92 in females [19].  
In the present study including a lung-healthy, non-smoking, German population derived from 
a population-based sample with an expected high overall HRQL, we aimed to investigate 
whether specific health dimensions of the EQ-5D are associated with spirometric indices, also 
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considering possible sex differences. Since physical activity was found to be associated with 
better HRQL [4, 5], and further, associations between physical inactivity and decreased lung 
function have been reported [20, 21], we also assessed whether a direct association exists 
between physical inactivity and lung function, and whether the consideration of inactivity 
affects the association of EQ-5D dimensions with spirometric indices.  
 
Methods 
Study population 
The KORA (Cooperative Health Research in the Region of Augsburg) research platform 
comprises several population-based cohort studies established in 1996. Regular follow-up 
examinations are conducted within KORA as described previously [22, 23]. The present 
analysis was based on the KORA F4L survey, which is the three-year follow-up of the KORA 
F4 study including participants with lung function measurements, and the KORA Age survey.  
Spirometric measurements were obtained from 1051 adults aged 45–65 years of the KORA 
F4L follow-up, examined in 2010, and from 935 participants aged 65–90 years of the KORA 
Age study, examined in 2009. Of all participants with obtained spirometry (N=1986), 12 
participants were excluded after visual inspection of the flow-curves revealed unreproducible 
measurements according to international standards [24], resulting in 1974 participants with 
valid measurements. Further, two participants from KORA Age who did not respond to the 
EQ-5D questionnaire were excluded. Finally, data of 1972 participants with both, spirometry 
measurements and information on EQ-5D were available. 29 (1.5%) participants did not report 
on all health dimensions; of those, 25 (86%) had one missing only. All the participants provided 
information on physical inactivity. Information on self-reported physician diagnoses of common 
diseases including asthma, hay fever, stroke or myocardial infarction, current medication 
intake up to seven days before examination, as well as sociodemographic variables, was 
obtained from standardized interviews and questionnaires.  
Since the present study focusses on apparently lung-healthy subjects, from the participants 
with valid spirometry who provided information on EQ-5D and inactivity (N=1972), those 
reporting (i) a doctor’s diagnosis of emphysema, asthma, chronic bronchitis or COPD, or (ii) 
the current use of pulmonary medication including inhaled sympathomimetics, 
anticholinergics, and steroids, or oral leukotriene antagonists, or (iii) respiratory symptoms, 
i.e. cough or phlegm lasting more than 3 months a year, or (IV) subjects with airflow limitation 
as indicated by a measured FEV1/FVC <0.7 [25], were excluded from all analyses (N=692). 
Additionally, current smokers were excluded in order to avoid potential modification of 
underlying associations caused by smoking (N=140). Subjects with Parkinson’s disease (N=8) 
were also excluded.  
 
EQ-5D and physical inactivity 
The EQ-5D-3L questionnaire was used for the assessment of HRQL. The EQ-5D-3L is a 
generic, preference-based HRQL instrument, which collects information on the health state of 
five health dimensions: mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression [15]. One of three levels of severity (no problems, some problems, and 
extreme problems) can be chosen for each of the five dimensions. The German time-trade-off 
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tariff proposed by Greiner et al. was used to calculate an index-based utility score (EQ-5D 
utility) ranging from -0.205 to 0.999 [26] with higher values indicating better health. In addition 
to the results for EQ-5D dimensions which are our main focus, we report results for the EQ-
5D utility. According to the observed utility score in COPD patients, we categorized the EQ-
5D utility in our population into three groups: (1) those with best health (0.999, used as the 
reference group), (2) those with a still slightly greater utility (≥0.887) than the mean of COPD 
grade 1 in Wacker et al. [27], and those with EQ-5D utility <0.887.The distribution of the EQ-
5D utility was highly skewed (S1 Figure A1); 539 (48%) had the best possible utility score of 
0.999, followed by 386 (35%) with a utility score ≥0.887. Only 193 (17%) subjects had scores 
<0.887, of which 31 (16%) had a utility score <0.7. Therefore, the validity of the continuous 
results should be interpreted with caution and analyses with categorized utility score were 
considered. 
Assessment of physical activity levels was done as part of the standardized interview. The 
assessment method for activity was first applied and validated in the first MONICA Augsburg 
(Multinational Monitoring of Trends and Determinants in Cardiovascular Disease) Survey in 
1984/1985 that was performed prior to the KORA studies in the region of Augsburg. Physical 
inactivity, defined in terms of the amount of performed exercise, was categorized according to 
a combination of answers derived by two questions: (1) How often do you exercise in summer? 
and (2) How often do you exercise in winter? Possible answers were (a) regularly, >2 
hours/week, (b) regularly, 1-2 hours/week, (c) less than 1 hour/week, (d) not at all. A 
categorization matrix is displayed in Figure 1. Subjects were categorized as active (a in both 
questions), moderately active (one a in combination with b or c; or b in both questions), slightly 
active (one d in combination with a or b; or c in combination with b), or inactive (c or d in both 
questions). Subjects engaging regularly in >2 hours of physical activity per week, i.e those 
categorized as active, who nearly meet the WHO recommended threshold of 2.5 hours of 
physical activity per week [28], were used as the reference category to determine if less activity 
is associated with lower lung function.  
Figure 1 Categorization of activity levels 
 
Participants were categorized into activity levels I-IV based on the duration of reported exercise in 
summer and winter. 
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Lung function assessment 
Standardized spirometry was performed in line with the American Thoracic Society and 
European Respiratory Society recommendations [24] by the same study nurse in both studies. 
Flow-volume curves were obtained using a pneumotachograph-type spirometer 
(MasterScope, Jaeger, Hoechberg, Germany). Under guidance of the trained examiner, 
subjects performed 3 to 8 spirometric maneuvers per test. A detailed description has been 
published previously [29]. Spirometric parameters included FEV1, FVC, FEV1/FVC, and forced 
expiratory flow between 25% and 75% of exhaled FVC (FEF25-75). The analyzed parameters 
point towards different domains of respiratory function [30, 31]. FVC is a measure of the 
maximal breathable lung volume, determined during forced exhalation. FEV1 is dependent on 
both, lung volume and airway size. The ratio of both parameters (FEV1/FVC) is indicative of 
airway function and a low ratio is associated with airflow limitation. FEF25-75 measures airflow 
in the mid and small conducting airways. Sex, age, height and ethnicity are important 
predictors of lung function and were therefore used in prediction equations from the Global 
Lung Function Initiative (GLI) to provide standardized references across different populations 
[8]. Compared to adjustment in multiple linear regression models standardized GLI z-scores 
comprise a more complex and refined adjustment for sex, age, height and ethnicity accounting 
for non-linear relationships. Thus, we report results for standardized z-scores for each 
parameter to provide information which is comparable to other investigations as z-scores are 
standardized to a mean of 0 and a standard deviation of 1 and further to support our results 
found when using absolute values.  
 
Statistical analyses 
Data from KORA F4L and KORA Age were pooled since study protocols and lung function 
assessment were assessed equally and were also performed in the same study center. 
Population characteristics were described by means and corresponding standard deviations 
or percentages (%, N). Differences between males and females were assessed using 
Pearsons’s chi-squared test (categorical variables) and t-test for lung function parameters. 
Cramér's V was calculated to assess correlations between categorical variables. The number 
of subjects reporting extreme problems in any health dimension was low, therefore the 
answers “having some problems” (range 2-48% for the five dimensions) and “having extreme 
problems” (range 0-2%) were combined, resulting in a dichotomous variable for each EQ-5D 
dimension (no problems vs. any problems). As sensitivity analysis, subjects reporting extreme 
problems in the investigated dimension were excluded from the analyses.  
To avoid overadjustment, separate adjusted linear regression models were calculated to 
examine the relationships between each EQ-5D health dimension or physical inactivity as 
exposure with each spirometric parameter serving as outcome. For EQ-5D dimensions 
showing a significant association with lung function, regression models were performed 
adjusting for both, the EQ-5D dimension of interest and physical inactivity. Interaction effects 
between the EQ-5D dimensions and physical inactivity were tested for each EQ-5D dimension 
separately by inclusion of an interaction term with activity levels in linear regression models 
adjusted for sex, age, height and weight. To account for sex differences occurring in the 
distribution of inactivity levels as well as anxiety/depression, and pain/discomfort, we 
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assessed interaction effects between the analyzed exposures and sex and further report 
stratified analyses for females and males. 
The main model was adjusted only for those variables mainly accounting for inter-individual 
variability of lung function (i.e. sex, age, height), and for weight as a possible confounding 
factor. To address other possible confounding factors we additionally adjusted the main model 
for the following covariates separately: (A) study (KORA F4L vs. KORA Age), (B) education 
level categorized as low (<10 years of school), medium (10 years of school) and high (>10 
years of school), (C) doctor’s diagnosis of hay fever (ever), (D) season categorized as 
autumn/winter (spirometry obtained in September to February) or spring/summer (March to 
August), (E) a history of smoking (yes vs. no), (F) self-reported acute respiratory infections in 
the three weeks prior to lung function testing, and for common comorbidities: (G) hypertension, 
(H) diabetes, (I) cancer, (J) stroke, (K) myocardial infarction, or (L) multimorbidity, defined as 
the presence of at least two diseases (N=228) (G-K). Diabetes was based on self-reported 
physician diagnosis or use of antidiabetic agents. Subjects with self-reported hypertension, 
the use of antihypertensive medication, or a measured blood pressure ≥140⁄90 mmHg were 
defined as having hypertension.  
Models in which GLI z-scores for spirometric parameters (already including adjustment for 
sex, age, height, and ethnicity) served as outcome were adjusted for additional variables only. 
All participants were Caucasian, therefore ethnicity was not considered in models with 
absolute values. Outliers were defined as greater/less than the mean plus/minus 4 times the 
standard deviation in lung function parameters (separately for males and females). Subjects 
meeting this definition for any spirometric parameter (N=2) were excluded from analyses for 
the relevant parameter only. All analyses were performed using the statistical software R, 
version 3.2.0 [30]. P-values below 0.05 were considered statistically significant. 
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Results 
The population characteristics and lung function measurements of the 1132 analyzed 
apparently lung-healthy participants (male 48%, mean age 64±12 years) are shown in Table 
1. Analyzed participants had mean GLI z-scores for FEV1 and FVC of 0.71 and 0.61, 
respectively. The mean EQ-5D utility score was 0.91. 42% reported no problems for all 
dimensions and this percentage was higher in males compared to females (46% vs. 38%, 
respectively, p<0.01). Only 2.8% reported extreme problems for any health dimension, with 
the highest prevalence in the health dimension pain/discomfort (2%). Between the different 
EQ-5D dimensions, the highest correlation was present between having problems with 
mobility and problems with usual activities (Cramér’s V= 0.49, p<0.01 in chi-squared test). 
Applying continuous EQ-5D utility in regression models adjusting for sex, age, height and 
weight suggests an association between better lung function and higher EQ-5D utility (S1 
Figure A1, S2 Table A1). Further, subjects in the lowest EQ-5D category had a -87 ml (95% 
CI: -160; -15) lower FEV1 and -96 (95% CI: -187; -4) lower FVC compared to those within the 
category with the best possible utility.  
Data on self-reported time spent in exercise revealed that 32% of the participants engaged 
regularly (>2 hours/week) in physical activity, while 24% were categorized as inactive, i.e. 
engaging in physical activity <1 hour/week or not at all (p<0.01).  
 
Table 1 Population characteristics 
 Males  
(n=545) 
Females 
(n=587) 
Total  
(n=1132) 
 Mean (SD) or % (N) 
Age, years  65 (12) 64 (12) 64 (12) 
Height, cm* 174 (7) 161 (6) 167 (10) 
Weight, kg* 87 (15) 72 (13) 79 (16) 
Education*    
 Low (< 10 years of school) 53.0 (289) 58.3 (342) 55.7 (631) 
 Medium (= 10 years of school) 18.3 (100) 26.4 (155) 22.5 (255) 
 High (> 10 years of school) 28.6 (156) 15.3 (90) 21.7 (246) 
Smoking status*    
 Never smoker  43.3 (236) 66.3 (389) 55.2 (625) 
 Ever smoker 56.7 (309) 33.7 (198) 44.8 (507) 
Hypertension, yes 59.4 (323) 54.0 (317) 56.6 (640) 
Myocardial infarction, yes* 7.2 (39) 2.9 (17) 5.0 (56) 
Stroke, yes* 5.9 (32) 2.9 (17) 4.3 (49) 
Diabetes, yes 11.6 (63) 11.3 (66) 11.4 (129) 
Cancer, yes 10.8 (59) 8.7 (51) 9.7 (110) 
Hay fever ever, yes 10.8 (59) 12.9 (76) 11.9 (135) 
Lung function - Spirometric outcomes    
FEV1, l* 3.61 (0.73) 2.56 (0.57) 3.07 (0.84) 
FVC, l* 4.65 (0.92) 3.25 (0.72) 3.92 (1.08) 
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 Males  
(n=545) 
Females 
(n=587) 
Total  
(n=1132) 
 Mean (SD) or % (N) 
FEV1/FVC*  0.78 (0.04) 0.79 (0.05) 0.78 (0.05) 
FEF25-75, l/s* 3.17 (1.01) 2.34 (0.78) 2.74 (0.99) 
Z-score FEV1 0.72 (0.98) 0.70 (1.00) 0.71 (0.99) 
Z-score FVC 0.62 (0.95) 0.60 (0.93) 0.61 (0.94) 
Z-score FEV1/FVC* 0.10 (0.59) 0.01 (0.65) 0.05 (0.63) 
Z-score FEF25-75* 0.41 (0.74) 0.25 (0.82) 0.33 (0.79) 
Generic health-related quality of life    
EQ-5D - utility score  0.91 (0.13) 0.91 (0.12) 0.91 (0.13) 
No problems in any EQ-5D-dimension* 45.9 (249) 37.8 (221) 41.7 (470) 
EQ-5D – Health dimensionsa    
 Mobility    
 no problems in walking about 83.1 (453) 82.6 (485) 82.9 (938) 
 some problems in walking about  16.9 (92) 17.4 (102) 17.1 (194) 
 confined to bed  - - - 
 Self-care    
 no problems with self-care  96.5 (525) 98.3 (576) 97.4 (1101) 
 some problems washing or 
dressing 
3.5 (19) 1.4 (8) 2.4 (27) 
 unable to wash or dress 
him/herself 
0 (0) 0.3 (2) 0.2 (2) 
 Usual activities    
 no problems with performing usual 
activities  
87.9 (478) 85.8 (502) 86.8 (980) 
 some problems with performing 
usual activities  
11.9 (65) 14.0 (82) 13.0 (147) 
 unable to perform usual activities  0.2 (1) 0.2 (1) 0.2 (2) 
 Pain/Discomfort*    
 no 53.1 (288) 46.2 (270) 49.6 (558) 
 moderate 44.7 (242) 51.9 (303) 48.4 (545) 
 extreme 2.2 (12) 1.9 (11) 2.0 (23) 
 Anxiety/Depression*    
 no 82.9 (450) 72.7 (426) 77.6 (876) 
 moderate 16.6 (90) 26.3 (154) 21.6 (244) 
 extreme 0.6 (3) 1.0 (6) 0.8 (9) 
Physical activity*    
 Inactive  22.2 (121) 25.6 (150) 23.9 (271) 
 Slightly active  13.4 (73) 14.0 (82) 13.7 (155) 
 Moderately active  26.6 (145) 34.1 (200) 30.5 (345) 
 Active  37.8 (206) 26.4 (155) 31.9 (361) 
*p-value<0.05 in t-test or chi-squared test (males vs. females). acomparisons between sexes were 
performed using dichotomous variables (no vs. any) 
SD: standard deviation. FEV1: forced expiratory volume in 1 second. FVC: forced vital capacity.  
FEF25-75: forced expiratory flow between 25% and 75% of FVC. 
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Self-reported physical inactivity and lung function 
In regression models adjusted for sex, age, height, and weight, associations of physical 
inactivity with FVC and GLI z-scores for FEV1 and FVC were found (Table 2, S2 Table A2). 
Less activity was associated with lower FVC, e.g. inactive subjects had an estimated 
difference in FVC of -83 ml (95%CI: -166; 0) compared to the most active subjects. Estimates 
for physical inactivity were negative, although not significant, with FEV1 (-49 ml, 95% CI: -115; 
16) (Table 2), whereas significant associations were seen for the GLI z-score for FEV1 (-0.23, 
95% CI: -0.39; -0.08) and for FVC (-0.28, 95% CI: -0.43; -0.14) (S2 Table A2). For FVC, slightly 
active participants had an estimated decrease of -111 ml (95% CI: -209; -14) compared to 
active participants, which was 28 ml higher than for inactive participants. However, this did not 
hold true for the model based on the z-score for FVC with a lower decrease in the slightly 
active group (-0.24, 95% CI: -0.41; -0.07) than in the inactive group. Adjustment for further 
covariates, such as hay fever or multimorbidity, did not substantially change the 
aforementioned results i.e. effect estimates changed by a maximum of 8 ml e.g. in models for 
FVC after additional adjustment for stroke (p=0.08) (S2 Table A3). No interaction effects 
(p>0.05) between sex and physical activity levels were present in the main model. When 
stratified by sex, associations remained significant in females, whereas comparable 
tendencies, but no significant associations, were present among males, regardless of whether 
absolute values or GLI z-scores were assessed (S2 Tables A4-A7). Inactive females had a -
98 ml (95%CI: -177; -19) lower FEV1 and a -140 ml (95% CI: - 240; -40) lower FVC compared 
to the most active females (S2 Table A4). No associations were observed for FEV1/FVC or 
FEF25-75. 
 
 
Associations of EQ-5D dimensions with lung function 
After adjusting for sex, age, height and weight in regression models, having problems with 
mobility, and with usual activities were associated with lower FEV1 and FVC (Table 2). FEV1 
was -99 ml (95% CI: -166; -32) and FVC was -109 ml (95% CI:-195; -24) lower among subjects 
with mobility problems. Subjects reporting problems with performing usual activities had a -97 
ml (95% CI: -169; -26) lower FEV1 and a -124 ml (95% CI: -214; -33) lower FVC, respectively. 
A negative association was found for being anxious/depressed with FVC (p=0.05) and for 
problems with mobility with FEF25-75 (p=0.048), but no associations were found for the 
dimensions self-care and pain/discomfort or with FEV1/FVC. Results were comparable when 
applying GLI z-scores instead of absolute lung function values, except for being 
anxious/depressed, which showed an association with z-scores for FEV1 and FVC (S2 Table 
A2). Further, adjustment for potential confounding covariates, e.g. hay fever or season, or the 
exclusion of subjects reporting extreme problems in the investigated dimension led to similar 
results (S2 Tables A3 and A8). After adjustment for stroke, myocardial infarction, or 
multimorbidity the effect estimates decreased by about 6-22%, but were still statistically 
significant (p<0.05). For example, subjects who had problems with usual activities showed a 
decrease in FEV1 by -80 ml (95% CI: -153; -8), instead of -97 ml, and FVC by -105 ml (95% 
CI: -197; -13), instead of -124 ml, after additional adjustment for multimorbidity. The effect 
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estimates for subjects with mobility problems were -85 ml (95% CI: -153; -17), instead of -99 
ml for FEV1, and -94 ml (95% CI: -180; -7), instead of -109 ml for FVC. 
EQ-5D dimensions showed no interaction effect with sex in the main regression models, 
except for interactions between mobility problems and sex in the FEV1 and FEF25-75 models. 
In females, associations found in the total population for mobility and usual activities with FEV1 
and FVC remained significant (mobility: FEV1: β= -81 ml, p=0.04; FVC: β= -109 ml, p=0.03; 
usual activities: FEV1: β= -86 ml, p=0.04; FVC: β=-106 ml, p=0.04) (S2 Table A4). Results for 
males showed similar estimates, but were significant only for the association between FEV1 
and mobility (mobility: FEV1: β= -118 ml, p=0.04; FVC: β= -111 ml, p=0.12; usual activities: 
FEV1: β= -119 ml, p=0.05; FVC: β= -151 ml, p=0.05) (S2 Tables A5). No associations were 
observed with FEV1/FVC and FEF25-75. Having problems with self-care, having pain/discomfort 
or being anxious/depressed were not associated with any spirometric indice. Comparable 
results were obtained when applying GLI z-scores (S2 Tables A6 and A7). 
 
Effect modification between EQ-5D dimensions and physical inactivity 
Physical inactivity showed weak correlations with the EQ-5D dimensions, with the highest 
correlations observed with anxiety/depression and mobility problems (Cramér’s V 0.16 and 
0.15, respectively, p<0.01). No interaction effects, i. e. only interaction terms with p>0.05 were 
present between each EQ-5D dimension and physical activity levels in linear regression 
models adjusted for sex, age, height and weight. The observed associations between the EQ-
5D dimensions mobility and usual activities with FEV1 or FVC were not affected by further 
adjustment for physical activity (S2 Tables A9 and A10).  
 
116 P
ublications com
prised w
ithin this thesis: P
ublication V
 
  
Table 2 Results of multiple linear regression analyses 
 FEV1, ml FVC, ml FEV1/FVC, % FEF25-75, ml/s  
 β (95% CI) p-value β (95% CI) p-value β (95% CI) p-value β (95% CI) p-value 
EQ-5D         
 Problems with         
 Mobility         
 no ref.   ref.  ref.  ref.  
 some -99 (-166; -32) <0.01  -109 (-195; -24)  0.01  -0.33 (-1.05; 0.40)  0.37   -123 (-246; -1)  0.048  
 Self-care         
 no ref.   ref.  ref.  ref.  
 some/unable to  -9 (-162; 143)  0.90   -19 (-212; 174)  0.85  -0.74 (-2.40; 0.92)  0.38   45 (-231; 321)  0.75  
 Usual activities         
 no ref.   ref.  ref.  ref.  
 some/unable to  -97 (-169; -26)  0.01   -124 (-214; -33)  0.01  -0.26 (-1.03; 0.51)  0.51   -106 (-236; 23)  0.11  
 Pain/Discomfort         
 no ref.   ref.  ref.  ref.  
 moderate/extreme  -5 (-54; 45)  0.85   -10 (-73; 53)  0.75  0.02 (-0.51; 0.55)  0.94   6 (-84; 96)  0.89  
 Anxiety/Depression         
 no ref.   ref.  ref.  ref.  
 moderate/extreme  -49 (-107; 8)  0.09   -72 (-145; 1)  0.05  0.13 (-0.48; 0.75)  0.67   -19 (-124; 85)  0.71  
Physical activity         
 Active ref.   ref.  ref.  ref.  
 Moderately active  -51 (-111; 10)  0.10   -81 (-158; -5)  0.04   0.30 (-0.35; 0.95)  0.36   -2 (-111; 108)  0.98  
 Slightly active  -58 (-135; 19)  0.14   -111 (-209; -14)  0.02   0.73 (-0.09; 1.55)  0.08   23 (-117; 163)  0.75  
 Inactive  -49 (-115; 16)  0.14   -83 (-166; 0)  0.049  0.23 (-0.47; 0.93)  0.51   -8 (-127; 110)  0.89  
The linear regression models included one EQ-5D dimension variable or physical activity and sex, age, height, and weight. 
CI: confidence interval. FEV1: forced expiratory volume in 1 second. FVC: forced vital capacity. FEF25-75: forced expiratory flow between 25% and 75% of 
FVC. 
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Discussion 
Volumetric lung function indices were negatively associated with having problems with mobility 
and usual activities in an apparently lung-healthy study population, despite almost half of the 
examined subjects reporting no problems in any EQ-5D dimension. After stratification by sex, 
associations were more pronounced in females than in males although the prevalence of 
problems in mobility or in usual activities was comparable between sexes. The physical activity 
level did not modulate the associations observed with these EQ-5D dimensions. However, 
being physically inactive showed a similar tendency as EQ-5D to be associated with lower 
volumetric indices. About half of the population reported to have pain/discomfort, but no 
associations with lung function were present.  
The frequency distribution of reporting problems in the EQ-5D dimensions was comparable to 
those observed in a population-based survey among 1966 German adults in 2006, which also 
revealed the highest prevalence for the dimension pain/discomfort (33.8%). Only 3.1% 
reported extreme problems in any of the 5 dimensions [19] compared to 2.8% in the present 
study population.  
Being physically inactive was associated with lower FEV1 and FVC, remaining significant 
among females only when performing sex-stratified analyses. This may be due to the fact that 
men were more often categorized as active (37.8% vs. 26.4% for men and women, 
respectively) and less often as inactive (22.2% vs. 25.6%, respectively). A similar pattern was 
also demonstrated in a German Health survey [32]. 33.7% of the participants aged 18-79 years 
reported no sports activity; with lower inactivity in males than in females (33.0% vs. 34.3%, 
respectively). Further, males engaged more often in regular (≥2 hours/week) sports activity 
compared to females (29.3% vs. 21.6%) [32]. Investigations on self-reported physical activity 
in adults have shown that physically active subjects have higher volumetric lung function 
parameters and a slower lung function decline compared to inactive participants [20, 21]. 
Depending on the level of inactivity, FEV1 was reduced between 20 and 170 ml [21]. The 
magnitude and direction of findings correspond to our results, which indicated about 100 ml 
lower FVC in inactive subjects compared to active ones.  
In our population, associations of EQ-5D with lung function were mainly seen for dimensions 
related to physical functioning, mobility and usual activities. Notably, the level of physical 
activity did not modify these associations, suggesting that regular activity and these two 
perceived EQ-5D dimensions may exert different pathways of functioning in lung-healthy 
subjects, which might also be supported by the low correlation detected between these 
entities. Despite the fact that a different measure, the SF-36, was applied to assess HRQL, 
two studies from the UK also found positive associations of self-reported physical functioning 
with FEV1 and inconclusive results for the mental component in the general population [13, 
14]. Thus, taken together, these and our current findings suggest that volumetric lung function 
indices are associated with physical functioning in lung-healthy adults.  
Corresponding results were shown among subjects with COPD, where impairments of 
respiratory function are reflected by the increasing GOLD grades 1-4. While subjects with 
COPD grade 1 presented no significant effects for the mental or physical score obtained by 
the SF-12 in comparison to healthy controls of the KORA F4 study, subjects with higher grades 
of COPD showed a lower physical functioning score, but no associations with the mental 
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component [17]. Further, in a population-based survey across 17 countries lower physical and 
mental scores were found in subjects with COPD in comparison to those without COPD; 
confirming stronger effects for the physical than for the mental score [3].  
Data from the German COPD cohort COSYCONET showed a decrease in mean EQ-5D utility 
with increasing COPD grade, i.e. from 0.85 in COPD grade 1 to 0.74 in COPD grade 4 [27]. 
Our mean EQ-5D utility of 0.91 in lung-healthy subjects fits to the lower results reported for 
the COPD cohort. Interestingly, despite the high overall utility score of EQ-5D in our study 
population, associations were still detectable for problems in mobility or usual activities, and 
being inactive. Applying the EQ-5D utility showed a similar negative trend with lower lung 
function as shown by Wacker et al. among COPD patients [27], and suggests a negative 
association of EQ-5D utility and lung function already in apparently lung-healthy adults.  
 
Strength and limitations 
A major strength of the present study is the standardized assessment of lung function and the 
possibility to investigate a range of spirometric indices in an apparently lung-healthy general 
adult population. While HRQL is commonly investigated in lung disease, to our knowledge no 
evidence exists for the association between EQ-5D dimensions and lung function in the 
general population without chronic lung diseases.  
The cross-sectional design of our analysis does not allow us to draw conclusions about long-
term effects or causal relations, i.e. we cannot determine causal pathways between EQ-5D 
dimensions and activity levels e.g. if inactivity is caused by worse quality of life or vice versa. 
Thus, we can only assess if inactivity influences the association between EQ-5D dimensions 
and lung function. All information on lung diseases, stroke or myocardial infarction was 
assessed via self-reports and was not verified by a physician. Similarly, physical activity 
assessment was questionnaire-based only. We analyzed a preselected lung-healthy adult 
population with an age range of 45 to 89 years, of whom 20% had at least 2 chronic health 
conditions not directly related to lung function impairment. Although we applied information on 
doctor’s diagnoses of lung diseases, lung medication intake and a FEV1/FVC <0.07 as 
exclusion criteria, we still might have missed some participants with undiagnosed asthma. 
Post-bronchodilation data were not available to detect subjects with reversible airway 
limitation. Further, our results should be interpreted with caution due to the small effect 
estimates of about 80-120 ml for volumetric indices with significance levels near 0.05 resulting 
in an arguable clinical relevance. We did not adjust for multiple testing as the spirometric 
indices as well as the EQ-5D dimensions were correlated. Across the sensitivity analyses the 
same trend was evident, while not all results remained statistically significant. Thus, further 
studies are needed to support our findings of the association between physical functioning 
and lung function in healthy lungs. Our study was population-based and therefore the 
addressed population is not comparable to a clinical cohort or narrower age ranges. However, 
problems in mobility or usual activities and inactivity were associated with slightly lower lung 
function indices after adjustment for other common chronic diseases or being inactive.  
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Conclusion 
Having problems with mobility or usual activities was associated with slightly lower lung 
function in lung-healthy, non-smoking, German adults. Physical activity levels did not modify 
the associations with EQ-5D dimensions. Associations found were more pronounced among 
females than in males. Other health-related EQ-5D dimensions, e.g. problems with self-care, 
having pain/discomfort or being anxious/depressed, showed no (or unstable) associations with 
spirometric indices. Our results suggest that, comparable to observations in subjects with 
chronic lung diseases, the health dimensions which are directly related to movement may be 
associated with volumetric lung function already in lung-healthy subjects.  
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Figure A1 Distribution of EQ‐5D utility and z‐scores for FEV1 and FVC with corresponding 
linear regression line (blue line) and 95% confidence interval (shaded area) 
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Table A1 Results of multiple linear regression models with EQ-5D utility as exposure 
 FEV1, ml FVC, ml FEV1/FVC, % FEF25-75, ml/s 
 β (95% CI) p β (95% CI) p β (95% CI) p β (95% CI) p 
EQ-5D utility, continuous 209 (12; 405) 0.04 229 (-19; 478) 0.07 1.35 (-0.75; 3.46) 0.21 265 (-93; 622) 0.15 
EQ-5D utility, categorized        
 =0.999  ref.   ref. ref.  ref.  
 ≥0.887 25 (-29; 79) 0.37 10 (-59; 78) 0.78 0.46 (-0.12; 1.04) 0.12 64 (-35; 162) 0.20 
 <0.887 -87 (-160; -15) 0.02 -96 (-187; -4) 0.04 -0.50 (-1.27; 0.28) 0.21 -111 (-243; 20) 0.10 
The models were adjusted for sex, age, height, weight and one EQ-5D utility variable (continuous or categorized). 
CI: confidence interval. FEV1: forced expiratory volume in 1 second. FVC: forced vital capacity. FEF25-75: forced expiratory flow between 25% and 75% of 
FVC.
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Table A2 Results of multiple linear regression models applying GLI z-scores – Total population 
 Z-score FEV1 Z-score FVC Z-score FEV1/FVC Z-score FEF25-75 
EQ-5D β (95% CI) p β (95% CI) p β (95% CI) p β (95% CI) p 
 Problems with       
 Mobility       
 no ref.   ref. ref.  ref.  
 some  -0.23 (-0.38; -0.08) <0.01  -0.27 (-0.41; -0.12) <0.01  0.06 (-0.04; 0.16)  0.24   -0.05 (-0.18; 0.07)  0.39  
 Self-care        
 no ref.   ref. ref.  ref.  
 some/unable to  0.01 (-0.35; 0.37)  0.98   -0.09 (-0.42; 0.25) 0.62   0.04 (-0.19; 0.28)  0.72   0.14 (-0.15; 0.43)  0.34  
 Usual activities        
 no ref.   ref. ref.  ref.  
 some/unable to  -0.27 (-0.43; -0.10) <0.01  -0.30 (-0.46; -0.14) <0.01  0.02 (-0.09; 0.13)  0.68   -0.11 (-0.24; 0.03)  0.13  
 Pain/Discomfort        
 no ref.   ref. ref.  ref.  
 moderate/extreme  -0.04 (-0.16; 0.07)  0.47   -0.09 (-0.2; 0.01) 0.09   0.07 (-0.01; 0.14)  0.07   0.03 (-0.06; 0.13)  0.48  
 Anxiety/Depression       
 no ref.   ref. ref.  ref.  
 moderate/extreme -0.14 (-0.28; 0)  0.04   -0.16 (-0.29; -0.03) 0.02   0.02 (-0.06; 0.11)  0.59   -0.02 (-0.13; 0.09)  0.70  
Physical activity        
 Active ref.   ref. ref.  ref.  
 Moderately active  -0.15 (-0.29; 0)  0.047  -0.16 (-0.30; -0.03) 0.02   0.01 (-0.08; 0.10)  0.80   -0.04 (-0.16; 0.07)  0.48  
 Slightly active  -0.17 (-0.35; 0.01)  0.07   -0.24 (-0.41; -0.07) 0.01   0.11 (-0.01; 0.23)  0.06   -0.02 (-0.17; 0.13)  0.78  
 Inactive  -0.23 (-0.39; -0.08) <0.01  -0.28 (-0.43; -0.14) <0.01  0.05 (-0.05; 0.15)  0.29   -0.08 (-0.21; 0.04)  0.19  
Regression models for standardized Global Lung Function Initiative z-scores that are already adjusted for ethnicity, sex, age, and height were adjusted 
only for weight and one EQ-5D dimension or physical activity variable at a time. 
CI: confidence interval. FEV1: forced expiratory volume in 1 second. FVC: forced vital capacity. FEF25-75: forced expiratory flow between 25% and 75% of 
FVC.
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Table A3 Results of selected sensitivity analyses 
 Linear regression models were adjusted for sex, age, height, weight, one EQ-5D dimension or physical activity and additionally for 
 Hay fever Season Stroke Myocardial infarction Multimorbidity 
 β (95% CI) p β (95% CI) p β (95% CI) p β (95% CI) p β (95% CI) p 
FEV1, ml         
 Mobility         
 no problems ref.   ref.  ref.  ref.  ref.  
 some problems -99 (-166; -31) <0.01 -100 (-168; -33) <0.01 -93 (-160; -25) 0.01 -80 (-148; -12) 0.02 -85 (-153; -17) 0.01 
 Usual activities          
 no problems ref.   ref.  ref.  ref.  ref.  
 some/unable to -97 (-169; -26) 0.01 -99 (-170; -28) 0.01 -87 (-158; -15) 0.02 -76 (-148; -4) 0.04 -80 (-153; -8) 0.03 
Physical activity          
 Active ref.   ref.  ref.  ref.  ref.  
 Moderately active  -51 (-112; 10)  0.10   -50 (-111; 10)  0.10  -50 (-111; 10)  0.10   -52 (-112; 9)  0.09   -52 (-113; 9)  0.09  
 Slightly active  -58 (-136; 19)  0.14   -58 (-135; 19)  0.14  -56 (-133; 21)  0.16   -63 (-140; 14)  0.11   -64 (-141; 13)  0.11  
 Inactive  -51 (-117; 15)  0.13   -51 (-117; 14)  0.13  -44 (-110; 22)  0.19   -48 (-114; 17)  0.15   -46 (-111; 20)  0.17  
FVC, ml         
 Mobility         
 no problems ref.   ref.  ref.  ref.  ref.  
 some problems  -109 (-194; -24)  0.01   -112 (-197; -26)  0.01  -98 (-184; -13)  0.02   -88 (-174; -1)  0.047   -94 (-180; -7) 0.03 
 Usual activities          
 no problems ref.   ref.  ref.  ref.  ref.  
 some/unable to  -124 (-215; -34)  0.01   -126 (-217; -36)  0.01  -105 (-196; -14)  0.02   -99 (-191; -8)  0.03   -105 (-197; -13) 0.03 
Physical activity          
 Active ref.   ref.  ref.  ref.  ref.  
 Moderately active  -82 (-158; -5)  0.04   -80 (-157; -4)  0.04  -80 (-157; -4)  0.04  -83 (-159; -7)  0.03   -84 (-161; -8)  0.03  
 Slightly active  -112 (-209; -15)  0.02   -111 (-208; -14)  0.03  -111 (-208; -14)  0.03  -118 (-215; -21)  0.02   -119 (-216; -22)  0.02  
 Inactive  -85 (-168; -2)  0.046   -87 (-170; -4)  0.04  -75 (-158; 8)  0.08  -83 (-165; 0)  0.05   -80 (-163; 3)  0.06  
 
CI: confidence interval. FEV1: forced expiratory volume in 1 second. FVC: forced vital capacity.
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Table A4 Results of multiple linear regression models – Females 
 FEV1, ml FVC, ml FEV1/FVC, % FEF25-75, ml/s  
EQ-5D β (95% CI) p β (95% CI) p β (95% CI) p β (95% CI) p 
 Problems with        
 Mobility        
 no ref.   ref. ref.  ref.  
 some  -81 (-160; -2)  0.04   -109 (-210; -9)  0.03   0.14 (-0.90; 1.18)  0.79   -61 (-210; 89)  0.43  
 Self-care         
 no ref.   ref.  ref.  ref.  
 some/unable to  41 (-176; 258)  0.71   34 (-242; 310)  0.81   -0.06 (-2.90; 2.78)  0.97   213 (-197; 623)  0.31  
 Usual activities         
 no ref.   ref.  ref.  ref.  
 some/unable to  -86 (-167; -5)  0.04   -106 (-209; -3)  0.04   -0.34 (-1.40; 0.73)  0.54   -101 (-254; 53)  0.20  
 Pain/Discomfort         
 no ref.   ref.  ref.  ref.  
 moderate/extreme  -4 (-63; 54)  0.89   -13 (-87; 61)  0.73  0.23 (-0.54; 0.99)  0.56   0 (-110; 111)  0.99  
 Anxiety/Depression        
 no ref.   ref. ref.  ref.  
 moderate/extreme  -41 (-103; 22)  0.20   -58 (-137; 22) 0.15  0.13 (-0.69; 0.95)  0.75   -14 (-132; 104)  0.81  
Physical activity         
 Active ref.   ref. ref.  ref.  
 Moderately active  -45 (-117; 27)  0.22   -62 (-153; 29) 0.18   0.18 (-0.76; 1.13)  0.70   9 (-127; 145)  0.90  
 Slightly active  -84 (-176; 8)  0.07   -126 (-242; -9)  0.04   0.55 (-0.66; 1.76)  0.37   -37 (-211; 138)  0.68  
 Inactive  -98 (-177; -19)  0.02   -140 (-240; -40)  0.01   0.21 (-0.83; 1.25)  0.69   -33 (-183; 117)  0.67  
The models were adjusted for age, height, weight and one EQ-5D dimension or physical activity variable at a time. 
CI: confidence interval. FEV1: forced expiratory volume in 1 second. FVC: forced vital capacity FEF25-75: forced expiratory flow between 25% and 75% 
of FVC.
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Table A5 Results of multiple linear regression models – Males 
 FEV1, ml FVC, ml FEV1/FVC, % FEF25-75, ml/s  
EQ-5D β (95% CI) p β (95% CI) p β (95% CI) p β (95% CI) p 
 Problems with        
 Mobility        
 no ref.   ref. ref.  ref.  
 some  -118 (-227; -8)  0.04   -111 (-250; 27)  0.12  -0.82 (-1.82; 0.19)  0.11   -184 (-378; 11)  0.07  
 Self-care         
 no ref.   ref.  ref.  ref.  
 some/unable to  -5 (-219; 209)  0.96   -13 (-284; 257)  0.92  -1.02 (-3.03; 0.98)  0.32   -2 (-382; 378)  0.99  
 Usual activities         
 no ref.   ref.  ref.  ref.  
 some/unable to  -119 (-240; 2)  0.05   -151 (-304; 1)  0.05  -0.24 (-1.35; 0.88)  0.68   -130 (-345; 84)  0.23  
 Pain/Discomfort         
 no ref.   ref.  ref.  ref.  
 moderate/extreme  -12 (-92; 69)  0.78   -13 (-115; 88)  0.80  -0.25 (-0.98; 0.49)  0.51   3 (-139; 146)  0.96  
 Anxiety/Depression        
 no ref.   ref. ref.  ref.  
 moderate/extreme  -56 (-160; 47)  0.28   -86 (-216; 44) 0.19  0.14 (-0.81; 1.08)  0.77   -23 (-206; 161)  0.81  
Physical activity         
 Active ref.   ref. ref.  ref.  
 Moderately active  -65 (-163; 32)  0.19   -112 (-235; 12) 0.08  0.41 (-0.48; 1.31)  0.36   -21 (-195; 153)  0.82  
 Slightly active  -47 (-170; 76)  0.46   -111 (-267; 44)  0.16  0.87 (-0.26; 1.99)  0.13   64 (-155; 283)  0.57  
 Inactive  -36 (-141; 70)  0.51   -61 (-194; 72)  0.37  0.10 (-0.87; 1.06)  0.84   -40 (-228; 147)  0.67  
The models were adjusted for age, height, weight and one EQ-5D dimension or physical activity variable at a time. 
CI: confidence interval. FEV1: forced expiratory volume in 1 second. FVC: forced vital capacity FEF25-75: forced expiratory flow between 25% and 75% 
of FVC.
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Table A6 Results of multiple linear regression models applying GLI z-scores – Females 
 Z-score FEV1 Z-score FVC Z-score FEV1/FVC Z-score FEF25-75 
EQ-5D β (95% CI) p β (95% CI) p β (95% CI) p β (95% CI) p 
 Problems with       
 Mobility       
 no ref.   ref. ref.  ref.  
 some  -0.20 (-0.42; 0.01)  0.07   -0.28 (-0.48; -0.08) 0.01   0.14 (0; 0.28)  0.05   0.01 (-0.17; 0.18)  0.95  
 Self-care        
 no ref.   ref. ref.  ref.  
 some/unable to  0.04 (-0.57; 0.66)  0.89   -0.11 (-0.68; 0.47) 0.71   0.14 (-0.27; 0.55)  0.50   0.29 (-0.22; 0.80)  0.27  
 Usual activities        
 no ref.   ref. ref.  ref.  
 some/unable to  -0.23 (-0.46; 0)  0.049   -0.26 (-0.47; -0.05) 0.02   0.04 (-0.12; 0.19)  0.65   -0.08 (-0.27; 0.11)  0.42  
 Pain/Discomfort        
 no ref.   ref. ref.  ref.  
 moderate/extreme  -0.02 (-0.18; 0.14)  0.82   -0.10 (-0.25; 0.05) 0.21   0.11 (0.01; 0.22)  0.04   0.06 (-0.07; 0.20)  0.36  
 Anxiety/Depression       
 no ref.   ref. ref.  ref.  
 moderate/extreme -0.12 (-0.30; 0.06)  0.20   -0.12 (-0.29; 0.04) 0.14   0.02 (-0.10; 0.14)  0.70   -0.01 (-0.16; 0.14)  0.93  
Physical activity        
 Active ref.   ref. ref.  ref.  
 Moderately active -0.09 (-0.30; 0.11)  0.37   -0.10 (-0.29; 0.09) 0.32   0.01 (-0.13; 0.15)  0.89   0 (-0.17; 0.17)  0.99  
 Slightly active  -0.19 (-0.45; 0.07)  0.16   -0.25 (-0.49; -0.01) 0.045  0.11 (-0.07; 0.28)  0.23   -0.03 (-0.25; 0.19)  0.82  
 Inactive  -0.25 (-0.48; -0.03)  0.03   -0.33 (-0.53; -0.12) <0.01  0.11 (-0.04; 0.26)  0.15   -0.03 (-0.21; 0.16)  0.77  
Regression models for standardized Global Lung Function Initiative z-scores that are already adjusted for ethnicity, sex, age, and height were 
adjusted only for weight and one EQ-5D dimension or physical activity variable at a time. 
CI: confidence interval. FEV1: forced expiratory volume in 1 second. FVC: forced vital capacity. FEF25-75: forced expiratory flow between 25% and 75% 
of FVC. 
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Table A7 Results of multiple linear regression models applying GLI z-scores – Males 
 
 Z-score FEV1 Z-score FVC Z-score FEV1/FVC Z-score FEF25-75 
EQ-5D β (95% CI) p β (95% CI) p β (95% CI) p β (95% CI) p 
 Problems with       
 Mobility       
 no ref.   ref. ref.  ref.  
 some  -0.23 (-0.44; -0.01)  0.04   -0.22 (-0.43; -0.02) 0.03   -0.02 (-0.15; 0.12)  0.80   -0.08 (-0.25; 0.09)  0.34  
 Self-care        
 no ref.   ref. ref.  ref.  
 some/unable to  -0.05 (-0.49; 0.38)  0.82   -0.11 (-0.53; 0.30) 0.60   -0.01 (-0.29; 0.26)  0.93   0.03 (-0.31; 0.38)  0.84  
 Usual activities        
 no ref.   ref. ref.  ref.  
 some/unable to  -0.26 (-0.51; -0.02)  0.04   -0.29 (-0.53; -0.06) 0.01   0.01 (-0.14; 0.17)  0.86   -0.10 (-0.29; 0.10)  0.33  
 Pain/Discomfort        
 no ref.   ref. ref.  ref.  
 moderate/extreme -0.02 (-0.18; 0.14)  0.79   -0.04 (-0.20; 0.11) 0.57   0.03 (-0.07; 0.13)  0.59   0.04 (-0.09; 0.17)  0.54  
 Anxiety/Depression       
 no ref.   ref. ref.  ref.  
 moderate/extreme -0.10 (-0.31; 0.12)  0.37   -0.13 (-0.33; 0.07) 0.21   0.04 (-0.09; 0.17)  0.55   0.02 (-0.14; 0.19)  0.80  
Physical activity       
 Active ref.   ref. ref.  ref.  
 Moderately active  -0.15 (-0.35; 0.05)  0.14   -0.18 (-0.38; 0.01) 0.06   0.04 (-0.09; 0.16)  0.58   -0.03 (-0.19; 0.13)  0.71  
 Slightly active  -0.10 (-0.35; 0.16)  0.46   -0.18 (-0.42; 0.07) 0.15   0.13 (-0.03; 0.29)  0.11   0.04 (-0.16; 0.24)  0.71  
 Inactive  -0.12 (-0.33; 0.10)  0.29   -0.14 (-0.35; 0.07) 0.19   0.01 (-0.13; 0.14)  0.94   -0.07 (-0.24; 0.10)  0.43  
Regression models for standardized Global Lung Function Initiative z-scores that are already adjusted for ethnicity, sex, age, and height were adjusted 
only for weight and one EQ-5D dimension or physical activity variable at a time. 
CI: confidence interval. FEV1: forced expiratory volume in 1 second. FVC: forced vital capacity. FEF25-75: forced expiratory flow between 25% and 75% 
of FVC.
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Table A8 Linear regression results after exclusion of subjects reporting extreme problems or being unable to 
 FEV1, ml FVC, ml FEV1/FVC, % FEF25-75, ml/s  
EQ-5D β (95% CI) p β (95% CI) p β (95% CI) p β (95% CI) p 
 Problems with        
 Mobility*        
 no ref.   ref. ref.  ref.  
 some -99 (-166; -32) <0.01  -109 (-195; -24) 0.01  -0.33 (-1.05; 0.40)  0.37   -123 (-246; -1)  0.048  
 Self-care        
 no ref.   ref. ref.  ref.  
 some  3 (-155; 161)  0.97   -5 (-205; 195) 0.96   -0.75 (-2.47; 0.97)  0.39   58 (-228; 344)  0.69  
 Usual activities        
 no ref.   ref. ref.  ref.  
 some  -101 (-173; -29)  0.01   -131 (-222; -40) <0.01  -0.20 (-0.97; 0.57)  0.61   -101 (-232; 29)  0.13  
 Pain/Discomfort        
 no ref.   ref. ref.  ref.  
 moderate  2 (-48; 53)  0.92   -3 (-67; 61) 0.93   0.07 (-0.47; 0.61)  0.80   17 (-74; 108)  0.71  
 Anxiety/Depression        
 no ref.   ref. ref.  ref.  
 moderate  -43 (-102; 15)  0.15   -63 (-137; 11) 0.09   0.12 (-0.50; 0.75)  0.70  -20 (-126; 86)  0.71  
*None of the participants reported to be confined to bed, therefore all participants remained in the models. 
The models were adjusted for sex, age, height, weight and one EQ-5D dimension at a time.  
 
CI: confidence interval. FEV1: forced expiratory volume in 1 second. FVC: forced vital capacity. FEF25-75: forced expiratory flow between 25% and 75% 
of FVC.
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Table A9 Results of multiple linear regression models with adjustment for problems with mobility and 
physical activity 
 Models adjusted for both, mobility and physical inactivity 
 Total populationa Malesb Femalesb 
FEV1, ml β (95% CI) p β (95% CI) p β (95% CI) p 
EQ-5D      
 Problems with      
 Mobility      
 no ref.   ref. ref.  
 some -96 (-164; -18) 0.01 -114 (-225; -3) 0.04 -74 (-154; 5) 0.07 
Physical activity      
 Active ref.   ref. ref.  
 Moderately active -46 (-107; 14) 0.13 -56 (-154; 42) 0.26 -43 (-115; 28) 0.24 
 Slightly active -58 (-135; 19) 0.14 -49 (-172; 73) 0.43 -82 (-174; 10) 0.08 
 Inactive -41 (-106; 25) 0.23 -24 (-130; 82)  0.66 -92 (-171;-13) 0.02 
FVC, ml      
EQ-5D      
 Problems with      
 Mobility      
 no ref.   ref. ref.  
 some -104 (-189; -18) 0.02 -105 (-245; 35) 0.14 -100 (-200; 1) 0.05 
Physical activity      
 Active ref.   ref. ref.  
 Moderately active -77 (-153; 0) 0.05 -103 (-227; 20) 0.10 -60 (-151; 31) 0.20 
 Slightly active -111 (-208, -14) 0.03 -114 (-269; 42) 0.15 -123 (-239; -7) 0.04 
 Inactive -74 (-157; 9) 0.08 -50 (-183; 84) 0.47 -133 (-233; -32) 0.01 
aModel was adjusted for sex, age, height, weight, mobility and physical activity. 
bModel was adjusted for age, height, weight, mobility and physical activity. 
 
CI: confidence interval. FEV1: forced expiratory volume in 1 second. FVC: forced vital capacity.  
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Table A10 Results of multiple linear regression models with adjustment for problems with usual activities 
and physical activity 
 Models adjusted for both, usual activity and physical inactivity 
 Total populationa Malesb Femalesb 
FEV1, ml β (95% CI) p β (95% CI) p β (95% CI) p 
EQ-5D      
 Problems with      
 Usual activities      
 no ref.   ref. ref.  
 some/unable to -91 (-163; -20) 0.01 -114 (-236; 8) 0.07 -79 (-160; 2) 0.06 
Physical activity      
 Active ref.   ref. ref.  
 Moderately active -43 (-103; 18) 0.17 -56 (-155; 42) 0.26 -38 (-110; 34) 0.30 
 Slightly active -50 (-127; 28) 0.21 -39 (-163; 84) 0.53 -74 (-166; 18) 0.12 
 Inactive -39 (-104; 27) 0.25 -25 (-131; 81) 0.64 -86 (-165; -7) 0.03 
FVC, ml      
EQ-5D      
 Problems with      
 Usual activities      
 no ref.   ref. ref.  
 some/unable to -113 (-203; -22) 0.02 -141 (-295; 12) 0.07 -95 (-198; 8) 0.07 
Physical activity      
 Active ref.   ref. ref.  
 Moderately active -70 (-147; 6) 0.07 -101 (-225; 23) 0.11 -52 (-143; 40) 0.27 
 Slightly active -100 (-197; -3)  0.04 -102 (-257; 54) 0.20 -112 (-228; 5) 0.06 
 Inactive -69 (-152; 14) 0.10 -48 (-181; 86) 0.49 -124 (-225; -24) 0.02 
aModel was adjusted for sex, age, height, weight, usual activities and physical activity. 
bModel was adjusted for age, height, weight, usual activities and physical activity. 
 
CI: confidence interval. FEV1: forced expiratory volume in 1 second. FVC: forced vital capacity.  
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